Mitochondrial signaling pathway in Alzheimer´s disease: disclosure of new therapeutic targets by Silva, Diana Filipa Ferreira da
 
2014
2014
D
ia
n
a 
Fi
lip
a 
Fe
rr
e
ir
a 
d
a 
Si
lv
a
Mitochondrial signaling pathway in Alzheimer´s disease: 
disclosure of new therapeutic targets
U
n
iv
e
rs
id
ad
e
 d
e
 C
o
im
b
ra
Diana Filipa Ferreira da Silva
Tese de Doutoramento em Biociências na especialidade de Neurociências, 
orientada por Doutora Sandra Morais Cardoso e Doutor António Matos Moreno 
e apresentada ao Departamento de Ciências da Vida da Universidade de Coimbra
M
it
o
ch
o
n
d
ri
al
 s
ig
n
al
in
g 
p
at
h
w
ay
 i
n
 A
lz
h
e
im
e
r´
s 
d
is
e
as
e
: 
d
is
cl
o
su
re
 
o
f 
n
e
w
 t
h
e
ra
p
e
u
ti
c 
ta
rg
e
ts
 
 Diana Filipa Ferreira da Silva 
 
Mitochondrial signaling pathway in 
Alzheimer´s disease: disclosure of new 
therapeutic targets 
 
 
Via de sinalização mitochondrial na Doença 
de Alzheimer: descoberta de novos alvos 
terapêuticos 
 
 
 
 
 
 
 
 
Tese de Doutoramento em Biociências, orientada por Doutora Sandra Morais Cardoso e Doutor 
António de Matos Moreno e apresentada ao Departamento de Ciências da Vida da Faculdade de 
Ciências e Tecnologia da Universidade de Coimbra 
 
2014 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertação apresentada ao Departamento de Ciências da Vida da Faculdade de 
Ciências e Tecnologia da Universidade de Coimbra para prestação de provas de 
Doutoramento em Biociências, na especialidade de Neurociências 
 
 
 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(…) 
O sonho é ver as formas invisíveis  
Da distância imprecisa, e, com sensíveis 
Movimentos da esp´rança e da vontade 
Buscar na linha fria do horizonte 
A árvore, a praia, a flor, a ave, a fonte – 
Os beijos merecidos da Verdade.  
 [Fernando Pessoa, in Mensagem] 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Agradecimentos 
Um obrigado muito especial à minha orientadora Sandra Morais Cardoso. Obrigada 
pela presença, pelos ensinamentos, pela motivação. Obrigada por tudo. Foi e continuará 
a ser um grande privilégio trabalhar consigo.  
Obrigada ao Dr António Moreno, meu co-orientador, pela disponibilidade, prontidão e 
pelo gosto com que partilha tão grande sabedoria. 
Obrigada à Raquel e à Daniela, elas que foram as minhas mentoras no início desta 
caminhada e que estiveram sempre prontas a ajudar. Muito obrigada em especial à 
Raquel pela ajuda e amizade.  
Agradeço aos colegas do laboratório a amizade e entre ajuda. A união sempre fez a 
força, e a vossa amizade faz do laboratório um local ideal para trabalhar. Obrigada Ana 
Plácido, Sónia, Cristina, Emanuel, Inês, Ana Duarte e Renato. 
Thank you Dr Russell Swerdlow for the opportunity to work with you and for the 
teaching and scientific discussions. Thank you for enjoying Science so much and share 
that passion with me. I felt so welcome in your laboratory that I cannot forget the great 
people I met there: Eva, Jane, Lezi and Narita.  
Obrigada ao Centro de Neurociências e Biologia Celular pela oportunidade e aos 
técnicos e funcionários do centro por todo o auxílio prestado no desenvolvimento do 
trabalho experimental. 
Obrigada aos meus amigos, os de sempre, pela força que me dão só por acreditarem que 
faço tudo com “uma perna às costas”! Merci beaucoup à Liliana, Marilyn, Sandrina e 
Marta. 
Obrigada à minha família por fazerem da minha casa um lugar à parte do mundo: 
obrigada mãe, pai, Bruno, Filipe e Carla.  
 Fundação para a Ciência e a Tecnologia e Fundo Europeu para o Desenvolvimento 
Regional o financiamento da minha bolsa (SFRH/BD/72644). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
À minha famíla. 
 
 
 
 
 
 
 i 
 
Table of Contents 
SUMMARY .................................................................................................................... vi 
CHAPTER 1 .................................................................................................................. 17 
General introduction .................................................................................................... 17 
1.1 INTRODUCTION .............................................................................................. 18 
1.2 Ageing as a risk factor for AD ........................................................................... 18 
1.3 Mitochondrial function in AD ........................................................................... 19 
1.4 AD: a disorder of protein misfolding ................................................................ 24 
1.5 Mitochondrial DNA ............................................................................................ 27 
1.6 Mitochondrial driven oxidative stress ............................................................... 31 
1.7 Mitochondrial Dynamics in AD ......................................................................... 34 
1.7.1 Mitochondrial morphology.......................................................................... 34 
1.7.2 Mitochondrial content and Biogenesis ....................................................... 34 
1.7.3 Mitochondrial Fusion and Fission .............................................................. 36 
1.7.4 Mitochondrial metabolic control of intracellular cargo transport .......... 40 
1.7.5 Mitochondrial metabolic control of the autophagic-lysosomal pathway 44 
1.8 Apoptosis .............................................................................................................. 48 
1.9 New therapeutic strategies in AD ...................................................................... 49 
1.9.1 Mitochondrial mass manipulation .............................................................. 49 
1.9.2 Redox state manipulation ............................................................................ 50 
1.9.3 Cytoskeletal manipulation ........................................................................... 51 
Objectives .................................................................................................................. 54 
Chapter 2 ....................................................................................................................... 56 
Materials and Methods ................................................................................................ 56 
2.1 Chemicals ............................................................................................................. 57 
2.2 Human Subjects .................................................................................................. 57 
2.2.1 Creation of cybrid cell lines ......................................................................... 59 
 ii 
 
2.3 Cybrid and parental SHSY5Y neuronal differentiation ................................. 60 
2.4 Mitochondrial function and structural evaluation .......................................... 61 
2.4.1 Cytochrome oxidase Vmax assays .............................................................. 61 
2.4.2 Citrate synthase assay .................................................................................. 61 
2.4.3 Analysis of Adenine nucleotides .................................................................. 62 
2.4.4 Analysis of mitochondrial membrane potential (∆Ψm) ............................. 62 
2.4.5 Respiration and glycolysis analysis ............................................................. 63 
2.4.6 Electron microscopy ..................................................................................... 64 
2.4.7 Immunocytochemistry and confocal visualization of mitochondrial 
network ................................................................................................................... 65 
2.4.8 Western blot analysis of Flux modifying proteins ..................................... 66 
2.4.9 Western blot analysis of mitochondrial mass and dynamics proteins..... 67 
2.5 Apoptotic cell death evaluation ......................................................................... 69 
2.5.1 Western blot analysis of mitochondrial cytochrome c and Beta-amyloid 
content .................................................................................................................... 69 
2.6 NAD metabolism ................................................................................................. 70 
2.6.1 NAD+/NADH assay ....................................................................................... 70 
2.6.2 Evaluation of SIRT2 protein levels and NAD+ savage pathway enzyme 71 
2.7 DNA and RNA isolation and quantification ..................................................... 72 
2.7.1 Purification of genomic DNA ...................................................................... 72 
2.7.2 Purification of total RNA ............................................................................. 72 
2.7.3 cDNA reaction .............................................................................................. 72 
2.7.4 Quantitative real time PCR ......................................................................... 73 
2.8 Oxidative stress evaluation ................................................................................ 73 
2.8.1 Superoxide anion (O2•–) formation ............................................................. 73 
2.8.2 Determination of protein carbonyls groups ............................................... 74 
2.8.3 Measurement of TBARS levels ................................................................... 74 
2.8.4 Vitamin E measurements............................................................................. 75 
 iii 
 
2.9.1 Confocal microscopy analysis of α-tubulin and acetylated tubulin ......... 75 
2.9.2 Preparation of cell extracts containing soluble α-tubulin ........................ 76 
2.9.3 Western blot analysis of acetylated tubulin and Tau phosphorylation ... 76 
2.10 Autophagy assessment ...................................................................................... 77 
2.10.1 Cell treatment ............................................................................................. 77 
2.10.2. Western blot analysis of proteins involved in autophagic pathway ..... 77 
2.10.3 Immunocytochemistry of LC3 and Lamp1 .............................................. 78 
2.10.4 Live imaging on AVs movements .............................................................. 79 
2.11 Sirtuin2 modulation .......................................................................................... 80 
2.11.1 Sirtuin2 inhibition with AK1 ..................................................................... 80 
2.12 Animals .............................................................................................................. 81 
2.12.1 Isolation and treatment of primary cortical neurons ............................. 82 
2.12.2 Primary cortical neurons mitochondrial membrane potential (∆Ψm)... 83 
2.12.3 Primary cortical neurons immunobloting................................................ 83 
2.13 Data analysis ...................................................................................................... 84 
Chapter 3 ....................................................................................................................... 85 
Prodromal metabolic phenotype in MCI cybrids: Implications for Alzheimer´s 
disease. ........................................................................................................................... 85 
3.1 INTRODUCTION .............................................................................................. 86 
3.2 RESULTS ............................................................................................................ 88 
3.2.1 Mitochondrial metabolism alterations ....................................................... 88 
3.2.2 Mitochondria: ultrastructure and distribution. ........................................ 90 
3.2.3 Oxidative stress markers are increased in AD, MCI cybrids and patients 
plasma. .................................................................................................................... 93 
3.2.4 Mitochondrial Aβ monomers/oligomers content. ...................................... 95 
3.3 DISCUSSION ...................................................................................................... 95 
Chapter 4 ..................................................................................................................... 101 
 iv 
 
Bioenergetic Flux, Mitochondrial Mass, and Mitochondrial Morphology Dynamics 
in AD and MCI Cybrid Cell Lines ............................................................................ 101 
4.1 INTRODUCTION ............................................................................................ 102 
4.2 RESULTS .......................................................................................................... 103 
4.2.1 COX Vmax activities .................................................................................. 103 
4.2.2 Oxygen and glucose fluxes ......................................................................... 105 
4.2.3 Energy and redox intermediates ............................................................... 108 
4.2.4 Flux modifying genes and proteins ........................................................... 111 
4.2.5 Mitochondrial mass and morphology ....................................................... 119 
4.3 DISCUSSION .................................................................................................... 124 
Chapter 5 ..................................................................................................................... 131 
Sirtuin 2-dependent mechanism of microtubule network disruption and 
autophagic-lysosomal pathway failure in Alzheimer´s disease .............................. 131 
5.1 INTRODUCTION ............................................................................................ 132 
5.2 RESULTS .......................................................................................................... 133 
5.2.1 Loss of mitochondral potential correlates with mitochondria network 
alterations in MCI and sAD cybrids. ................................................................. 133 
5.2.2 Mitochondrial dynamics is altered in sAD cells harboting patient 
mitochondria. ....................................................................................................... 136 
5.2.3 SIRT2 activation induce microtubule network deficits. ......................... 139 
5.2.4 Microtubule breakdown impairs autophagy completion. ...................... 143 
5.2.5 Autophagic deficits in sAD cells. ............................................................... 146 
5.2.6 Mitophagy alterations in MCI and sAD cells. ......................................... 149 
5.2.7 Lysosomal inhibition induces AD related features ................................. 151 
5.2.8 Sirtuin 2 loss of function prevents ALP dysfunction through the 
restoration of tubulin acetylation. ..................................................................... 154 
5.3 DISCUSSION .................................................................................................... 157 
Chapter 6 ..................................................................................................................... 159 
 v 
 
Concluding Remarks .................................................................................................. 159 
Chapter 7 ..................................................................................................................... 163 
REFERENCES ........................................................................................................... 163 
 
 
 vi 
 
 
SUMMARY   
 
The etiology of sporadic Alzheimer´s disease remains largely unknown. Data from 
literature show that a bioenergetics failure, especially due to mitochondrial dysfunction, 
is a common event in Alzheimer’s disease and mild cognitive impairment, a clinical 
syndrome that frequently precedes symptomatic Alzheimer´s disease. Mitochondria 
play a pivotal role in cellular metabolism since they regulate key aspects of cellular 
metabolism by ATP production, also have important functions in intracellular calcium 
homeostasis, endogenous reactive oxygen species production and decide cellular fate by 
regulating programmed cell death.  
The use of cytoplasmic hybrid cell lines that contain mitochondria from Alzheimer´s 
disease and mild cognitive impairment subjects allow to infer that mitochondrial 
dysfunction, through complex IV decreased activity, are an upstream event in the 
pathology of Alzheimer´s disease. Further, the transfer of mitochondria from 
Alzheimer´s disease subjects, mild cognitive impairment and control subjects to 
mtDNA depleted cells enable to study downstream events driven by mitochondrial 
dysfunction. Previous studies using Alzheimer´s disease cybrids showed decreased 
complex IV, we extended these results by showing that in mild cognitive impairment 
cybrids complex IV dysfunction is also present. Besides decreased complex IV activity, 
Alzheimer´s disease and mild cognitive impairment cybrids also exhibit decreased 
mitochondrial membrane potential which favors the release of cytochrome c, an initiator 
of programmed cell death. Mitochondrial network is disrupted and more susceptible to 
stress in both groups. Also, oxidative stress markers are increased in Alzheimer´s 
disease cybrids while mild cognitive impairment cybrids did not reach the same 
damaged state.  
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Since we have established that mitochondrial dysfunction is present in both groups of 
study we moved to evaluate its downstream effects. We found that mitochondrial 
respiration is decreased and mitochondrial oxidative phosphorylation is less coupled in 
Alzheimer´s disease and mild cognitive impairment cybrids. This drives a decrease in 
ATP/ADP ratio and activates a number of compensatory response pathways like 
AMPK. This is accompanied by a shift of Sirtuin1 from the nucleus to the cytosol and a 
decrease in its phosphorylation as well as a decrease in PGC1α levels. Nevertheless 
mitochondrial copy number as well as other markers for mitochondrial mass are 
increased.  
Our next goal was to access macroautophagy state in both goups. Macroautophagy is 
responsible for the degradation of protein aggregates and dysfunctional mitochondria, in 
a process called mitophagy. If this process is compromised in Alzheimer´s disease that 
may be explanation for the conflicting results on mitochondrial content stated above. 
Cytoplasmic hybrid cell lines were differentiated into neurons to have better 
understanding of the pathogenic processes on the brain. We found that mitochondrial 
network in Alzheimer´s disease and mild cognitive impairment groups is less 
interconnected and fragmented. This is in accordance with increased levels of proteins 
that orchestrate mitochondrial fission such as DRP1 and Fis1 and unchanged proteins 
responsible for mitochondria fusion, OPA1, MFN1 and 2. Further, the rise in the levels 
of Sirtuin2 in AD cybrids, a tubulin deacetylase that we found to be located only in the 
cytosol of differentiated cybrids, cause the breakdown of microtubules, which does not 
allow the completion of macroautophagic process since the transport of 
autophagosomes along microtubules to lysosomes is impeded in Alzheimer´s disease 
cybrids. Surprisingly, mild cognitive impairment cybrids are able to mount 
compensatory responses by increasing macroautophagy and microtubule stability. 
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Because macroautophagy and, consequently mitophagy is impaired in Alzheimer´s 
disease, Abeta oligomers and other protein aggregates will accumulate and cause further 
toxicity. The exposure of Alzheimer´s disease cybrids to Sirtuin2 specific inhibitor 
AK1, prevented the loss of acetylated tubulin and consequently ameliorated 
macroautophagy process and the clearance of Abeta oligomers.  
In this thesis we show that mitochondrial dysfunction present in Alzheimer´s disease 
and mild cognitive impairment cybrids, triggers several pathways of the cellular 
metabolism including Sirtuin2 activation, which damages microtubules and 
compromises macroautophagy. We provide insights that mitochondrial regulation of 
microtubule-dependent cellular traffic compromises the degradation of aberrant protein 
aggregates and dysfunctional mitochondria. This innovate viewpoint of Alzheimer´s 
disease may pave the path for new therapeutic strategies targeting Sirtuin2, aiming to 
restore microtubule network proper function.  
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SUMÁRIO  
 
A etiologia da doença de Alzheimer permanece amplamente desconhecida. Várias 
evidências têm mostrado que a disfunção bioenergética, especialmente a disfunção 
mitocondrial, ocorre na doença de Alzheimer e em défice cognitivo ligeiro, uma 
síndrome que frequentemente precede a sintomatologia da doença de Alzheimer. As 
mitocôndrias têm um papel primordial no metabolismo celular pois regulam aspetos 
chave do metabolismo celular sendo responsáveis pela produção de ATP, têm funções 
importantes na homeostasia do cálcio intracelular, na produção de espécies reativas de 
oxigénio e decidem o destino celular regulando a morte celular programada. O uso de 
linhas celulares de híbridos citoplasmáticos, que contêm mitocôndrias de sujeitos 
portadores de doença de Alzheimer e défice cognitivo ligeiro, permite inferir que a 
disfunção mitocondrial, através do decréscimo da atividade do complexo IV é um 
evento precoce na patologia da doença de Alzheimer. Ademais a transferência de 
mitocôndrias de pacientes da doença de Alzheimer, defeito cognitivo ligeiro e controlos 
para células depletadas do seu ADN mitocondrial, permite o estudo de eventos devidos 
e posteriores à disfunção mitocondrial. Estudos já efetuados recorrendo aos cíbridos da 
doença de Alzheimer mostraram um decréscimo na atividade do completo IV. Nós 
mostramos que também os cíbridos de défice cognitivo ligeiro têm um compromisso na 
actividade do complexo IV. Para além desta alteração no complexo IV, os cíbridos da 
doença de Alzheimer e défice cognitivo ligeiro também exibem um decréscimo no 
potencial de membrana mitocondrial o que favorece a libertação de citocromo c, um 
iniciador da morte celular programada. A rede mitocondrial está interrompida e mais 
susceptível a stress em ambos os grupos. Os marcadores de stress oxidativo estão 
aumentados nos cíbridos da doença de Alzheimer enquanto os cíbridos de défice 
cognitivo ligeiro ainda não atingem o mesmo nível de dano. Como estabelecemos que a 
 x 
 
disfunção mitocondrial está presente em ambos os grupos de estudo avaliamos os seus 
efeitos posteriores. Descobrimos que a respiração mitocondrial está decrescida e a 
fosforilação oxidativa mitocondrial está menos acoplada nos cíbridos da doença de 
Alzheimer e de défice cognitivo ligeiro. Tal conduz a um decréscimo no rácio 
ATP/ADP e ativa um número de respostas compensatórias como a via da AMPK. Tal é 
acompanhado por uma mudança na compartimentação da Sirtuina1 do núcleo para os 
citosol e uma diminuição da sua fosforilação tal como uma diminuição nos níveis de 
PGC1α. No entanto o número de cópias de DNA mitocondrial, tal como outros 
marcadores de massa mitocondrial estão aumentados.  
O nosso próximo objetivo foi determinar a via da macroautofagia em ambos os grupos. 
A macroautoafagia é responsável pela degradação de agregados proteicos e 
mitocôndrias disfuncionais, por um processo denominado mitofagia. Se este processo se 
encontrar comprometido na doença de Alzheimer então os resultados acima descritos 
sobre o aumento do conteúdo mitocondrial pode ser explicado. As linhas de híbridos 
citoplasmáticos foram diferenciadas em neurónios para obter um melhor entendimento 
dos processos patogénicos no cérebro. Descobrimos que a rede mitocondrial nos grupos 
de doença de Alzheimer e défice cognitivo ligeiro está menos interconectada e 
fragmentada. Esta observação está de acordo com os níveis elevados de proteínas que 
orquestram a fissão mitocondrial, tal como DRP1 e Fis1, e os níveis inalterados de 
proteínas responsáveis pela fusão mitocondrial, OPA1, MFN1 e 2.  
O aumento nos níveis proteicos da Sirtuina2, uma deacetilase da tubulina que 
encontrámos localizada apenas no citosol dos cíbridos diferenciados, causa o colapso 
dos microtúbulos o que não permite a completação do processo macroautofágico pois o 
transporte de autofagossomas, ao longo dos microtúbulos, está impedido nos cíbridos de 
doença de Alzheimer. Surpreendentemente os cíbridos de défice cognitivo ligeiro 
 xi 
 
conseguem orquestrar respostas compensatórias aumentando a macroautofagia e a 
estabilidade dos microtúbulos. Devido ao comprometimento da macroautofagia e, 
consequentemente da mitofagia, os oligómeros de Abeta e outros agregados proteicos 
vão acumular agravando a toxicidade celular. A exposição dos cíbridos de Alzheimer a 
um inibidor específico da Sirtuina2, AK1, preveniu a perda de tubulina acetilada e, 
consequentemente melhorou o processo autofágico e a degradação dos oligómeros de 
Abeta.  
Nesta tese mostramos que a disfunção mitocondrial, amplamente presente nos cíbridos 
da doença de Alzheimer e défice cognitivo ligeiro, está envolvida em várias vias do 
metabolismo celular promovendo alterações do estado redox, activação da Sirtuina2 o 
que causa danos nos microtúbulos e compromete a macroautofagia. Nós mostramos que 
a regulação do tráfego dependente dos microtúbulos pela mitocôndria compromete a 
degradação de agregados proteicos aberrantes bem como mitocôndrias disfuncionais. 
Este inovador ponto de vista da doença de Alzheimer pode favorecer o aparecimento de 
novas estratégias terapêuticas visando a Sirtuina2, tendo como objetivo restaurar a 
função da rede microtubular.  
 xii 
 
 
LIST OF ABBREVIATIONS 
 
 ketoglutarate dehydrogenase complex (KDHC) 
2-deoxyglucose (2-DG) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) 
8-hydroxy-2-deoxyguanosine (2DG) 
Activity-dependent neuroprotective protein (ADNP) 
Adenosine diphosphate (ADP) 
Adenosine monophosphate (AMP) 
Adensine triphosphate (ATP) 
Alzheimer’s disease (AD) 
AMP-activated protein kinase (AMPK) 
Amyloid precursor protein (APP) 
Amyotrophic lateral sclerosis (ALS) 
Apolipoprotein E gene (APOE) 
Autophagic lysosomal pathway (ALP) 
Autophagic vacuole (AV) 
Beta amyloid (Aβ) 
Bovine serum albumin (BSA) 
Carbonyl cyanide-p-trifluoromethoxyphenylhydrazone (FCCP)       
 xiii 
 
Central nervous system (CNS) 
Citrate synthase (CS) 
Clinical Dementia Rating Sale (CDR) 
Coenzyme Q (CoQ) 
Complementary DNA (cDNA) 
Cyclin-dependent protein kinase 5 (cdk5) 
Cytochrome oxidase (COX) 
Cytoplasmic hybrid (Cybrid) 
Davunetide (NAP) 
Dihydroehidium (DHE) 
Dimethyl sulfoxide (DMSO) 
Dinitrophenylhydrazine (DNPH) 
Ditiotreitol (DTT) 
Dulbecco’s modified Eagle’s medium (DMEM) 
Dynamin related protein (Drp) 
Electron microscopy (EM) 
Electron transport chain (ETC) 
Ethylene glycol tetraacetic acid (EGTA) 
Ethylenediamine tetraacetic acid (EDTA) 
Fetal Bovine Serum (FBS) 
 xiv 
 
Fission 1 (Fis1) 
Glutathione peroxidase (GPx) 
Glutathione reductase (GR) 
High Performance Liquid Chromatography (HPLC) 
Histone deacetylases (HDAC) 
Huntinton’s disease (HD) 
Hydrogen peroxide (H2O2) 
Hypoxia-inducible factor 1-alpha (HIF1α) 
Knock-out (KO) 
Lipoic acid (LA) 
Lysosomal Storage Diseases (LSD) 
Malondialdehyde (MDA) 
Mammalian target of rapamycin (mTOR) 
Microtubule associated protein (MAP)  
Microtubule-associated protein light chain 3 (LC3) 
Mild cognitive impairment (MCI)  
Mini Mental State Examination (MMSE) 
Mitochondrial DNA (mtDNA) 
Mitofusin (Mfn) 
Mitogen-activated protein kinase (P38) 
 xv 
 
Neurofibrillary tangle (NFT) 
Nicotinamide adenine dinucleotide (NAD) 
Nicotinamide mononucleotide adenylyltransferase (NMNAT) 
Nicotinamide phosphoribosiyltransferase (NAMPT) 
Nitric oxide (NO) 
Non-glycolysis extracellular acidification rate (ECAR) 
Optic atrophy 1 (Opa1) 
Oxygen consumption rate (OCR) 
Parkin-interacting substrate (PARIS) 
Peroxisome proliferator activated receptor gamma coactivator 1 (PGC1α) 
PGC-1-related coactivator (PRC) 
Phenylmethanesulfonyl Fluoride (PMSF) 
Phosphate buffered saline (PBS) 
Polythylene glycol (PEG) 
Polyvinylidene difluoride (PVDF) 
Presenilin (PS1) 
Pyruvate dehydrogenase complex (PDHC) 
Quantitative real-time PCR (qPCR) 
Reactive oxygen species (ROS) 
Reduced Nicotinamide adenine dinucleotide (NADH) 
 xvi 
 
Retinoic acid (RA) 
Sirtuin (SIRT) 
S-nitrosocysteine (SNOC) 
S-nitrosylation (SNO) 
Sodium dodecyl sulfate (SDS) 
Superoxide dismutase (SOD) 
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
Tetramethylrhodamine, methyl ester (TMRM) 
Thiobarbituric acid reactive substances (TBARS) 
Transcription factor A of the mitochondria (TFAM) 
Translocase of outer membrane (TOM) 
Tris-beffered saline (TBS) 
Wild-type (WT) 
 
 
 
 
 17 
 
 
 
CHAPTER 1 
 
 
 
General introduction
Chapter 1 | General Introduction 
 
18 
 
 
1.1 INTRODUCTION 
 
Alzheimer's Disease (AD) is a progressive and chronic condition, accounting for 65-
70% of all dementia cases and, consequently, is a major health and socioeconomic 
problem (Rosa et al., 2014). Since Alois Alzheimer’s first reports were presented and 
published at the begining of the 20th century (Alzheimer, 1907, 1911; Alzheimer et al., 
1995), a boost in AD research occurred, nevertheless, successful therapies that can cure, 
or even alleviate the disease are still out of reach (Hunter and Brayne, 2013). The 
identification of a major mitochondrial metabolic deficiency in AD patient’s brains and 
or peripheral cell models opened new windows for the identification of new therapeutic 
targets. The recognition that mitochondrial function decays with age places ageing has a 
pivotal risk factor for the development of AD (Lin and Beal, 2006; Swerdlow et al., 
2010, 2013; Swerdlow and Khan, 2009). It is believed that genetic and environmental 
factors may act synergistically in the onset of the sporadic AD (Bicalho et al., 2013; 
Meng and D'Arcy, 2013). Mitochondrial dysfunction likely starts a cascade of events 
that spread across specific neurons and culminate with neuronal loss across the brain.  
 
1.2 Ageing as a risk factor for AD 
Mutations dominantly inherited in presenilin-1 (PS-1), presenilin-2 (PS-2) and amyloid 
precursor protein (APP) allow to explain the early-onset familial forms of AD although 
only a small percentage, about 13% of patients, exhibit this familial trait (Bettens et al., 
2013; Campion et al., 1999). The vast majority of AD patients develop this condition 
later in life where mutations are rarely found (Shepherd et al., 2009). Characterized to 
be multi-factorial and heterogeneous, sporadic AD may be the result of stochastic 
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driven ageing process. Ageing exerts a deleterious effect on neuronal activity and there 
have been some clues stating environmental and epigenetic variations that contribute to 
AD pathology (Cacabelos, 2007; Cacabelos et al., 2005). Genetic analyses suggest that 
several genes exert influence in the susceptibility of an individual to develop AD 
(Mattson, 2004). The ε4 allele of the apolipoprotein E (apoE) gene was identified as a 
major risk factor for late-onset AD across populations (Belinson and Michaelson, 2009; 
Chang et al., 2013; Raber et al., 2004). APOE plays an important role in the metabolism 
of lipoproteins and cholesterol and has been associated with increased deposition of Aβ, 
brain inflammation, impaired neuronal plasticity and repair (Belinson and Michaelson, 
2009; Rhinn et al., 2013). Even though the correlation between the presence of APOE 
alleles and the emergence of AD sporadic cases is well documented, their products, 
even present in homozygoty, are not determinants for AD development (Laws et al., 
2003). Besides, in the vast majority of AD sporadic cases the referred alleles are absent. 
The etiology of sporadic AD remains elusive and, in the last years, the first steps have 
been taken in order to find therapeutic targets that allow a true beneficial outcome, 
which is mandatory since this disease represents a major health problem in developed 
societies, and is predicted to increase disproportionately as the global elderly population 
increases (Da et al., 2013). 
 
1.3 Mitochondrial function in AD 
Proposed by Swerdlow and Khan (Swerdlow and Khan, 2004), the ‘mitochondrial 
cascade hypothesis’ enabled to compass some handicaps of another proposed theory for 
AD etiology, the ‘Aβ cascade hypothesis’ first proposed by Hardy and Selkoe in 2002 
(Hardy and Selkoe, 2002). These authors stated that the primordial event in AD 
etiopathology is the production of Aβ derived from APP processing and that its brain 
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accumulation culminates in generalized neurodegeneration. More recently, it was 
suggested that this theory should only be applied to familial early-onset AD cases 
(Castello and Soriano, 2013; Swerdlow, 2007b). Mitochondrial cascade hypothesis 
relies on the central idea that similar mechanisms underlie brain ageing and AD 
(Swerdlow, 2012b). Mitochondrial dysfunction is believed to occupy an upstream 
position in the pathogenesis of the disease, giving rise to the histopathological and 
pathophysiological features of AD (Swerdlow et al., 2010, 2013; Swerdlow and Khan, 
2009). Supporting Swerdlow and Khan point of view is the systemic mitochondrial 
dysfunction in AD, which cannot simply represent a consequence of neurodegeneration 
(Swerdlow, 2007b; Swerdlow et al., 2013). 
 
 
 
 
 
 
 
 
 
Figure 1. Mitochondrial Cascade Hypothesis for sporadic Alzheimer´s disease (Adapted from 
Swerdlow, 2012). 
 
In addition, inherited polymorphic variations of mtDNA (mitochondrial DNA), together 
with the age-related mitochondrial changes, determine a functional threshold that when 
is reached triggers AD-characteristic histopathology (Swerdlow et al., 2010, 2013; 
Swerdlow and Khan, 2009). The mitochondrial dysfunction and consequent superoxide 
Chapter 1 | General Introduction 
 
21 
 
anion overproduction seems to be the bridge between ‘mitochondrial cascade 
hypothesis’ and ‘Aβ cascade hypothesis’. Over the years many evidences have been 
presented in order to unify the cellular processes responsible for ageing, mitochondrial 
dysfunction and, consequently, neurodegenerative diseases, such as late onset AD. A 
number of studies have demonstrated that mitochondrial integrity declines with age 
(Breitenbach et al., 2013; Gomes et al., 2013; Shigenaga et al., 1994), affecting multiple 
brain functions such as memory, learning and sensory processes (Aliev et al., 2009; 
Boumezbeur et al., 2010). Age dependent mitochondrial abnormalities leads to the 
decline of mitochondrial function, namely decreased oxidative phosphorylation and 
ATP synthesis mainly due to an increase in superoxide anion production and 
accumulation of mtDNA mutations (Beal, 2005; Shi et al., 2008; Wang et al., 2013). 
Experiments performed with platelets from AD patients, age-matched controls and 
young control subjects showed that mitochondrial membrane potential was higher in 
young controls than in AD patients and aged control subjects (Shi et al., 2008). These 
observations point to mitochondrial dysfunction occurring during ageing that can 
predispose elderly individuals to age related disorders. To further support the rational of 
mitochondrial dysfunction as an early event in AD etiology, subjects with Mild 
Cognitive Impairment (MCI), considered a nosological entity or a translational state 
between normal ageing and AD (Morris et al., 2001; Padurariu et al., 2010), have been 
studied. The early markers of metabolic dysfunction observed in AD have also been 
found in MCI subjects, such as mtDNA oxidative damage, reported as a major risk for 
AD development and progression (Manczak et al., 2004; Migliore et al., 2005). Studies 
made in lymphocytes showed significantly higher levels of primary oxidative mtDNA 
damage in AD and MCI subjects compared with control subjects (Migliore et al., 2005).  
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In the AD brain, particular enzymes that mediate glucose metabolism may have either 
altered amounts or altered Vmax activities. For example, the neuron enolase is highly 
expressed, and also shows a high degree of oxidative modification (Butterfield and 
Lange, 2009). Within the mitochondria themselves, the measured activities of pyruvate 
dehydrogenase complex (PDHC) and the Krebs cycle enzyme α-ketoglutarate 
dehydrogenase complex (KDHC), are reduced (Gibson et al., 1998). The KDHC 
activity reduction is likely a consequence of post-translational modification due to 
oxidative stress (Shi et al., 2011). The activity of isocitrate dehydrogenase, another 
proximal Krebs cycle enzyme, is reduced. Activities of enzymes in the distal Krebs 
cycle, including succinate dehydrogenase and malate dehydrogenase, are increased 
(Gibson et al., 2010). 
Regarding the electron transport chain (ETC), COX activity has consistently been 
observed to be lower in AD subject brains than it is in control subject brains (Swerdlow, 
2011a; Swerdlow and Kish, 2002). Histochemical approaches reveal that AD brain 
hippocampi contained higher numbers of COX-activity deficient neurons (Cottrell et al., 
2001). Some studies have suggested neuroanatomically limited reductions, which are 
consistent with the possibility that the COX activity deficit is due to reduced synaptic 
activity (Simonian and Hyman, 1993). Other studies have utilized spectrophotometric 
Vmax measurements from brain homogenates (Swerdlow and Kish, 2002). In one 
study, dividing the COX Vmax to the density of a COX protein subunit on a Western 
blot rendered the activity comparable to that of the corrected control group activity 
(Kish et al., 1999). The authors concluded reduced COX in AD brains is a consequence 
of reduced COX enzyme. Another study, though, found that COX activity, when 
divided by the amount of spectrally determined COX was still low (Parker and Parks, 
1995). It was further demonstrated that COX kinetics were altered, and that the 
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holoenzyme’s low KM binding site was absent. These data argue that COX is 
structurally altered in the AD brain. Peripherally, COX activity was found to be 
decreased in platelets from AD subjects whereas the protein subunits are normally 
present (Cardoso et al., 2004a) and this fact is not a consequence of tissue degeneration, 
ROS (reactive oxygen species)-induced membrane damage, deficient antioxidant 
defenses neither decreased synthesis rates. This data supports the idea that 
mitochondrial dysfunction is a primary or at least a non-amyloid dependent process 
(Cardoso et al., 2004a). Fibroblasts from sporadic AD patients revealed a greater 
amount of abnormal mitochondrial morphology and distribution when compared to age-
matched normal human fibroblasts (Wang et al., 2008a). AD cybrid cell lines 
(cytoplasmic hybrids) have shown to correlate in many ways to AD pathophysiology, 
for instance, decreased COX activity (Cardoso et al., 2004a; Silva et al., 2013a; Silva et 
al., 2013b; Swerdlow et al., 1997), decline in bioenergetics over time in culture 
(Trimmer et al., 2004) and decrease viability in comparison to control cybrids (Onyango 
et al., 2005). It is well accepted that changes observed in AD cybrids recapitulate the 
early events of the disease (Trimmer et al., 2000). Cybrid technique was first described 
by King and Attardi (King and Attardi, 1989) and is based on the central idea that 
cybrid cells lines result from the repopulation of a host mtDNA depleted cell (ρ0) with 
different mtDNA, having the same nuclear background. 
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Figure 2. Cytoplasmic hybrids. ρ0 cell lines are generated by chronically treating an established cell line 
with ethidium bromide (EtBr). This blocks mtDNA replication and leads to its total depletion from the 
EtBr-treated cells. Due to a lack of mtDNA-encoded oxidative phosphorylation complex subunits, the 
resultant cell lines are unable to complete electron transport chain transport and oxidative 
phosphorylation. The ρ0 cells can then be fused with platelets isolated from patient blood samples to 
generate cytoplasmic hybrid (cybrid) cell lines. Cybrid lines contain mtDNA from the platelet donors, and 
nuclear DNA from the ρ0 cell line. This relationship lets investigators study how specific mtDNA 
sequences affect cell bioenergetics, and how these effects infl uence downstream cell biochemical, 
molecular, and physiologic parameters. (Adpated from Silva, 2012). 
 
1.4 AD: a disorder of protein misfolding 
Independent of its etiology, AD is characterized clinically by chronic and progressive 
dementia, including severe memory loss, profound changes in behavior and personality, 
incapacitating patients even in their daily tasks (Mattson, 2004). Histopathological 
hallmarks are intracellular NFT (neurofribrillary tangles) of abnormally phosphorylated 
tau, neuropil threads, dystrophic neurites and extracellular senile plaques composed of 
Aβ (Iqbal and Grundke-Iqbal, 2008). The presence of the referred hallmarks in AD 
brains is a necessary prerequisite for the definitive postmortem diagnosis of AD. 
Anatomically, AD brains are characterized by a severe atrophy, which correlates with a 
reduction of cell density in brain regions involved in learning and memory, as a 
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consequence of generalized degeneration of synapses and death of neurons (Mattson, 
2004). The course of AD neurodegeneration is initiated in the entorhinal cortex and 
spreads to the hippocampus, temporal cortex, frontoparietal cortex and, finally, to 
subcortical nuclei causing severe dementia (Reddy and McWeeney, 2006). Since the 
first description of an AD patient by Alois Alzheimer, some decades were required to 
finally isolate and identify AD-related brain areas and histopathological hallmarks 
(Small and Duff, 2008). This isolation allowed inferring that senile or neuritic plaques 
are mainly composed of deposits of amyloid fibrils surrounded by dystrophic neuritis, 
activated microglia and reactive astrocytes (Sorrentino and Bonavita, 2007). In AD 
brains, Aβ is concentrated around meningeal and cerebral vessels and in the gray matter 
as Aβ plaques (Gotz et al., 2004).  
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Figure 3. Histopatological hallmarks of Alzheimer´s disease brain: a) amyloid plaques, b) 
neurofibrillary tangles. c) Neuronal death results in severe brain shrinkage and d) decreased glucose 
utilization by neuronal cells. (Adapted from LaFerla and Oddo, 2005 and Mattson 2004) 
 
Aβ is a 4 kDa proteolytic fragment that presents more often two carboxyl-terminal 
variants of Aβ: Aβ1-40 mainly secreted from cultured cells and found in cerebrospinal 
fluid and Aβ1-42, which is the main component of amyloid deposits in the brain (Neve et 
al., 2000), resulting from cleavage of amyloid-β precursor protein (βAPP) (Reddy and 
McWeeney, 2006; Selkoe, 2001). APP is a type I integral membrane glycoprotein 
through a single transmembrane domain (Evin et al., 2003), which possesses a large 
extracellular glycosylated N-terminus and a shorter cytoplasmic C-terminus (Marlow et 
al., 2003). Aβ region is located at the cell surface or in the luminal side of endoplasmic 
reticulum and Golgi membranes where part of the peptide is anchored. Along the 
secretory pathway APP is cleaved sequentially by β-secretase (BACE1 a β-site of APP 
cleaving enzyme) at the N-terminal end (Marlow et al., 2003) originating a soluble 
βAPP fragment and a membrane-associated C-terminal fragment, βCTF (Sambamurti et 
al., 2002; Yu et al., 2004). This fragment then suffers cleavage by gamma secretase, a 
proteolytic complex composed of presenilin, nicastrin, APH-1 (anterior pharynx-
defective 1) and PEN-2 (presenilin enhancer 2) (Gotz et al., 2008) at the C-terminal, in 
(
c
) 
(d
) 
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the amyloidogenic pathway (Mattson, 2004) originating a series of beta-sheet 
containing peptides, the Aβ peptides. The second classical neuropathological lesion 
present in AD brains is NFT which consist in intracellular bundles of abnormal fibers 
aggregated into paired helical filaments (Sorrentino and Bonavita, 2007). NFT were 
found to be mainly composed of an abnormally hyperphosphorylated form of the 
microtubule-associated protein, tau. Its physiological functions inside the cell include 
the assembly and stabilization of microtubules (Gotz et al., 2004; Zhang et al., 2009). 
Other roles have been attributed to tau, such as signal transduction, organization of 
neuronal cytoskeleton, intracellular axonal transport, generation of cell polarity and 
shape and anchoring of phosphatases and kinases (Maas et al., 2000; Noble et al., 2013; 
Sorrentino and Bonavita, 2007). NFTs are found in cell bodies, apical and distal 
dendrites and in dystrophic neurites associated with amyloid plaques (Gotz et al., 2008). 
In an AD context, it was shown that tau is 3 to 4 fold more phosphorylated due to the 
activity of some groups of kinases like, glycogen-synthase kinase-3β, cyclin-dependent 
protein kinase 5 (cdk5), c-AMP protein dependent and stress-activated protein kinases 
(Gong and Iqbal, 2008). The consequence of an augmented tau phosphorylation is a 
change in its conformation, its dissociation from microtubules, and a potential increase 
in cell toxicity (Zhang et al., 2009). Ultimately, these changes in microtubule 
conformation affect morphology and biological functions of neurons, such as axonal 
transport deficits (Schwalbe et al., 2013). 
 
1.5 Mitochondrial DNA 
The consensus on the role of mtDNA in sporadic AD development has not been 
reached, namely the discrepant data concerning mtDNA content. These findings are not 
as diametrically opposed as it may seem. The amount of mtDNA may vary from neuron 
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to neuron, and may further associate with the health of the neuron. Healthier neurons 
may have an increased amount of mtDNA, while more affected neurons may have 
decreased amounts. Certainly, in AD brain hippocampi the number of neurons that 
show succinate dehydrogenase activity but which lack COX activity is increased 
(Cottrell et al., 2001). Because succinate dehydrogenase is entirely encoded by nuclear 
genes while COX contains mtDNA-encoded subunits, this suggests AD neurons have 
abnormally high levels of mutated mtDNA, or else a severe state of mtDNA depletion. 
In addition to changes in the content of mtDNA, differences in the quality of mtDNA 
have been reported. A probe specific to mtDNA that detect the 5 kD common deletion 
found in AD brain hippocampal neurons showed a marked increase in the amounts of 
this deletion (Hirai et al., 2001). Other studies using different approaches have also 
found that relative to controls, AD brains contain increased amounts of the 5 kD 
mtDNA deletion (Corral-Debrinski et al., 1994; Hamblet and Castora, 1997). 
Oxidative modifications of the mtDNA are increased in AD brains, as evidenced by 
higher levels of 8-hydroxy-2-deoxyguanosine (2DG) (Mecocci et al., 1994). Oxidation-
related nucleotide modifications can induce replication errors and an accumulation of 
somatic mutations. Some AD brain studies that surveyed mtDNA protein coding genes 
have reported a quantitative increase in the number of these mutations, although others 
have not (Chang et al., 2000; Lin et al., 2002). Another study determined levels of low-
abundance heteroplasmic mutations in the mtDNA D-loop control region. Specific 
mutations were found in AD brains that were not present in control brains, and the 
overall burden of control region mutations was markedly increased in the AD brains 
(Coskun et al., 2004). This study also reported reductions in an mtDNA-derived 
transcript, as well as a decreased mtDNA to nuclear DNA ratio. 
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While some have focused on characterizing presumably somatic, acquired mutations, 
others have probed whether inherited mtDNA sequences and mutations are present. To 
date, particular homoplasmic mtDNA mutations have been reported in AD subjects, but 
the causality of these mutations has been virtually impossible to prove (Swerdlow, 
2011a). In any scenario, inherited homoplasmic mtDNA mutations are at most an 
extremely rare cause of AD. 
Excess deletion mutations have not been demonstrated in AD subject peripheral tissues, 
but it is important to note that in general, deletions are uncommon in some peripheral 
tissues, such as blood, probably because these cells are not post-mitotic. An increase in 
control region point mutations was reported in AD subject lymphocytes (Coskun et al., 
2010). Of course, mtDNA haplogroup association studies have utilized mtDNA from 
blood samples, and a number of these association studies have reported associations 
(Swerdlow, 2011a). 
Studies using cybrid cell lines consistently suggest that if mtDNA does in fact differ 
between AD and control subjects, then these differences are not brain-limited 
(Swerdlow, 2011a). These mtDNA-depleted cell lines, referred to as ρ0 cell lines, do 
not have a functional oxidative phosphorylation apparatus because they lack 13 crucial 
mtDNA-encoded proteins (7 from complex I, 1 from complex III, 3 from complex IV, 
and 2 from complex V). mtDNA contained within the transferred mitochondria 
populates the cell lines and restores their aerobic competence. The resulting unique cell 
lines are true cytoplasmic hybrids because they contain cytosolic components from two 
sources, the original ρ0 cell line and the cells that provided their functional 
mitochondria. Biochemical differences, although often subtle, are demonstrable 
between cybrid cell lines whose mtDNA is reconstituted from different sources. 
Because different cybrid cell lines prepared using the same parent ρ0 line have identical 
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nuclear DNA genes, and because cell lines are expanded and maintained under identical 
conditions, these biochemical differences presumably reflect and arise from differences 
in their mtDNA. 
Additional indirect support for systemic mtDNA differences between AD and non-AD 
individuals comes from AD endophenotype studies. An endophenotype is a partial or 
limited manifestation of a condition that is not sufficient to render a diagnosis of that 
condition. The presence of an endophenotype state does not necessarily indicate the 
affected individual will acquire the condition, although it does infer the individual has 
an increased risk of developing the condition.  
In recent years numerous studies have reported AD-consistent endophenotypes can be 
demonstrated in the asymptomatic, middle-aged offspring of AD subjects. Interestingly, 
these endophenotypes are more profound in the children of AD mothers than they are in 
the children of AD fathers (Swerdlow, 2011a). This suggests that although both parents 
contribute to AD risk, AD mothers contribute to a greater extent. This, in turn, implies 
that a maternally-inherited genetic factor influences the development of AD (Mosconi et 
al., 2010a). 
These AD endophenotype studies have been conducted using metabolic, structural, and 
biochemical approaches. Fluorodeoxyglucose positron emission tomography (FDG 
PET) studies show the children of AD mothers, but not the children of AD fathers, have 
patterns of reduced glucose utilization that resembles patterns observed in AD subjects 
themselves (Mosconi et al., 2007; Mosconi et al., 2009). MRI studies show increased 
atrophy and rates of brain atrophy in the middle-aged offspring of AD mothers as 
compared to the middle-aged offspring of AD fathers (Berti et al., 2011; Honea et al., 
2011; Honea et al., 2010). Oxidative stress and Aβ changes can be observed in the 
children of AD mothers (Mosconi et al., 2010b). As they age, the children of AD 
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mothers accumulate greater amounts of Aβ in their brain parenchyma than do the 
children of AD fathers (Mosconi et al., 2010c). Collectively, these findings suggest that 
a maternally-inherited genetic factor influences AD risk, and that this is more likely to 
be mtDNA than an epigenetic or sex-linked factor. 
 
 
1.6 Mitochondrial driven oxidative stress 
ROS are a frequent by-product of electron leakage from the inner mitochondrial 
membrane during mitochondrial oxidative phosphorylation. It is estimated that up to 4% 
of O2 used by mitochondria is converted to superoxide radical (Hansford et al., 1997; 
Inoue et al., 2003; Markesbery and Lovell, 1998; Morten et al., 2006; Turrens and 
Boveris, 1980), and that approximately 109 to 1011 ROS are produced per cell per day 
(Bonda et al., 2010; Feinendegen, 2002; Ji, 1999; Petersen et al., 2007). Under normal 
conditions, ROS are rapidly cleared by enzymes such as SOD (superoxide dismutase) 1, 
SOD2, catalase, and glutathione peroxidase (GPx). When mitochondria are perturbed, 
however, ROS production may exceed the cell’s ability to neutralize them, resulting in 
oxidative damage to the cell (Smith et al., 2000). Aging itself is associated with elevated 
ROS production by mitochondria (Ames et al., 1995; Shigenaga et al., 1994), and 
accumulation of oxidative damage over time may contribute to the noted association 
between advancing age and AD. Oxidative stress is thought to be one early 
manifestation of AD (Nunomura et al., 2001). Studies in post-mortem AD brains 
indicate widespread oxidative damage. Four-hydroxynonenal and acrolein, which are 
aldehydes produced by lipid peroxidation, and isoprostanes, which are pro-
inflammatory products of arachidonic acid peroxidation, are significantly elevated in 
hippocampi from AD brains (Markesbery and Lovell, 1998; Pratico et al., 1998; Sayre 
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et al., 1997; Singh et al., 2010). This indicates that excessive lipid oxidation occurs in 
the AD brains. Additionally, both nuclear and mitochondrial DNA and RNA also 
display evidence of oxidative damage (Gabbita et al., 1998; Mecocci et al., 1994; 
Nunomura et al., 1999). Brains from individuals affected with AD further display 
increased protein oxidation, as evidenced by carbonyl-alterations of specific proteins 
(Castegna et al., 2002a; Castegna et al., 2002b; Smith et al., 1991; Sultana et al., 2010).  
Many studies suggest that oxidative damage is also present in individuals with MCI, 
(Aluise et al., 2011; Butterfield et al., 2006b; Butterfield et al., 2007; Keller et al., 2005; 
Lovell and Markesbery, 2008; Markesbery and Lovell, 2007; Pratico et al., 2002). In 
fact, data from the literature suggest that levels of oxidative markers directly correlate 
with severity of cognitive impairment as well as symptomatic progression from MCI to 
AD (Ansari and Scheff, 2010; Keller et al., 2005).  
Extensive oxidative damage likely has significant consequences for neurons, as 
oxidative modification of proteins and other molecular components can alter cell 
function (Butterfield et al., 1997; Lauderback et al., 2001; Subramaniam et al., 1997; 
Sultana and Butterfield, 2009). As a major source for ROS production, mitochondria are 
themselves at risk of acquiring oxidative damage. The activities of certain mitochondrial 
enzymes including isocitrate dehydrogenase, PDHC, KDHC, and COX are significantly 
reduced in the AD brain (Aksenov et al., 1999; Bubber et al., 2005; Butterfield et al., 
2006a; Gibson et al., 1998; Manczak et al., 2004; Yates et al., 1990). These enzyme 
impairments may represent a consequence or cause of ROS production, or both. For 
instance, COX dysfunction might further elevate ROS production by stalling electron 
transfer (Barrett et al., 2004; Skulachev, 1996; Sullivan and Brown, 2005; Sullivan et 
al., 2004). Thus, dysfunctional mitochondria in AD may give rise to and perpetuate a 
vicious cycle of oxidant production in which impairment of one mitochondrial enzyme 
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elevates ROS production that in turn impairs the function of other mitochondrial 
enzymes, further increasing ROS production (Bonda et al., 2010; Zhu et al., 2004).  
As discussed before, AD features are not brain limited, and that is also valid for 
oxidative stress damage. One study evaluated the presence of oxidative stress in 
platelets and erythrocytes from controls and AD patients. This study found elevated 
oxidative stress markers in AD patients in the form of thiobarbituric acid-reactive 
substances, nitric oxide synthase activity, and Na,K-ATPase activity, suggesting that 
oxidative stress is present systemically in AD (Kawamoto et al., 2005). Another study 
found that ROS are elevated in circulating neutrophils from AD patients (Vitte et al., 
2004). Plasma from AD subjects shows significantly decreased levels of the 
antioxidants lycopene, lutein, and carotene when compared to plasma from control 
subjects, and leukocytes from AD patients display elevated levels of oxidized DNA 
(Mecocci et al., 2002; Mecocci et al., 1998; Migliore et al., 2005; Morocz et al., 2002).  
Oxidative stress is also ubiquitous in patients with MCI, suggesting that the oxidative 
damage progresses. Interestingly, many studies further suggest that between MCI and 
AD subjects, no major differences in oxidative stress markers, such as malondialdehyde 
and oxidized glutathione, exist (Baldeiras et al., 2008; Bermejo et al., 2008; Padurariu et 
al., 2010). These studies propose that the primary biochemical differences between MCI 
and AD lie in the levels and activity of antioxidants such as superoxide dismutase, 
glutathione peroxidase, and vitamin E. This suggests that a loss of one’s ability to 
compensate for oxidative stress may underlie or else serve as a marker of MCI-to-AD 
progression.  
Additional evidence suggests that oxidative stress markers may correlate with disease 
progression and severity in AD patients. Torres and colleagues recently found that 
plasma levels of malondialdehyde, a lipid peroxidation product, directly associate with 
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impaired cognitive function in AD patients. The authors also found that the ratio of GR 
(glutathione reductase) activity to GPx activity, which provides an indication of a cell’s 
antioxidant capacity, associates with cognitive function (Torres et al., 2011). It has also 
been reported that in AD subjects, serum levels of vitamin E, a dietary antioxidant, 
relate to cognitive status (Baldeiras et al., 2008; Panza et al., 2010).   
Data such as these have encouraged investigators to attempt to develop peripheral AD 
diagnostic and biomarker tests (Burns et al., 2009; Pratico, 2005). While a definitive 
biomarker with adequate sensitivity and specificity remains to be identified, a plethora 
of data suggests that at least on a biochemical and molecular level, AD is a systemic 
disorder. 
 
1.7 Mitochondrial Dynamics in AD 
1.7.1 Mitochondrial morphology 
Mitochondria in AD brains show a cristae disruption and intra-mitochondrial 
accumulations of osmiophilic material (Baloyannis, 2006, 2011; Saraiva et al., 1985). 
There is an increased range of mitochondrial size, with more enlarged mitochondria but 
also elevated numbers of exceptionally small mitochondria (Hirai et al., 2001). Overall, 
the average size of AD neuron mitochondria is smaller than it is in control brain neurons 
(Baloyannis, 2006; Hirai et al., 2001). Altogether these data show that mitochondrial 
network is altered in AD. 
 
1.7.2 Mitochondrial content and Biogenesis 
How mitochondrial mass changes in AD brains is not straightforward. Using PCR-
based approaches to quantify mtDNA reveals genomic DNA samples prepared from AD 
subject brain cortices contains lesser amounts of amplifiable mtDNA (Brown et al., 
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2001; de la Monte et al., 2000). The simplest explanation for this is that AD brains have 
reduced amounts of mtDNA, and by extension a reduced mitochondrial mass. However, 
in a study in which a labeled oligonucleotide probe was used to detect mtDNA in 
hippocampal neurons, an intricate picture emerged (Hirai et al., 2001). mtDNA levels 
were reduced when only mtDNA within normal-appearing mitochondria was 
considered. Nevertheless, a large number of mitochondria were also found within 
phagosomes, and these mitochondria also hybridized with mtDNA oligonucleotide 
probe. When this additional mtDNA was taken into account, the AD hippocampal 
neurons actually contained more mtDNA. 
Mitochondrial mass has been assessed using alternative approaches, including an 
immunochemical quantification of mitochondrial-localized proteins. In one study an 
antibody against an mtDNA-encoded cytochrome oxidase (COX) subunit, COX1, was 
found to be increased in AD brain hippocampal neurons (Hirai et al., 2001). In a 
different study, tangle-free hippocampal neurons showed more COX1 and COX4 
staining, while staining was markedly reduced in tangle-bearing neurons (Nagy et al., 
1999). Other authors reported cytochrome COX protein in general was reduced in AD 
brain homogenates (Kish et al., 1999). Since immunobloting for mtDNA-encoded 
proteins is a very indirect index of mitochondrial mass, mtDNA expression in the form 
of mitochondrial RNA has also been evaluated. Northern blot-based studies found 
some, but not all, mitochondrial RNA transcripts were reduced (Chandrasekaran et al., 
1994), and nuclear-encoded oxidative phosphorylation subunit expression was also 
reduced (Liang et al., 2008). Findings from other studies suggest a more complex 
picture. For example, Manczak and colleagues reported COX subunit expression was 
actually increased in at least some AD brain neurons (Manczak et al., 2004). The 
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authors concluded this up-regulation might represent a compensatory response to 
perturbed COX function.  
Electron microscopy (EM) has been used to quantify AD neuron mitochondria. Several 
studies have reported the number of normal appearing mitochondria was decreased 
(Baloyannis, 2006; Hirai et al., 2001). In one study there was a concomitant increase in 
mitochondria located within phagosomes (Hirai et al., 2001). 
Collectively these studies suggest that within the AD brain the total number of 
mitochondria is increased despite the normal-appearing mitochondria are diminished. 
Whether this reflects decreased turnover, decreased synthesis, or both is not entirely 
clear. Potentially pertinent to this question, two relatively recent studies measured 
protein levels of peroxisome-proliferator activated receptor gamma coactivator 1 
(PGC1a), a transcriptional co-activator that serves as a master regulator of 
mitochondrial mass (Qin et al., 2009; Sheng et al., 2012). Both these studies found 
PGC1a levels were reduced in AD brains. 
 
1.7.3 Mitochondrial Fusion and Fission 
Mitochondrial dynamics impairment has been widely implicated in neurodegenerative 
disorders such as AD (Chan, 2006a; Su et al., 2010). Mitochondria can undergo 
consecutives cycles of fusion – two mitochondria fuse giving origin to only one 
organelle; and fission -  where occurs a breakdown of a mitochondrion in other smaller 
parts (Detmer and Chan, 2007), relying on a large group of conserved proteins, the 
dynamin-related GTPasesA balance between these two events is crucial to maintain 
mitochondrial functional integrity, especially in neurons where mitochondrial fission 
and fusion are mandatory for the formation of synapses and dendritic spines (Arduino et 
al., 2011). Mitochondrial fission enables the isolation of deficient mitochondria and 
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allows their removal by autophagy, specifically, mitophagy, whereas mitochondrial 
fusion is required for mtDNA complementation and precedes the isolation of healthier 
mitochondrial pools.  
 
 
 
 
 
 
 
 
Figure 4. Mitochondrial life cycle. The mitochondrial life cycle starts with growth and division of pre-
existing organelles (biogenesis) and ends with degradation of impaired or surplus organelles by 
mitophagy (turnover). In-between, mitochondria undergo frequent cycles of fusion and fission that allow 
the cell to generate multiple heterogeneous mitochondria or interconnected mitochondrial networks, 
depending on the physiological conditions. (Adapted from Seo et al., 2010). 
 
Fusion is orchestrated by mitofusins, Mfn1 and Mfn2, which are responsible for outer 
membrane fusion and Opa1 (Optic atrophy 1), involved in fusion of outer and 
intermembranes. On the other hand fission requires Drp1 (Dynamin related protein) to 
start the formation of a ring-like complex within mitochondrial surface that constricts 
the organelle initiating fission. Then, complete constriction of the membranes takes 
place via hFis (Fission 1) (Chan, 2006b; Yoon et al., 2003). Analyses of AD brains 
show down regulation of the Mnf1, Mnf2, and Opa1 fusion genes and increased 
expression of the Fis1 fission gene (Manczak et al., 2011b; Wang et al., 2009). The 
variation in the levels of fission-mediating protein, Drp1, are less clear since it has been 
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reported a reduction and an increase (Manczak et al., 2011a; Wang et al., 2009). 
Regardless, Drp1 activity is inactivated by S-nitrosylation (SNO-Drp1), and Cho and 
colleagues reported high levels of SNO-Drp1 in brain biopsies from AD subjects (Cho 
et al., 2009). Increased Drp1 activity could lead to perturbed mitochondrial fission, 
which would result in an accumulation of fragmented and bioenergetically impaired 
mitochondria, and ultimately reduce synapse energy supplies (Barsoum et al., 2006).  
Drp1, Opa1, Mfn1, Mfn2, and Fis1 proteins re-distribute so that they accumulate in the 
cell soma. Neuronal processes are therefore depleted of these fission-fusion proteins 
(Wang et al., 2009). The authors of this study also manipulated mitochondrial fission-
fusion proteins in M17 cells and hippocampal primary neurons, and found this affected 
intracellular mitochondrial distributions. They concluded altered mitochondrial fission-
fusion protein dynamics may play an important role in mitochondrial distribution and, 
consequently, synaptic dysfunction in AD neurons.  
 
 
Figure 5. Dynamics of the mitochondrial network in mammalian cells. During fusion, two 
mitochondria dock through coiled-coil-domain interactions between mitofusins that are anchored into the 
outer mitochondrial membrane (OMM; their GTPase domains face the cytosol), whereupon optic atrophy 
protein 1 (OPA1), which is anchored partially on the inner mitochondrial membrane (IMM), participates 
in the membrane fusion process b). During fission, fission protein 1 (Fis1) circumscribing the outer 
B A 
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mitochondrial membrane recruits the large GTPase and dynamin-like protein 1 (DRP1) through its 
tetratricopeptide repeats (TPR), which subsequently coalesces into foci at mitochondrial scission sites c). 
(Adapted from Youle and Karbowski, 2005). 
 
In primary cortical neuronal cultures exposed to S-nitrosocysteine (SNOC), a nitric 
oxide (NO) donor, uncontrolled fission occurs and this appears to represent an upstream 
and early event in SNOC-induced neuronal death (Barsoum et al., 2006). Further, when 
mitochondrial fission is blocked by expression of the dominant negative Drp1K38A, 
cell death is reduced. Accordingly, when cultured cerebrocortical neurons were exposed 
to Aβ, S-nitrosylation of Drp1 occurred and resulted in the formation of SNO-Drp1 
dimers (Westermann, 2009). This pattern is similar to what is found in the brains of 
human AD patients (Cho et al., 2009). 
Along with changes in brain metabolism a great number of studies performed in 
peripheral tissues allow us to suggest that AD can constitute a systemic disease 
affecting several tissues. Similarly, M17 cells that over-express wild type APP or APP 
carrying the Swedish mutation show mitochondrial fragmentation and redistribution of 
their mitochondria (Wang et al., 2008b). In both sporadic AD fibroblasts and M17 cells 
over-expressing APP, mitochondria cluster in the perinuclear region while the number 
of mitochondria in the cell periphery falls. Whether perturbed mitochondrial fission and 
fusion in sporadic AD subject fibroblasts is truly caused by Aβ overproduction is 
unclear, but the simple fact that mitochondrial dynamics are altered outside the brains of 
sporadic AD subjects contributes to the increasing realization that at biochemical and 
molecular levels, AD is not a brain-limited disease (Wang et al., 2008a).   
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1.7.4 Mitochondrial metabolic control of intracellular cargo transport 
Neurons are highly differentiated cells with widespread synapses, branched dendritic 
arbors, and axons that can achieve a considerable size. The delivery of mitochondria to 
regions of the neuron with high bioenergetics demand is required for proper neuron 
function (Hollenbeck and Saxton, 2005; Li et al., 2004; MacAskill et al., 2010; Mattson 
et al., 2008). This mitochondrial transport is impaired in a number of neurodegenerative 
disorders. For example, it has been reported that mutant huntingtin protein in 
Huntington’s disease enhances mitochondrial Drp1 activity, disrupts mitochondrial 
trafficking, and induces mitochondrial fission (Reddy and Shirendeb, 2011). 
Anterograde mitochondrial transport is significantly reduced in neuronal cultures of 
SOD1-mutant mice, suggesting that impaired mitochondrial trafficking is an early event 
in amyotrophic lateral sclerosis (ALS) (De Vos et al., 2007). Additionally, 
mitochondrial transport is impaired in dopaminergic neurons from a Parkinson’s disease 
(PD) mouse model (Sterky et al., 2011). Given the prevalence of altered mitochondrial 
transport in other neurodegenerative diseases, it is likely that this critical phenomenon is 
also impaired in AD. Indeed, mitochondrial distribution is abnormal in AD brains 
(Wang et al., 2009). One study showed that mitochondrial transport in AD patient 
brains is significantly decreased compared to control brains (Dai et al., 2002). In an 
elegant study by Trimmer and Borland, fluorescently-labeled mitochondria in 
differentiated cybrid cell lines generated from AD patients displayed reduced trafficking 
to neurite-like processes compared to control cybrid lines (Trimmer and Borland, 2005). 
This study provides further evidence that mitochondrial transport may be impaired in 
AD. Additionally, this study suggests that impaired mitochondrial transport in AD is 
mediated by mitochondrial function itself and ultimately by mtDNA. Other studies 
suggest that mitochondrial transport is altered in cell cultures treated with Aβ (Calkins 
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and Reddy, 2011; Wang et al., 2009) and in mouse models of AD (Calkins et al., 2011; 
Massaad et al., 2010; Pigino et al., 2003). In general, it appears that Drp1 changes of 
expression may impair mitochondrial transport by perturbing a functional relationship 
that exists between Drp1 and the dynein-dynactin transport complex (Ishihara et al., 
2009; Varadi et al., 2004; Wang et al., 2009). Therefore, although mitochondrial 
transport is certainly difficult to study in the autopsy brain, data suggest that in AD 
perturbed mitochondrial fission-fusion dynamics may contribute to the apparent 
presence of impaired mitochondrial transport. Intracellular transport relies on 
microtubules that wire neuronal cell body to the synapse. It has been widely 
documented that AD neurons have changes at cytoskeleton level being a reduction of 
assembled microtubules evident when compared with control cases (Cash et al., 2003; 
Santa-Maria et al., 2005). Disruption in microtubule dynamics results in incapacity of 
many subcellular processes to go on, which conducts to retrograde degeneration 
accompanied by synaptic loss and neuronal cell death (Li et al., 2007a). Evidence points 
to a mitochondrial dysfunction and an increase in superoxide anion production to be the 
cause of redox equilibrium changes, which have a straight influence on microtubule 
disassembly (Santa-Maria et al., 2005). Causative influence of microtubule dysruption 
on tau phosphorylation was studied by Miyasaka and colleagues (Miyasaka et al., 
2010). Authors concluded that microtubule network disruption induces Tau to dissociate 
from microtubules, which leads to a subsequent phosphorylation. Cash and co-workers 
(Cash et al., 2003) found, in brain biopsies of AD patients, alterations in the 
microtubules of pyramidal neurons, mitochondrial abnormalities and increase oxidative 
damage, before detectable changes in Tau. Further, it was demonstrated that in 
SHSY5Y treated with Aβ1-42, mitochondrial dysfunction, microtubule network 
dysruption, results in Tau increased phosphorylation and impairment of the autophagic 
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pathway. Restoring microtubule network assembly with Taxol, a known microtubule 
stabilizer, induced the degradation, by macroautophagy, of Aβ1-42- mediated 
mitochondrial damaged and cell demise is avoided (Silva et al., 2011a). Additionally to 
tau detachment from microtubules, posttranslational modification of tubulin may also 
have a role on microtubule disassemble in AD. Mammalian sirtuins (SIRTs) are 
homologues of the silent information regulator factor 2, first described in 
Saccharomyces cerevisiae (Denu, 2005; Michan and Sinclair, 2007). These proteins 
have been found in organisms from all domains of life, ranging from prokaryotes to 
humans (Moniot et al., 2012). The SIRT family is composed of seven members (SIRT1-
SIRT7) who are characterized by the presence of an approximately 275-amino-acid core 
that require nicotinamide adenine dinucleotide (NAD+) for their enzymatic activity 
(Moniot et al., 2012). These proteins catalyze mainly deacetylation reactions in a variety 
of substrates including histones, transcription factors and apoptotic modulators (Michan 
and Sinclair, 2007; Yu and Auwerx, 2009). Although the molecular mechanisms 
underlying the ageing process are not fully understood, in the last years a body of 
evidence emerged pointing to SIRTs as mediators of life extension, described in a wide 
range of organisms including yeast, insects and rodents (Han, 2009; Outeiro et al., 
2008). It is consensual that SIRTs differ in their sub-cellular localization, where SIRT1, 
SIRT6 and SIRT7 are predominantly in the nucleus, SIRT3, SIRT4 and SIRT5 in the 
mitochondria, whether SIRT2 resides mostly in the cytoplasm (Michan and Sinclair, 
2007). SIRT2 can be found associated with the microtubule network showing affinity to 
acetylated tubulin as a substrate, in comparison to acetylated histone (North et al., 
2003). North and colleagues (North et al., 2003) demonstrated using GFP-SIRT2 that 
SIRT2 deacetylated Lys40 of α-tubulin, and colocalize with the microtubule network. In 
the same experiments, using SIRT2 knockout mice it was shown that tubulin was 
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hyperacetylated. Even though SIRTs have been related with some potential protective 
effects, not everything is perfect in the SIRT world. In fact, SIRT2 activation has been 
reported to promote cell death (Han, 2009). Chong and collaborators (Chong et al., 
2005) demonstrated that nicotinamide, a known inhibitor of SIRTs activity could reduce 
anoxia-induced neuronal injury in primary rat hippocampal neuronal cultures. 
Nicotinamide increased cell viability, prevented caspase activation, reduced DNA 
fragmentation and increased phosphorylation of proteins like Akt (serine/threonine 
protein kinase) and Bad (Bcl-2-associated death promoter), preventing apoptosis. Only 
indirectly we can infer that, at least part of these results is due to SIRT2 inhibition. 
Studies made in a triple-transgenic model of AD (3xTg-AD) expressing APPSwe, 
PS1M146V, and tauP301L transgenes showed that nicotinamide was able to prevent 
cognitive deficits through the inhibition of brain SIRTs associated with increased levels 
of deacetylated tubulin (Green et al., 2008). Further, 3xTg-AD mice at 8 months of age 
have high levels of tau phosphorylation in serine and threonine residues. Remarkably, 
treatment with nicotinamide significantly reduced Thr231-phosphotau (Green et al., 
2008). Since acetylation of tubulin, a primary substrate of SIRT2, was implicated in 
nicotinamide-dependent results, is tempting to infer that SIRT2 inhibition by 
nicotinamide results in neuroprotection in this AD model. But, Wu and co-workers 
recently showed that an analog inhibitor of SIRT2 directly inhibits gamma-secretase 
(Wu et al., 2010). More recently results from cells overexpressing SIRT2 showed that 
inhibits lysosome-mediated autophagic turnover, impairing autopahgic flux (Gal et al., 
2012).  
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1.7.5 Mitochondrial metabolic control of the autophagic-lysosomal pathway 
In age-related diseases like AD, protein oligomerization and aggregation are prominent 
features that trigger neuronal disturbances including over-activation of macroautophagy 
(Cardoso et al., 2010). Macroautophagy, herein referred as autophagy, is a degradative 
pathway of the lysosomal system that allows the removal of cellular organelles and 
long-lived proteins (Boland et al., 2008). Autophagy is a tightly regulated process that 
begins with the formation of a cytosolic membrane under the control of multiple 
proteins, including microtubule-associated light chain 3. This complex controls the 
membrane elongation that sequestrates a region of the cytoplasm into a double-
membrane, the autophagosome (Levine and Kroemer, 2008). The degradation of 
sequestered materials is completed when autophasosomes fuse with lysosomes 
(autolysosomes), a process that allows the acidification and acquisition of proteolytic 
enzymes (Klionsky et al., 2008; Levine and Kroemer, 2008; Nixon, 2007). First 
described as a mainly starvation-inducible process, the constitutive role of autophagy as 
a quality control mechanism in the brain it is now recognized (Nixon, 2007).  
 
 
Figure 6. Schematic representation of the macroautophagy machinery. Macroautophagy begins with 
the formation of a double-layered isolation membrane (phagophore) around the moledcules and/or 
organelles to be degraded. The phagophore groes in size and completely engulfs the cargo, forming an 
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autophagosome. The autophagosome subsequently fuses with a lysosome, evolving into an autolysosome, 
wherein the cargo is digested. LC3 indicates light chain-3; LAMP2, lysosomal membrane-associated 
protein-2; and SNARE, Soluble N-ethylmaleimide-sensitive factor Attachment protein Receptor; Vps, 
vacuolar protein sorting. (Afapted from Dutta et al, 2012) 
 
 
This “self-eating” process is crucial for cellular maintenance providing essential 
elements for cellular metabolism (Cuervo, 2004). Further, it is well documented that the 
“autophagic-lysosomal pathway” (ALP) is simultaneously impaired and induced in AD 
brains (Nixon, 2007). Autophagic vacuoles accumulate within dystrophic neurites in the 
brain of AD patients and animal models, suggesting a progressive dysfunction of ALP 
process (Ghavami et al., 2014; Nixon et al., 2005) and, consequently, protein aggregates 
turnover is blocked.  
 
 
Figure 7. Dystrophic neurites in AD brains. A) Autophagosomes within dystrophic neurites, B) 
schematic representation of dystrophic neurites development in AD brains. Pathological accumulation of 
AVs is associated with impaired retrograde AVs transport or impaired auphagosome-lysosome fusion. 
(Adapted from Nixon 2005). 
 
Low levels of mRNA of beclin 1, a protein required for induction of autophagy in vivo, 
have been documented in MCI subjects and AD patients (Lee and Gao, 2008; Pickford 
B 
Chapter 1 | General Introduction 
 
46 
 
et al., 2008). In the APP mice model, low levels of beclin 1 were also detected and are 
associated with enhanced Aβ pathology, and impaired autophagy (Pickford et al., 2008). 
Likewise, mitochondrial dynamics impairment has been widely implicated in 
neurodegenerative disorders such as AD (Chan, 2006a; Zhu et al., 2013). Mitochondria 
are degraded by the autophagic process, herein referred as mitophagy (Moreira et al., 
2007). It was observed an increase in mitochondrial degradation products in vulnerable 
AD neurons, suggesting an augmented mitochondrial turn-over by mitophagy (Moreira 
et al., 2007). Electron microscopy analyses of AD brain samples stained for lipoic acid 
(LA) and COX-1 revealed that LA becomes associated with autophagic vacuoles in 
opposition to control cases. These observations demonstrated that mitochondria are key 
targets of autophagy in AD. A close interaction between autophagic vacuoles 
accumulation and Aβ deposition has been demonstrated. Endosomes and autophagic 
vacuoles, isolated from a variety of tissues, were shown to be enriched in APP and 
APP-cleaving secretases, namely in the gamma-secretase components PS-1 and 
nicastrin, which are required to generate Aβ (Mizushima, 2005; Vieira et al., 2010). 
This impairment in ALP leads to an exacerbation of Aβ production known to exert 
cytotoxicity (Boland et al., 2008). Yang and coworkers (Yang et al., 2008) reported that 
activated caspase-3 was found within dystrophic neurites, most exactly in autophagic 
vacuoles associated with amyloid plaques in PS/APP mice.  
Under these conditions, pro-apoptotic proteins accumulate and apoptotic cell death take 
place, culminating in the neurodegenerative process observed in AD brains. Valid 
proofs have been presented pointing to the link between Aβ-mediated toxicity and 
mitochondrial dysfunction. Aβ species have been found associated with mitochondria in 
human AD brains (Caspersen et al., 2005; Devi et al., 2006; Hirai et al., 2001; Manczak 
et al., 2006). Many studies showed that Aβ added extracellularly can act intracellularly 
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promoting mitochondrial dysfunction (Devi et al., 2006) by lowering enzymatic 
activities. Aβ treatments in isolated rat brain mitochondria induced deficits in energy 
metabolism (Casley et al., 2002). Data obtained using PC12 and NT2 cells showed that 
Aβ decreases the activity of mitochondrial respiratory chain complexes (Cardoso et al., 
2001; Pereira et al., 1999). PC12 cell line bearing APP Swedish mutation (APPSwe 
PC12) showed a decrease in COX activity and failure in other mitochondrial respiratory 
chain enzymes, when compared with wild-type APP-bearing cells or empty vector-
transfected cells (Keil et al., 2004). Furthermore, it was demonstrated that Aβ is targeted 
to mitochondria by TOM-40, one of the mitochondrial translocase proteins, and 
transported towards the matriz by the translocase of the inner membrane (TIM) 
(Hansson Petersen et al., 2008). As discussed before, mitochondrial dysfunction triggers 
abnormalities along microtubule cytoskeleton that can be responsible for the 
impairment of autophagic vacuoles retrograde transport towards the cell body where 
lysosomes are located. In support of this hypothesis, it has been shown that microtubule 
depolymerizing agents disrupt vesicular transport inducing rapid accumulation of 
autophagosomes (Arduino et al., 2012; Kochl et al., 2006). In opposition, microtubule 
polymerizing agents prevent cognitive deficits in AD mice model (Matsuoka et al., 
2008). Directly affecting mitochondria, some uncouplers were shown to disturb 
mitochondrial dynamics (Cappelletti et al., 2005; Silva et al., 2013a). In post-mitotic 
cells, the continuous accumulation of oxidative damage triggers the accumulation of 
non-functional mitochondria, a process that induces autophagy. Besides, damaged 
oxidative-modified proteins potentiate lipofuscin accumulation into the lysosome 
(Zheng et al., 2006). Lipofuscin is a polymeric material composed of oxidatively 
modified protein and lipid residues, which decreases lysosomal capacity and sensitizes 
cells to oxidative stress (Terman et al., 2006). Such evidence points to an interplay 
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between mitochondrial dysfunction, impaired microtubule network, and activation of 
the autophagic process, which creates a positive feedback loop where autophagic 
vacuoles are being continuously produced and accumulated due to lack of degradation 
within lysosomes (Cardoso et al., 2010; Cataldo et al., 1996; Silva et al., 2011b). 
 
1.8 Apoptosis 
AD brains experience significant neuron loss, which likely contributes to cognitive 
decline (Shimohama, 2000; Terry et al., 1991). While some neuronal loss could be due 
to necrosis, the vast majority is caused by apoptosis, a tightly-regulated form of 
programmed cell death (Barinaga, 1998). 
DNA fragmentation, as assessed by TUNEL staining, is a common hallmark of 
apoptosis. Neurons in AD brains display increased DNA fragmentation compared to 
control brains (Anderson et al., 1996; Broe et al., 2001; Colurso et al., 2003; Lassmann 
et al., 1995; Li et al., 1997; Smale et al., 1995; Su et al., 1994; Troncoso et al., 1996). 
Many of these studies also reveal morphologic changes associated with apoptosis 
including abnormal chromatin, an absence of nucleoli, and shrunken or irregular cell 
shapes (Shimohama, 2000). Other studies note an increased proportion of apoptotic to 
normal neurons (Broe et al., 2001). Correspondingly, AD brains express significantly 
higher levels of the pro-apoptotic proteins Bak and Bad (Kitamura et al., 1998; 
Shimohama, 2000). Other studies suggest that AD brains display elevated pro-apoptotic 
Bax (Su et al., 1997). Caspases 3 and 6 activities/levels, which are apoptosis 
“executioner” caspases, are increased in AD brains (Avila, 2010; Guo et al., 2004; 
Masliah et al., 1998; Rohn et al., 2001b; Selznick et al., 1999; Stadelmann et al., 1999), 
as are the initiator caspases 8 and 9 (Albrecht et al., 2007; Rohn and Head, 2009; Rohn 
et al., 2001a; Rohn et al., 2002).  
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Further evidence that apoptotic events are more frequent in AD brains than in age-
matched controls comes from experiments evaluating the presence of the cytoskeletal 
spectrin protein fodrin, which is cleaved early in the apoptotic cascade by caspases 
(Cribbs et al., 2004). Brains from AD patients display increased amounts of fodrin 
cleavage products (Ayala-Grosso et al., 2006; Masliah et al., 1991; Masliah et al., 
1990).  
Interestingly, evidence suggests that the pro-apoptotic shifts seen in AD subjects are not 
brain-limited. One study found that lymphocytes from AD patients were pre-disposed to 
apoptosis (Eckert et al., 2001). Another study reported increased fodrin cleavage in 
fibroblasts from AD patients (Peterson et al., 1991).  
In summary, substantial data suggest that apoptosis is elevated in AD. This is not 
surprising given the other molecular and biochemical perturbations observed in this 
disease. For example, oxidative stress can predispose cells to apoptosis (Buttke and 
Sandstrom, 1994; Ray et al., 2012; Sandstrom et al., 1994). The prolific oxidative 
damage present in AD may, therefore, contribute to increased apoptosis. 
 
1.9 New therapeutic strategies in AD 
1.9.1 Mitochondrial mass manipulation 
Increasing mitochondrial mass for the treatment of AD was first proposed in 2007 
(Ghosh et al., 2007; Swerdlow, 2007c). A rudimentary attempt to increase 
mitochondrial mass was previously attempted using the thiazolidinedione drugs 
rosiglitazone and pioglitazone. Although these drugs were originally considered for AD 
treatment based largely on their demonstrated anti-inflammatory effects, these drugs, 
which are used to treat type II diabetes, were subsequently shown to activate 
mitochondrial biogenesis signaling under pre-clinical testing paradigms. However, it is 
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doubtful that can reach levels within the brain that are high enough to activate 
mitochondrial biogenesis. Although the thiazolidinedione clinical trial data to date have 
not been uniformly negative, the overall impression these data give is that pioglitazone 
and rosiglitazone will provide no measurable benefit or, at best, an extremely small 
benefit (Geldmacher et al., 2011; Gold et al., 2010; Risner et al., 2006).  In the 
meantime, other ways to manipulate mitochondrial mass are in various stages of 
development.  
 
1.9.2 Redox state manipulation 
Redox state refers to a cell’s electron balance as defined by ratios of electron donor and 
acceptor molecule pairs. In this respect, an important indicator of a cell’s bioenergetic 
state is the ratio defined by amounts of nicotinamide adenine dinucleotide’s oxidized 
(NAD+) and reduced (NADH) derivatives. 
While bioenergetics help determine a cell’s redox state, a cell’s redox state can also 
influence its bioenergetic function. Data demonstrating this latter point comes from 
multiple lines of investigation. Caloric restriction shifts the liver’s redox balance 
towards a more oxidized state, and this is associated with mitochondrial biogenesis at 
least in the liver (Civitarese et al., 2007; Lambert et al., 2004; Lopez-Lluch et al., 2006) 
and also perhaps in the brain (Nisoli et al., 2005). Physical exercise, which should shift 
the muscle redox balance towards a more oxidized state, induces muscle mitochondrial 
biogenesis (Baar et al., 2002; Holloszy and Coyle, 1984; Hood, 2009).   
Theoretically, enzymes that depend on NAD+ levels, such as SIRT1, should activate in 
the setting of increased NAD+ (Guarente, 2007; Haigis and Guarente, 2006). SIRT1 
activation has been advocated for the treatment of several diseases, including AD 
(Anekonda and Reddy, 2006; Guarente, 2007; Haigis and Guarente, 2006). Polyphenol 
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compounds are believed to work as sirtuin activators (Baur, 2010; Lagouge et al., 2006).  
An AD clinical that will evaluate the effects of resveratrol, a polyphenol, on AD clinical 
status is scheduled to be performed.  
 
1.9.3 Cytoskeletal manipulation 
Mitochondrial dysfunction can induce cytoskeletal perturbations (Cardoso et al., 2010; 
Moreira et al., 2006). In the AD brain, reduced ATP levels may deregulate cytoskeleton 
homeostasis and microtubule integrity. Because features of neuron morphology, which 
include extended axons, branched dendritic arbors, and synaptic connections, both 
communication and continuity between a neuron’s cell body and its distal regions must 
be adequately maintained. In this regard it is well known that neurons are highly 
sensitive to disturbances in microtubule-dependent transport (Trimmer and Borland, 
2005).  
AD neurons show cytoskeletal changes. Compared to brains from control subjects 
microtubule assemblies are reduced (Cash et al., 2003; Santa-Maria et al., 2005). 
Surveys of AD brain pyramidal neurons suggest changes in microtubule homeostasis 
precede neurofibrillary tangle formation (Cash et al., 2003). NFT consist of the 
microtubule-associated protein (MAP) tau, which plays a role in microtubule function, 
neurite growth, and cytokeleton maintenance (Stamer et al., 2002). Although a number 
of tau residues are phosphorylated under physiological conditions, in AD tau 
phosphorylation increases 3 to 4-fold. Other studies show that tau over-expression alters 
cell shape, leads to a loss of polarization, and slows cell growth.  This is accompanied 
by a change in mitochondrial distribution; this change is characterized by organelle 
clustering (Ebneth et al., 1998). The associated microtubule perturbations are 
accompanied by changes in autophagy.  
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It ensures adequate levels of essential cell intermediates are maintained (Cuervo, 2004). 
APP, which is a transmembrane protein, can be processed by the endosomal-lysosomal 
pathway which initiates when material internalized by endocytosis or pinocytosis is 
sorted into endosomes (Nixon, 2007).  Data suggest that a change in the rate of 
autophagy or the factors which cause autophagic vacuoles to accumulate may contribute 
to Aβ overproduction in AD brains (Levine and Kroemer, 2008; Yu et al., 2004). 
Indeed, evidence from AD brains shows massive AV accumulation within dystrophic 
neurites occurs (Nixon et al., 2005; Yu et al., 2005).  Autophagy may therefore be 
simultaneously impaired and induced in AD. One potential explanation for this is that 
mitochondrial dysfunction may disrupt the microtubule cytoskeleton, and lead to 
impaired AV retrograde transport towards the cell body where lysosomes are located. In 
support of this, it has been shown that microtubule depolymerizing agents disrupt 
vesicular transport and induce rapid AV accumulation (Kochl et al., 2006). Vinblastine, 
which inhibits microtubule assembly, leads to microtubule depolymerization and 
prevents AV-lysosome fusion (Boland et al., 2008; Xie et al., 2010).  
Recently, Miyasaka and colleagues (Miyasaka et al., 2010) reported that tau 
hyperphosphorylation is more likely a consequence, as opposed to a cause, of 
microtubule disruption. This is consistent with the view that when the microtubule 
network is disrupted, tau dissociates from microtubules and becomes accessible to the 
kinases that promote its hyperphosphorylation (Silva et al., 2011a). For this reason, it 
was postulated that microtubule stabilizing agents could potentially reduce neuronal 
dystrophy (Lee et al., 1994; Silva et al., 2011b). Data consistent with this view come 
from experiments using taxol (paclitaxel), a microtubule polymerizing agent that has 
been shown to mitigate AD-associated pathology in AD model systems. In rats, taxol 
was found to protect cortical neurons from Aβ25-35 toxicity, decrease calpain activation, 
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and decrease cdk5/p25 complex formation (Li et al., 2003). In other models taxol 
pretreatment prevents tau hyperphosphorylation and reduces Aβ-induced apoptosis 
(Michaelis et al., 2002). In a hippocampal slice model of lysosomal dysfunction it was 
found that pretreatment with TX67, an analogue of taxol, restored pre and post synaptic 
proteins levels and reduced synapse damage (Butler et al., 2007).  
Recently, we demonstrated that in SH-SY5Y cells exposed to Aβ1-42, the resultant 
mitochondrial dysfunction perturbs AV transport via a microtubule dependent 
mechanism (Silva et al., 2011a). Taxol prevents Aβ1-42 induced disorganization of the 
tubulin cytoskeleton, which secondarily reduces both cytosolic and mitochondrial Aβ 
content by enhancing ALP function. 
Taxol, though, does not robustly access to the central nervous system (CNS) (Liu et al., 
2002). A drug with taxol-like properties, NAP (davunetide), an eight amino acid peptide 
derived from the activity-dependent neuroprotective protein (ADNP), was recently 
shown to cross the blood brain barrier after systemic or intranasal administration (Gozes 
et al., 2005). Although NAP was first described as an antioxidant, it is now recognized 
that following cell internalization NAP interacts with the microtubule cytoskeleton 
(Divinski et al., 2004; Gozes and Divinski, 2007). NAP has been shown to reduce tau 
hyperphosphorylation and Aβ accumulation in both in vitro and in vivo AD models, and 
also benefit cognitive test performance in some of these models (Gozes and Divinski, 
2004; Matsuoka et al., 2007; Matsuoka et al., 2008; Shiryaev et al., 2009; Vulih-
Shultzman et al., 2007). Although its biological effects remain to be fully investigated 
(Shiryaev et al., 2011), based on encouraging preclinical data and an apparent lack of 
toxicity NAP is now being tested in persons with AD and other disorders of the CNS 
(Greggio et al., 2011; Idan-Feldman et al., 2011; Javitt et al., 2011).  A recent phase IIa 
clinical study reported that intranasal NAP improved memory performance in patients 
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with an amnestic MCI syndrome, which is frequently an AD precursor state (Gozes et 
al., 2009). 
 
 
Figure 8. Current and anticipated mitochondrial medicine strategies. Dysfunctional mitochondria in 
AD result in reduced ATP availability (A), which promotes microtubule network breakdown (B), 
jeopardizing the transport of molecules and organelles along the cell. Further, it promotes tau dissociation 
from microtubules and its consequent hyperphosphorylation (C). These events compromise synapse 
energy supplies (D), and the transport of AVs toward the cell body (where lysosomes are located) is 
impeded (E). This promotes accumulation of Aβ aggregates, which may be formed by APP cleavage at 
AV membranes (F). Microtubule network stabilization may improve ALP function, promote transport 
along axons, and reduce Aβ production. Increasing mitochondrial mass may compensate for declines in 
mitochondrial function and their overall functional capacity. Shifting the cell redox balance to a more 
oxidized state may cause the cell bioenergetic infrastructure to function more efficiently, promote 
mitochondrial biogenesis, and activate pathways that allow cells to tolerate stress conditions (Adapted 
from Silva et al, 2012). 
 
Objectives  
AD and other neurodegenerative disorders are expected to constitute a major health 
problem as life expectancy increase. Efforts have been taken in order to tackle innovate 
therapies namely, addressing mitochondrial dysfunction, a striking feature in AD that 
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has great influence in the etiology of the disease, nevertheless the idea that 
mitochondrial dysfunction is the leading cause of AD is still a matter for debate within 
scientific community. Taking this into account, the major goal of this thesis was to 
prove that mitochondrial dysfunction-dependent events are responsible for intracellular 
trafficking failure, impairing ALP pathway and consequent Aβ peptides formation, 
which will cause further cellular damage. For this purpose we used AD, MCI and age-
matched control (CTR) cybrids, an ex-vivo cellular model, in order to evaluate 
mitochondrial contribution to sporadic AD pathology. We evaluated mitochondrial 
function in these cells and several pathways governed by mitochondrial function such 
as: oxidative stress, microtubule network disruption, and macroautophagy/mitophagy. 
Using several experimental approaches we attempt to elucidate the involvement of 
mitochondrial dysfunction-driven events in sporadic AD pathology development. 
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MATERIALS AND METHODS  
2.1 Chemicals 
 
Table 1. Chemicals 
Compound Company 
FCCP 
Oligomycin 
Rotenone 
NH4Cl 
Leupeptin 
Retinoic acid 
Aβ 1-42 
AK1 
Tubastatin 
2-DG 
Sigma 
Sigma 
Sigma 
Calbiochem 
Sigma 
Sigma 
American Peptide 
Sigma 
BioVision 
Seahorse Bioscience 
 
 
2.2 Human Subjects 
For experiments regarding Chapter 3, subject participation was approved by the Ethics 
Board of Coimbra University Hospital, and all subjects or responsible caregivers, 
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whenever appropriate, gave their informed consent. The study sample was recruited at 
the Dementia Clinic, Neurology Department of Coimbra University Hospital and 
included 5 patients with mild late onset AD with the age of 81±2,6; 5 MCI patients with 
the age of 76±3,4; and 3 age-matched controls - 81±3,6 with no subjective or objective 
evidence of cognitive impairment. As this study was focused on mitochondrial role in 
sporadic AD, we wanted to exclude other genetic risk factors associated with nuclear 
DNA, so we selected only female subjects over 65 years and ApoE-4 non-carrier 
patients. Patients underwent a methodical biochemical, neurological and imaging 
evaluation, and were in a stable condition, without acute co-morbidities. Cognitive and 
functional status was assessed by the Mini Mental State Examination (MMSE)(Folstein 
et al., 1975), Portuguese version (Guerreiro, 1998), Alzheimer’s Disease Assessment 
Scale – Cognitive (ADAS-Cog) (Mohs et al., 1983; Rosen et al., 1984), Portuguese 
version (Guerreiro M, 2003b), the Clinical Dementia Rating Sale (CDR) (Berg, 1988) 
and a comprehensive neuropsychological battery tests with normative data for the 
portuguese population (BLAD) (Guerreiro M, 2003a) exploring memory (Wechsler 
Memory Scale sub-tests) and other cognitive domains (including language, praxis, 
executive functions and visuo-construtive tests). Based on these instruments, patients 
were classified as probable AD or amnestic MCI. The diagnosis of probable AD was 
based on the guidelines of the Diagnostic and Statistical Manual of Mental Disorders – 
fourth edition (DSM-IV-TR) (1994) and the criteria of the National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA) (McKhann et al., 1984). MCI 
diagnosis was made in accordance with the criteria defined by Petersen et al. (Petersen 
et al., 2001), and the patients were classified as 0.5 in CDR. 
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For experiments regarding Chapter 4 and 5, subject participation was approved by the 
Kansas University Medical Center’s Institutional Review Board.  Subjects for this study 
were recruited from the University of Kansas Alzheimer’s Disease Center (KU ADC). 
Each subject was determined, based on cognitive testing and by a memory disorders 
subspecialist clinician, to meet criteria for normal cognition (control status), mild 
cognitive impairment (MCI), or sporadic Alzheimer’s disease (AD). After providing 
informed consent, sporadic AD (n = 8), MCI (n = 7), and age-matched control (n = 7) 
subjects underwent a 10 ml phlebotomy using tubes containing acid-citrate-dextrose as 
an anticoagulant. The age of the AD subject platelet donors was 71.5 ± 9.7 years, the 
age of the MCI platelet donors was 72.3 ± 6.6, and the age of the control subject platelet 
donors was 73.9 ± 7.7.  
 
2.2.1 Creation of cybrid cell lines  
Experiments regarding Chapter 3, NT2 ρ0 cells were briefly agitated in polyethylene 
glycol with platelets from the human subjects (Cardoso et al., 2004b). Seven days after 
plating the ρ0 growth medium, consisting of Optimem (Gibco-Invitrogen) 
supplemented with 10% non-dialysed FBS, 200 µg/ml sodium piruvate (Sigma), 100 
µg/ml uridine (Sigma) and 1% penicilina-streptomycin, was changed to cybrid selection 
medium. NT2 ρ0 cells lack intact mtDNA, do not possess a functional electron transport 
chain (ETC), and are auxotrophic for pyruvate and uridine (Cardoso et al., 2004b; 
Swerdlow et al., 1997). Maintaining cells in selection medium, consisting of Optimem  
supplemented with 10% dialized, heat inactivated fetal calf serum (Gibco-Invitrogen), 
penicilin (Sigma) (50U/ml), and streptomycin (Sigma) (50 µg/ml), removes ρ0 cells that 
have not been repopulated with platelet mtDNA.  
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Concerning experiments of Chapter 4 and 5, cybrid cell lines were created on an SH-
SY5Y cell nuclear background (Miller et al., 1996) by the KU ADC Mitochondrial 
Genomics and Metabolism Core. To generate the cybrid lines used in these studies, 
platelets from human subjects were mixed with SH-SY5Y cells previously depleted of 
endogenous mtDNA (ρ0 cells) as previously described (Swerdlow et al., 1996).   
During the overall cybrid generation procedure several different types of media were 
used. For each medium, Dulbecco’s modified Eagle’s medium (DMEM) was obtained 
from Gibco-Invitrogen, while non-dialyzed or dialyzed fetal bovine serum (FBS) was 
obtained from Sigma. SH-SY5Y ρ0 cell growth medium consisted of DMEM 
supplemented with 10% non-dialyzed FBS, 200 ug/ml sodium pyruvate, 150 ug/ml 
uridine, and 1% penicillin–streptomycin solution. SH-SY5Y cybrid selection medium 
consisted of DMEM supplemented with 10% dialyzed FBS and 1% penicillin–
streptomycin solution. The selection process lasted 6 weeks. After cell line selection 
was completed, each line was continuously maintained in a cybrid growth medium 
containing DMEM supplemented with 10% non-dialyzed FBS and 1% penicillin-
streptomycin solution for over 2 months prior to biochemical and molecular assays. 
 
2.3 Cybrid and parental SHSY5Y neuronal differentiation 
Control, MCI, AD cybrids and SH-SY5Y cell line (ATCC-CRL-2266) where plated at a 
confluence of about 70%. After 24h medium was renewed to DMEM containing 1% of 
FBS, 200 ug/ml sodium pyruvate, 150 ug/ml uridine, 1% penicillin–streptomycin 
solution and freshly supplemented with 10 µM of Retinoic Acid (RA). Medium 
containing RA was refreshed every 2 days. Cells were harvested and experiments were 
made 14-17 days after the beginning of the differentiation. 
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2.4 Mitochondrial function and structural evaluation 
2.4.1 Cytochrome oxidase Vmax assays  
Complex IV activity was measured according to the method of Wharton and Tzagoloff 
(Wharton DC, 1967) by measuring the decrease in absorbance at 550 nm that occurs as 
reduced cytochrome c is oxidized. Cytochrome c reduction was initially performed by 
adding ascorbate crystals to cytochrome c and placing the mixture in a dialysis 
membrane for 18–24 h against 0.01 M phosphate buffer, pH 7.0, at 4ºC. Reduced-
cytochrome c concentration was then determined with 0.1 M ferricyanide. The reaction 
mixture contained 0.01 M potassium phosphate, pH 7.0, and 50 µM reduced 
cytochrome c. The reaction was initiated by the addition of the mitochondrial sample at 
30ºC. The pseudo first order rate constant (K) was calculated, because the reaction is of 
first order with respect to cytochrome c. Results were obtained in K/min/mg of protein. 
Concerning Chapter 4, whole cell cytochrome oxidase (COX) Vmax activities were 
determined as previously described (Swerdlow et al., 1997). The total protein contained 
in each assayed cuvette was estimated using the DC Protein assay (BioRad, Hercules, 
California, USA). The relative amount of a COX protein subunit, COX4I1, was 
determined for each cell line by Western blot. COX activities in sec-1/mg protein values 
were calculated. The sec-1/mg protein Vmax activity for each line was also normalized 
to the amount of COX4I1 protein in the line. 
 
2.4.2 Citrate synthase assay 
Citrate synthase activity was determined by the method of Coore and team (Coore et al., 
1971) which follows, spectrophotometrically, the formation of 5-thio-2-nitrobenzoate at 
412 nm. The assay was initiated by the addition of 100 µM oxaloacetate at 30ºC. 
Results were obtained in nanomoles per minute per mg of protein. 
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2.4.3 Analysis of Adenine nucleotides  
ADP/ATP ratios were determined using the EnzyLightTM ADP/ATP Ratio Assay Kit 
(Bioassay Systems, CA, USA). Briefly, 1x105 cells per well were plated in 96 well 
plates. In the first step, cells were lysed to release ATP and ADP. ATP reacts with the 
kit substrate in an initial fluorescence reaction, which provided a direct indication of the 
ATP concentration. Next, we followed the change in fluorescence that occurred when 
ADP was converted to ATP. The difference between the initial and final fluorescences 
indicated the ADP concentration.  
 
2.4.4 Analysis of mitochondrial membrane potential (∆Ψm)  
Changes in mitochondrial membrane potential were detected using the fluorescent 
cationic dye rhodamine 123 (Rh123) or TMRM, as indicated. Cells were loaded with 
0.5 μM Rh123 or 300nM of TMRM (in the dark, at 37 ºC) and the fluorescence (λexc = 
505 nm and λem = 525 nm) was recorded during 45 min before, and 10 min after 
mitochondrial depolarization, using a Spectramax Plus 384 spectrofluoremeter 
(Molecular Devices) for Rh123. For TMRM the fluorescence (λexc = 540 nm and λem 
= 590 nm) was recorded during 5 min before and 3 min after mitochondrial 
depolarization, using the same device described above. Maximal mitochondrial 
depolarization (Δψm collapse) was performed in every individual experiment by adding 
1 μM FCCP (proton ionophore), which was always preceded by oligomycin (2 μg/ml) 
to prevent ATP synthase reversal. Either dye retention was determined by the difference 
between total fluorescence (after depolarization) and the initial value of fluorescence. 
Since positively charged dyes are retained by functional mitochondria with a high Δψm, 
a decrease of cellular retention of these dyes has been associated with a decrease in 
Δψm. 
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2.4.5 Respiration and glycolysis analysis 
Approximately 80,000 cells from each cybrid line were used to seed the wells of 
Seahorse XF cell culture microplates (Seahorse Bioscience, Billerica, MA). A standard 
manufacturer-recommended two-step seeding procedure was utilized. After achieving 
cell adherence, microplates were placed overnight in a 37o, 5% CO2 incubator.   
For respiratory analyses, on the assay day shortly before placing culture microplates in 
the Seahorse Analyzer the cells were washed in buffered DMEM and the medium was 
then changed to the actual assay medium, which consisted of buffered DMEM 
containing no pyruvate and no BSA. Oxygen consumption rate (OCR) respiration 
measurements were made using a 3 minute mix, 2 minute wait, and 3 minute read 
cycling protocol. During the first 4 reading periods total cell OCRs were determined, 
with the fourth reading providing the value used for the analysis. After the fourth 
reading wells were injected with 500 nM oligomycin and the resulting OCR was 
measured over 3 reading cycles. The third post-oligomycin reading cycle provided the 
post-oligomycin OCR. After this, we injected a mixture of rotenone (1 uM) and 
antimycin A (200 nM) and measured the resultant OCR over 3 reading cycles. The third 
post-rotenone/antimycin reading cycle provided the non-mitochondrial OCR. The non-
mitochondrial OCR was subtracted from the total OCR to yield the mitochondrial OCR, 
and from the post-oligomycin OCR to yield the mitochondrial proton leak OCR. After 
OCR measurements were completed, the cell mass in each well was estimated by 
measuring the total protein in each well (DC Protein Assay, BioRad). OCR values from 
each well were normalized to the amount of protein in that well to yield a final corrected 
OCR in pmol O2/minute/mg protein.  
For glycolysis analyses, on the assay day the cells were washed in unbuffered DMEM 
and following this the cells were placed in unbuffered DMEM containing no pyruvate, 
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no bovine serum albumin (BSA), and no glucose. The microculture plates were then de-
gassed in a non-CO2 incubator at 37oC for 1 hour before being placed into the Seahorse 
Analyzer. The wells were analyzed according to the procedure described in the 
Seahorse Glycolysis Stress Test kit. Briefly, initial measurements taken in the absence 
of glucose, and again after an injection of 2-deoxyglucose (to a final concentration of 
100 mM), provide a non-glycolysis extracellular acidification rate (ECAR). In between 
these two baseline ECAR measurements, glucose was added to each well at a 
concentration of 10 mM. The resulting ECAR minus the non-glycolysis ECAR (in these 
experiments, we specifically subtracted the post-2-deoxyglucose non-glycolysis ECAR) 
provided the glycolysis ECAR. Next, oligomycin was added to each well (in this case, 
at a 1 uM concentration). The resulting ECAR minus the non-glycolysis ECAR 
provided the glycolysis capacity ECAR. Subtracting the glycolysis ECAR from the 
glycolysis capacity ECAR yielded the glycolysis spare reserve capacity.   
 
2.4.6 Electron microscopy  
Cell suspensions were fixed with 3% glutaraldehyde in 0.1 M phosphate-buffered pH 
7.3 overnight at 4 °C. The fixed pellets were washed in 0.1 M phosphate-buffered. 
Pellets were then post-fixed with 1% osmium tetroxide during 2 h, dehydrated in grade 
ethanol and embedded in Spurr. The ultrathin sections were cut with an LKB ultra-
microtome ULTRATOME III, and then contrasted with uranyl acetate and with lead 
citrate for transmission electron microscopy. Electron microphotographs were taken 
with JEOL JEM-100 SX electron microscope operated at 80 kV. 
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2.4.7 Immunocytochemistry and confocal visualization of mitochondrial network  
Experiments presented in Chapter 3 consisted in 4h treatment with 5µM of FCCP AD, 
MCI and control (CT) cybrids that were then washed twice with PBS and fixed for 30 
min at room temperature using 4% paraformaldehyde. For experiments of Chapter 5, 
after the differentiation process described above, cells were fixed for 30 min at room 
temperature using 4% paraformaldehyde. Both sets of fixed cells were washed again 
with PBS, permeabilized with 0.2% Triton X-100, and blocked with 3% BSA. The 
permeabilized cells were incubated with primary antibody (1:100 anti-TOM20 from 
Santa Cruz, CA, USA) overnight in a wet chamber, at 4ºC. Afterward, cells were 
incubated 1h with appropriate secondary antibody (1:250 AlexaFluor 488 from 
Molecular Probes, Eugene, OR, USA). Finally, cells were washed in PBS, incubated for 
5 minutes with Hoechst 33342 (15mg/L in PBS, pH 7.4) in the dark and visualized by 
confocal microscopy. Images were acquired on a Zeiss LSM 510 meta-confocal 
microscope (63 × 1.4NA plan-apochromat oil immersion lens) by using the Zeiss 
LSM510 v3.2 software (Carl Zeiss, Inc., Thornwood, NY, USA) and analyzed using 
Zeiss LSM Image Examiner. 
To quantify two parameters of mitochondrial morphology, a custom-written ImageJ 
macro containing plug-ins (Dagda et al., 2009) was used, as described by Arduino and 
colleagues (Arduino et al., 2012). Cells stained with TOM20 antibody were extracted to 
grayscale, inverted to show mitochondria-specific fluorescence as black pixels and 
thresholded to optimally resolve individual mitochondria. This macro traces 
mitochondrial outlines, using the ‘analyze particles’ function. The area/perimeter ratio 
was employed as an index of mitochondrial interconnectivity, and inverse roundness 
was used as a measure of mitochondrial elongation. 
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2.4.8 Western blot analysis of Flux modifying proteins  
Cells were harvested with trypsin, centrifuged at 500 g for 5 minutes, re-suspended 
PBS, and centrifuged again. To prepare whole cell lysates, the washed cell pellet was 
suspended in M-PER Mammalian Protein Extraction Reagent (Pierce, Rockford, IL, 
USA) supplemented with Halt Protease Inhibitor Cocktail (Pierce) and gently shaken 
for 5 minutes as directed. To prepare pure nuclear and cytosolic lysates, the washed cell 
pellet was processed using an N-PER Nuclear and Cytoplasmic Extraction Reagent Kit 
(Pierce) as directed. Protein concentrations for all lysates were determined using a DC 
Protein Assay Kit (BioRad).  
For Western blot analyses, samples were boiled, diluted 1:5 in sample buffer, resolved 
by electrophoresis in pre-cast 4–12% gels (BioRad), and transferred to polyvinylidene 
difluoride (PVDF) membranes. Non-specific binding was blocked by gently agitating 
the membranes in 5% non-fat milk or 5% BSA, as recommended, and 0.1% Tween in 
PBS for 1 hour at room temperature. Blots were subsequently incubated in buffer 
containing a designated primary antibody. Primary antibodies purchased from Cell 
Signaling Technology (Beverly, MA, USA) included antibodies to phospho-sirtuin-1 
(Ser47), sirtuin 1, tubulin, HIF1α, phospho-P38, total P38, phospho-AMPK (Thr172), 
and total AMPK; these antibodies were each used at a 1:1000 dilution. Primary 
antibodies purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) included 
PGC1α antibody (used at a 1:500 dilution). An antibody to HDAC1 was purchased from 
Thermo Scientific (Pierce, Rockford, IL, USA) and used at a 1:1000 dilution. An 
antibody to PARIS (ZNF746) was obtained from the UC Davis/NIH NeuroMab Facility 
(Antibodies Inc., PO Box 1560, Davis, CA) and used at a 1:1000 dilution.  
After addition of a primary antibody membranes were incubated overnight at 4°C with 
gentle agitation. Blots were washed with PBS containing 0.1% Tween three times (each 
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time for 10 minutes), and incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody for 1 hour at room temperature with gentle agitation. 
After three washes, the blots were incubated with SuperSignal West Femto Maximum 
Sensitivity Substrate (Pierce). Chemiluminescence signals were detected using a Bio-
Rad ChemiDoc Imager and band densities determined using Quantity One Software. 
 
2.4.9 Western blot analysis of mitochondrial mass and dynamics proteins  
Regarding experiments from Chapter 4, cells were harvested with trypsin, centrifuged at 
500 g for 5 minutes, re-suspended PBS, and centrifuged again. Mitochondrial fractions 
were prepared as follows: cells were harvested and the pellet processed using a 
Mitochondrial Isolation Kit for Cultured Cells (MitoSciences, Abcam, MA, USA). To 
prepare whole cell lysates, the washed cell pellet was suspended in M-PER Mammalian 
Protein Extraction Reagent (Pierce, Rockford, IL, USA) supplemented with Halt 
Protease Inhibitor Cocktail (Pierce) and gently shaken for 5 minutes as directed. Protein 
concentrations for all lysates were determined using a DC Protein Assay Kit (BioRad). 
For Western blot analyses, samples were boiled, diluted 1:5 in sample buffer, resolved 
by electrophoresis in pre-cast 4–12% gels (BioRad), and transferred to polyvinylidene 
difluoride (PVDF) membranes. Non-specific binding was blocked by gently agitating 
the membranes in 5% non-fat milk or 5% BSA, as recommended, and 0.1% Tween in 
PBS for 1 hour at room temperature. Blots were subsequently incubated in buffer 
containing a designated primary antibody: α-tubulin, Drp1, total Drp1, mTOR, and 
COX4; these antibodies were each used at a 1:1000 dilution and were obtained from 
Cell Signaling Technology (Beverly, MA, USA). An antibody to COX2 was purchased 
from Molecular Probes (Molecular Probes, Eugene, OR, USA) and used at a 1:500 
dilution. An antibody to TFAM was purchased from Aviva Systems Biology (San 
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Diego, CA, USA) and used at a 1:1000 dilution. An antibody to Opa1 was purchased 
from BD Biosciences (San Jose, CA, USA) and used at a 1:1000 dilution. After addition 
of a primary antibody membranes were incubated overnight at 4°C with gentle 
agitation. Blots were washed with PBS containing 0.1% Tween three times (each time 
for 10 minutes), and incubated with the appropriate horseradish peroxidase-conjugated 
secondary antibody for 1 hour at room temperature with gentle agitation. After three 
washes, the blots were incubated with SuperSignal West Femto Maximum Sensitivity 
Substrate (Pierce). Chemiluminescence signals were detected using a Bio-Rad 
ChemiDoc Imager and band densities determined using Quantity One Software. 
In experiments from Chapter 5, cells were washed with PBS, scraped and homogenized 
in a buffer containing 250 mM sucrose, 20 mM Hepes, 1 mM EDTA, 1 mM EGTA, and 
protease inhibitors (0.1 M PMSF, 0.2 M DTT, and 1:1000 dilution of a protease 
inhibitor cocktail), and disrupted by homogenization. This suspension was centrifuged 
at 500 g for 12 min at 4ºC. The resulting supernatant was centrifuged at 9,500 g for 20 
min at 4ºC. Pellets resulting from this step constitute a crude mitochondrial fraction. 
Mitochondrial pellets were resuspended in sucrose buffer and freeze-thawed three 
times. The total amount of resulting mitochondrial fractions obtained were removed and 
stored at −80 °C. Protein content was determined using Bradford protein assay (Bio- 
Rad, Hercules, CA, USA). Mitochondrial fractions containing the same amounts of 
protein were diluted (1:6) with sample buffer and were separated by electrophoresis in 
10% SDS polyacrylamide gels. Both were transferred to PVDF membranes (Millipore, 
Billerica, MA, USA). Non-specific binding was blocked by gently agitating the 
membranes in 3% BSA and 0.1% Tween in TBS for 1h at room temperature. The blots 
were subsequently incubated with the respective primary antibodies overnight at 4°C 
with gentle agitation: 1:1000 anti-DRP1and p-DRP1 from Cell Signaling Technology 
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(Beverly, MA, USA); 1:1000 anti-OPA1 from BD Biosciences (San Jose, CA, USA); 
1:1000 anti-FIS1 from Imagenex (Port Coquitlam, BC, Canada); 1:1000 anti-Mitofusin 
1 and Mitofusion 2 from Abnova (Taipei City, Taiwan). Membranes were further 
washed three times with TBS, 0.1% Tween and then incubated with the corresponding 
alkaline phosphatase - conjugated secondary antibody (1:20,000, GE Healthcare UK 
Limited, Buckinghamshire, UK) for 1h at room temperature. The membranes were 
washed again three times and bound antibodies detected using the enhanced 
chemifluorescence reagent ECF (Amersham Biosciences UK Limited, 
Buckinghamshire, UK) according to the manufacturer’s instructions. Blots were 
visualized using a VersaDoc imaging system (Bio-Rad, Hercules, CA, USA) and 
quantified using Quantity-One software (Bio-Rad, Hercules, CA, USA). 
 
2.5 Apoptotic cell death evaluation 
2.5.1 Western blot analysis of mitochondrial cytochrome c and Beta-amyloid 
content  
For the analysis of mitochondrial cytochrome c and Aβ content, cells were washed with 
PBS, scraped and homogenized in a buffer containing 250 mM sucrose, 20 mM Hepes, 
1 mM EDTA, 1 mM EGTA, and protease inhibitors (0.1 M PMSF, 0.2 M DTT, and 
1:1000 dilution of a protease inhibitor cocktail), and disrupted by homogenization. This 
suspension was centrifuged at 500 g for 12 min at 4ºC. The resulting supernatant was 
centrifuged at 9,500 g for 20 min at 4ºC. Pellets resulting from this step constitute a 
crude mitochondrial fraction. Mitochondrial pellets were resuspended in sucrose buffer 
and freeze-thawed three times. The total amount of resulting mitochondrial fractions 
obtained were removed and stored at −80 °C. Protein content was determined using 
Bradford protein assay (Bio- Rad, Hercules, CA, USA). Mitochondrial fractions 
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containing the same amounts of protein were diluted (1:2) with sample buffer and were 
separated by electrophoresis on a 4–16% Tris–Tricine SDS gel to determine A 
oligomeric content. For mitochondrial cytochrome c equal amount of protein were 
resolved by electrophoresis in SDS polyacrylamide on 15% gels. Both were transferred 
to PVDF membranes (Millipore, Billerica, MA, USA). Non-specific binding was 
blocked by gently agitating the membranes in 3% BSA and 0.1% Tween in TBS for 1h 
at room temperature. The blots were subsequently incubated with the respective primary 
antibodies overnight at 4°C with gentle agitation (1:500 anti-cytochrome c and 1:1000 
6E10 mouse monoclonal anti-Aβ or anti-Abeta from Cell Signaling). Membranes were 
further washed three times with TBS, 0.1% Tween and then incubated with the 
corresponding alkaline phosphatase - conjugated secondary antibody (1:20,000, GE 
Healthcare UK Limited, Buckinghamshire, UK) for 1h at room temperature. The 
membranes were washed again three times and bound antibodies detected using the 
enhanced chemifluorescence reagent ECF (Amersham Biosciences UK Limited, 
Buckinghamshire, UK) according to the manufacturer’s instructions. Blots were 
visualized using a VersaDoc imaging system (Bio-Rad, Hercules, CA, USA) and 
quantified using Quantity-One software (Bio-Rad, Hercules, CA, USA). 
 
2.6 NAD metabolism 
2.6.1 NAD+/NADH assay  
Cells were harvested and assayed for NAD+/NADH levels using the Fluorescent 
NAD/NADH Detection Kit (Cell Technology, Inc, CA, USA). Briefly, 2x106 cells were 
harvested and divided into two different vials, one for NAD+ and another for NADH. 
Cells were then re-suspended in the appropriate extraction and lysis buffers. After 
vortexing, the lysates were incubated at 60ºC for 15 minutes. Immediately following 
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this the lysates were cooled and reaction buffer was added. Samples were centrifuged at 
8000 g for 5 minutes to clarify the supernatants. After this, centrifugation samples were 
assayed for NAD+/NADH with fluorescence measurements taken at excitation 530 nm 
and emission 590 nm.  
 
2.6.2 Evaluation of SIRT2 protein levels and NAD+ savage pathway enzyme   
For cellular fractionation for the detection of NAD+ enzymes of the Savage Pathway, 
cybrid cell lines were differentiated and cellular fractionation was performed, after 14 to 
17 days, as directed in Subcellular Proteome Extraction Kit, from Calbiochem 
(Billerica, MA, USA), in order to obtain cytosolic and nuclear fractions. All fractions 
containing the same amounts of protein were diluted (1:6) with sample buffer and were 
separated by electrophoresis in 10% SDS polyacrylamide gels. Proteins were transferred 
to PVDF membranes (Millipore, Billerica, MA, USA). Non-specific binding was 
blocked by gently agitating the membranes in 3% BSA and 0.1% Tween in TBS for 1h 
at room temperature. The blots were subsequently incubated with the respective primary 
antibodies overnight at 4°C with gentle agitation: 1:100 anti-NAMPT from Santa Cruz 
(CA, USA); 1:1000 anti HDAC1 and anti SIRT2 from Cell Signaling Technology 
(Beverly, MA, USA), and 1:5000 anti-actin (Sigma). Membranes were further washed 
three times with TBS, 0.1% Tween and then incubated with the corresponding alkaline 
phosphatase - conjugated secondary antibody (1:20,000, GE Healthcare UK Limited, 
Buckinghamshire, UK) for 1h at room temperature. The membranes were washed again 
three times and bound antibodies detected using the enhanced chemifluorescence 
reagent ECF (Amersham Biosciences UK Limited, Buckinghamshire, UK) according to 
the manufacturer’s instructions. Blots were visualized using a VersaDoc imaging 
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system (Bio-Rad, Hercules, CA, USA) and quantified using Quantity-One software 
(Bio-Rad, Hercules, CA, USA). 
 
2.7 DNA and RNA isolation and quantification  
2.7.1 Purification of genomic DNA 
Genomic DNA was extracted using a QIAamp DNA Mini Kit (QIAGEN, Valencia, CA, 
USA). Briefly, 2x106 cells were harvested with trypsin. The cell pellets were 
resuspended in PBS and Proteinase K was added. Cells were lysed using AL Buffer and 
purification was performed as directed in the QIAamp DNA Handbook. At the end of 
the purification process DNA was eluted from the columns using nuclease-free water.  
The resulting DNA was stored at -80ºC prior to use. 
 
2.7.2 Purification of total RNA 
Total RNA was extracted using a QIAamp RNA Blood Mini Kit (QIAGEN). Briefly, 
2x106 cells were harvested with trypsin. RTL buffer was added to help lyse the cells and 
then cell lysates were homogenized in QIAshredder spin columns. The resultant flow-
through was placed in QIAamp spin columns and the purification procedure was 
performed according to the QIAamp RNA Handbook. RNA was eluted from columns 
using nuclease-free water and the resulting RNA was stored at -80ºC prior to use. 
 
2.7.3 cDNA reaction  
cDNA was obtained using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems, Foster City, CA). cDNA reverse transcription reactions were prepared with 
10 ul of 2x RT master mix to which we added 1 µg of total RNA and sufficient 
nuclease-free water to bring the total reaction volume to 20 ul.  
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2.7.4 Quantitative real time PCR 
Quantitative real-time PCR (qPCR) was performed using the TaqMan Universal PCR 
Master Mix (Applied Biosystems, Foster City, CA) and ready-to-use TaqMan Gene 
Expression Assays (Applied Biosystems). We quantified mRNA levels deriving from 
the following genes: HIF1, PGC1α, PGC1b, PRC, TFAM, COX4, cytochrome c, 
sirtuin1, and Bax. GAPDH was used as an internal loading control. qPCR amplification 
was determined utilizing an Applied Biosystems StepOnePlus Real-Time PCR System 
(Applied Biosystems). 
To quantify mtDNA, we used the TaqMan Gene Expression Assay Kit (Applied 
Biosystems) and primers towards two mtDNA-encoded genes, NADH dehydrogenase 
subunit 1 (ND1) and the 16S RNA gene, as well as to the nuclear 18s rRNA gene. The 
relative mtDNA to nuclear DNA copy number ratio was determined using the 
comparative ∆∆CT method, in which ND1/18S and 16S/18S ratios were calculated. 
 
2.8 Oxidative stress evaluation   
2.8.1 Superoxide anion (O2•–) formation  
Superoxide anion (O2
•–) formation was determined by using the fluorescence probe 
dihydroehidium (DHE) (Molecular Probes, Invitrogen). DHE is permeable to cell 
membrane and in cytoplasm is converted to ethidium by O2
•– emitting fluorescence 
(Bindokas et al., 1996). Briefly, 5 µM DHE dissolved in Krebs medium was incubated 
in cells during 1 h at 37ºC. Fluorescence measurements were taken during 1 h (518 nm 
excitation; 605 nm emission). Mitochondrial contribution to O2
•– production was 
determined by challenging cells with 5uM of rotenone (complex I inhibitor) and 
fluorescence measurements were taken for 1h (518nm excitation; 605 nm emission). In 
order to correct the DHE fluorescence values for variations in total protein content in 
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the wells, cell protein in each well was quantified by the BioRad protein assay. The 
values were obtained as slope per mg protein for each condition and then expressed in 
relation to control in absolute values. 
 
2.8.2 Determination of protein carbonyls groups 
Protein carbonyl content was determined as described by Levine et al. (Levine et al., 
1994), with slight modifications in plasma and CT, MCI and cybrids cellular extracts 
under basal conditions. Cellular and plasma proteins were precipitated with 10% TCA 
(trichloroacetic acid) and then incubated with 10 mM DNPH (dinitrophenylhydrazine) 
in 2 M HCl (or 2M HCl alone for the blanks), for 1 h at room temperature. The protein 
hydrazone derivatives were precipitated with 20% trichloroacetic acid and the 
precipitates were washed three times with 1 mL ethanol:ethylacetate (1:1). During each 
washing, the homogenized pellet was vortexed and left in the washing solution for 10 
min at room temperature before centrifugation. The final pellet was resuspended in 6 M 
guanidine HCl, and incubated during 15 min at 37ºC. The carbonyl content was 
determined spectrophotometrically, using a microplate reader, at 360 nm on the basis of 
molar absorbance coefficient of 22,000 M-1 cm-1. 
 
2.8.3 Measurement of TBARS levels  
Cells where harvested in ice-cold PBS and equal amounts of protein was used to 
determine TBARS. TBARS levels were determined by using the thiobarbituric acid 
assay (TBA), according to a modified procedure described by Ernster and Nordenbrand 
(Ernster L, 1967). The amount of TBARS formed was calculated using a molar 
coefficient of 1.56x105 mol-1 cm-1 and expressed as nmol TBARS/mg protein. Levels 
of lipid peroxidation in plasma were measured by the formation of a thiobarbituric acid 
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(TBA) adduct of malondialdehyde (MDA), separated by High Performance Liquid 
Chromatography (HPLC) (Draper and Hadley, 1990) using an analytical column 
Spherisorb ODS2 5 μm (250 × 4.6 mm), eluted with 60% (v/v) potassium phosphate 
buffer 50 mM, pH 6.8, and 40% (v/v) methanol at a flow rate of 1 mL/min. 
Spectrophotometric detection of the TBA-MDA adducts occurred at 532 nm. 
 
2.8.4 Vitamin E measurements  
Plasma levels of vitamins E were quantified after lipid extraction by HPLC using an 
analytic column Spherisorb ODS1-5 μm (250 × 4.6 mm), eluted at 2.5 mL/minute with 
a water solution of methanol (90%), at 45◦C, with spectrophotometric detection (Gilson, 
Lewis Center, Ohio, USA) at 295 nm (De Leenheer et al., 1979; Vatassery, 1978). 
 
2.9 Microtubule network evaluation  
2.9.1 Confocal microscopy analysis of α-tubulin and acetylated tubulin  
Cells were fixed for 10 min at room temperature using 4% paraformaldehyde. Both sets 
of fixed cells were washed again with PBS, permeabilized with 0.2% Triton X-100, and 
blocked with 3% BSA. The permeabilized cells were incubated with primary antibody 
(1:2,000 anti-alpha-tubulin; 1:2,000 anti-acetylated-tubulin both from Sigma ) overnight 
in a wet chamber, at 4ºC. Afterward, cells were incubated 1h with appropriate 
secondary antibody (1:250 AlexaFluor 488 from Molecular Probes, Eugene, OR, USA). 
Finally, cells were washed in PBS, incubated for 5 minutes with Hoechst 33342 
(15mg/L in PBS, pH 7.4) in the dark and visualized by confocal microscopy. The cells 
stained with Acetylated Tubulin (Ac-Tub) were extracted to grayscale, inverted to show 
Ac Tub-specific fluorescence as black pixels and thresholded to optimally resolve Ac 
Tub staining. Background fluorescence and specific Ac Tub fluorescence were 
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determined. The final value for fluorescence intensity results from the subtraction of 
background fluorescence to specific fluorescence and the result is further divided by the 
number of cells from each image acquired.  
 
2.9.2 Preparation of cell extracts containing soluble α-tubulin 
To prepare soluble fractions of cell α-tubulin, cells were washed twice, very gently, 
with a microtubule stabilizing buffer (0.1M N-morpholinoethanesulfonic acid, pH 6.75, 
1mM MgSO4, 2mM EGTA, 0.1mM EDTA, 4M glycerol). Soluble proteins were 
extracted at 37ºC for 4-6 min in 100ul of microtubule stabilizing buffer containing 0.1% 
Triton X-100. Protein was quantified by the Bradford method. Samples were resolved 
by electrophoresis in SDS, 10% polyacrylamide gels and transferred to PVDF 
membranes (Millipore, Billerica, MA, USA). Non-specific binding was blocked by 
gently agitating the membranes in 3% BSA and 0.1% Tween in TBS for 1h at room 
temperature. The blots were subsequently incubated with the respective primary 
antibodies overnight at 4°C with gentle agitation- 1:10,000 anti-alpha tubulin and, 
1:5000 anti-actin, both from Sigma. Fluorescence signals were detected using a Biorad 
Versa-Doc Imager, and band densities were determined using Quantity One Software. 
 
2.9.3 Western blot analysis of acetylated tubulin and Tau phosphorylation  
Individual cell lines were washed in ice-cold phosphate-buffered saline (PBS) and lysed 
in hypotonic lysis buffer (25 mM HEPES, pH 7.5, 2 mM MgCl2, 1 mM EDTA and 1 
mM EGTA supplemented with 2 mM DTT, 0.1 mM PMSF and a 1:1000 dilution of a 
protease inhibitor cocktail) supplemented with 2 mM ortovanadate and 50 mM sodium 
fluoride. Protein content was determined using Bradford protein assay (Bio- Rad, 
Hercules, CA, USA) and equal amounts of protein were resolved by electrophoresis in 
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SDS, 10% polyacrylamide gels and transferred to PVDF membranes (Millipore, 
Billerica, MA, USA). Non-specific binding was blocked by gently agitating the 
membranes in 3% BSA and 0.1% Tween in TBS for 1h at room temperature. The blots 
were subsequently incubated with the respective primary antibodies overnight at 4°C 
with gentle agitation- 1:750 anti phospho-Tau Thr181 and 1:750 anti phospho-Tau 
Ser396, both from Santa Cruz Biotechnology (Santa Cruz, CA, USA); 1:1000 anti-
acetylated tubulin and 1:5,000 anti-actin, both from Sigma.  
 
2.10 Autophagy assessment 
2.10.1 Cell treatment  
Where indicated, autophagy modulation consisted of the treatment of differentiated 
cybrids with 15 mM ammonium chloride and 100 μM leupeptine for 4h, after 14-17 
days of differentiation. In differentiated SH-SY5Y cells, the ammonium chloride and 
leupeptin were added, in the above described concentrations, during 12h. The former 
combination efficiently blocks all types of autophagy, as it reduces the activity of all 
lysosomal proteases by increasing the lumenal lysosomal pH without affecting the 
activity of other intracellular proteolysis systems.  
 
2.10.2. Western blot analysis of proteins involved in autophagic pathway  
Individual cell lines were washed in ice-cold PBS and lysed in 1% Triton X-100 
containing hypotonic lysis buffer (25 mM HEPES, pH 7.5, 2 mM MgCl2, 1 mM EDTA 
and 1 mM EGTA supplemented with 2 mM DTT, 0.1 mM PMSF and a 1:1000 dilution 
of a protease inhibitor cocktail). Cell suspensions were frozen three times in liquid 
nitrogen and centrifuged at 20,000×g for 10 min. The total amount of resulting cell 
lysates obtained were removed and stored at −80 °C. Protein content was determined 
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using Bradford protein assay (Bio- Rad, Hercules, CA, USA). Samples containing the 
similar amount of protein were resolved by electrophoresis in SDS, 15% 
polyacrylamide gels and transferred to PVDF membranes (Millipore, Billerica, MA, 
USA). Non-specific binding was blocked by gently agitating the membranes in 3%  
BSA and 0.1% Tween in TBS for 1h at room temperature. The blots were subsequently 
incubated with the respective primary antibodies overnight at 4°C with gentle agitation 
–1:1000 anti LC3B, 1:100 anti Beclin 1; 1:1000 anti BCL2; 1:1000 anti PINK1; 1:1000 
anti Parkin (Cell Signaling Technology, Inc., Danvers, MA, USA); anti-SQSTM1/p62 
(1:1000); anti-actin (1:5000) both from Sigma; 1:500 anti-Ubiquitin (Santa Cruz, CA, 
USA). Membranes were washed with TBS containing 0.1% Tween three times (each 
time for 10 min), and then incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody for 1h at room temperature with gentle agitation. After 
three washes specific bands of interest were detected by developing with an alkaline 
phosphatase enhanced chemical fluorescence reagent (ECF from GE Healthcare). 
Fluorescence signals were detected using a Biorad Versa-Doc Imager, and band 
densities were determined using Quantity One Software. 
 
2.10.3 Immunocytochemistry of LC3 and Lamp1  
Cybrid cells were differentiated into neurons on ibidiTreat µ-Slide eight-well plates. 
Following 14-17 days of differentiation, cells were washed twice with with serum-free 
medium and fixed with 4% paraformaldehyde for 20 min at room temperature. The 
fixed cells were washed again with PBS, permeabilized with 0.2% Triton X-100 or 
Methanol at -20ºC during 20 min (for LC3B staining), and incubated with 3% BSA, to 
prevent nonspecific binding, for 30 min. Then, cells were incubated with primary 
antibodies: 1:400 rabbit monoclonal anti-LC3 XP® from Cell Signaling (Danvers, MA, 
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USA and 1:100 anti-LAMP-1 clone H4A3 from the Developmental Studies Hybridoma 
Bank (University of Iowa, Iowa City, IA, USA); overnight followed by washing with 
PBS and secondary antibody incubation for 1 h (1:250 alexa fluor 594 or 1:250 alexa 
fluor 488 from Molecular Probes (Eugene, OR, USA). After washing twice in PBS, 
nuclei were counterstained with Hoechst 33342. After a final wash, the coverslips were 
immobilized on a glass slide with mounting medium (DakoCytomation, Dako, Glostrup, 
Denmark). Images were acquired on a Zeiss LSM 510 meta-confocal microscope (63 × 
1.4NA plan-apochromat oil immersion lens) by using the Zeiss LSM510 v3.2 software 
(Carl Zeiss, Inc., Thornwood, NY, USA) and analyzed using Zeiss LSM Image 
Examiner. The number of LC3 puncta per cell were quantified using the ‘analyze 
particles’ function of the ImageJ v1.39k (NIH, Bethesda, MD, USA) program after 
thresholding of images with size settings from 0.2–10 pixel2 and a circularity of 0–1. 
The cells stained with Lamp1 were extracted to grayscale, inverted to show Lamp1-
specific fluorescence as black pixels and thresholded to optimally resolve Lamp1 
staining. Background fluorescence and specific Lamp1 fluorescence were determined. 
The final value for fluorescence intensity results from the subtraction of background 
fluorescence to specific fluorescence and the result is further divided by the number of 
cells from each image acquired.  
 
2.10.4 Live imaging on AVs movements   
Cybrid cells were differentiated into neurons on ibidiTreat µ-Slide eight-well plates. 
Following 14-17 days of differentiation, cells were washed twice with differentiation-
DMEM without phenol red and FBS and mitochondria were labeled with  Cyto-ID™ 
Green Detection Reagent provided in the Cyto-ID™ Autophagy Detection Kit (Enzo, 
Lausen, Switzerland), according to the manufacturer's instructions. After a gentle wash, 
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cells were kept in differentiation-DMEM without phenol red and FBS and were imaged 
autophagic vacuole movements. Time-lapse images were captured under a Zeiss LSM 
510 meta-confocal microscope with a stage-based chamber (5% CO2, 37°C). The 
inverted microscope was driven by the LSM software and images were taken every 2 s 
for a total of 4 min under 63× magnification (Zeiss Plan-ApoChromat 63×, 1.4NA). For 
transport analysis, mitochondria or autophagosomes were considered not mobile if they 
remained stationary for the entire recording period. Movement was counted only if the 
displacement was more than the length of the autophagosome (∼500 nm). For each 
time-lapse movie, autophagic vacuoles were manually tracked and transport parameters 
were generated using the ImageJ software plug-in Multiple Kymograph, submitted by J. 
Rietdorf and A. Seitz (European Molecular Biology Laboratory, Heidelberg, Germany). 
Movement velocity data were determined from the kymographic images and were 
calculated based on the slope (v = dx/dt) obtained for each profile along the recording 
time. Each series of images was recorded for at least three randomly selected Cyto-ID™ 
Green-labeled cells per culture and three independent cultures per condition. 
 
2.11 Sirtuin2 modulation  
2.11.1 Sirtuin2 inhibition with AK1 
After 14 to 17 days of differentiation, cybrid cell lines were incubated for 24h with 
10µM of AK1 (Sigma, a SIRT2 inhibitor, 5 µm of Tubastatin (BioVision South 
Milpitas Blvd., CA), HDAC6 inhibitor, as a control. After 4h of exposure to N/L, cells 
were washed with ice-cold PBS and lysed in 1% Triton X-100 containing hypotonic 
lysis buffer (25 mM HEPES, pH 7.5, 2 mM MgCl2, 1 mM EDTA and 1 mM EGTA 
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supplemented with 2 mM DTT, 0.1 mM PMSF and a 1:1000 dilution of a protease 
inhibitor cocktail) for LC3B analysis.  
Cell suspensions were frozen three times in liquid nitrogen and centrifuged at 20,000×g 
for 10 min. The total amount of resulting cell lysates obtained were removed and stored 
at −80 °C. Protein content was determined using Bradford protein assay (Bio- Rad, 
Hercules, CA, USA). Samples containing the similar amount of protein were resolved 
by electrophoresis in SDS, 10 or 15% polyacrylamide gels and transferred to PVDF 
membranes (Millipore, Billerica, MA, USA). Non-specific binding was blocked by 
gently agitating the membranes in 3% BSA and 0.1% Tween in TBS for 1h at room 
temperature. The blots were subsequently incubated with the respective primary 
antibodies overnight at 4°C with gentle agitation – 1:1000 anti-LC3B (Cell Signaling 
Technology, Inc., Danvers, MA, USA); 1:1000 anti-acetylated tubulin and 1:5000 anti-
actin (Sigma). Membranes were washed with TBS and 0.1% Tween three times (each 
time for 10 min), and then incubated with the appropriate horseradish peroxidase-
conjugated secondary antibody for 1h at room temperature with gentle agitation. After 
three washes specific bands of interest were detected by developing with an alkaline 
phosphatase enhanced chemical fluorescence reagent (ECF from GE Healthcare). 
Fluorescence signals were detected using a Biorad Versa-Doc Imager, and band 
densities were determined using Quantity One Software. 
 
 
2.12 Animals  
Sirtuin2 knockout mice (B6129) were obtained from The Jackson Laboratory (Bar 
Harbur, Maine, USA). Experiments involving animals were approved by and performed 
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in accordance with the University of Coimbra Institutional Animal Care and Use 
Committee guidelines and European Community Council Directive for the Care and 
Use of Laboratory Animals (86/609/ECC).  
 
2.12.1 Isolation and treatment of primary cortical neurons  
Primary neuronal cultures were obtained as described in (Agostinho and Oliveira, 
2003), with minor modifications. Frontal cortices were removed from embryonic day 
15-16 of C57BL/6 mice and Sirtuin2 knockout mice (B6129) and were aseptically 
dissected and combined in Ca2+ and Mg2+ free Krebs buffer [120 mM NaCl, 4.8 mM 
KCl, 1.2 mM KH2PO4, 13mM glucose, 10 mM HEPES (pH 7.4)] and then incubated in 
Krebs solution supplemented with BSA (0.3 g/l) containing trypsin (0.5 g/l) and DNase 
I (0.04 g/l) for 10 min at 378C. Tissue digestion was stopped by the addition of trypsin 
inhibitor (type II-S; 0.75 g/l) in Krebs buffer containing DNase I (0.04 g/l), followed by 
a centrifugation at 140 g for 5 min. After washing the pellet once with Krebs buffer, the 
cells were dissociated mechanically and resuspended in fresh Neurobasal medium 
supplemented with 2 mM L-glutamine, 2% B-27 supplement, penicillin (100 000 U/l) 
and streptomycin (100 mg/l). The cells were seeded on poly-L lysine (0.1 g/l)-coated 
dishes at a density of 0.33 × 106 cells/cm2 for western blotting and mitochondrial 
membrane potential assays. For immunofluorescence studies, neurons were mounted on 
poly-L-lysine-coated glass coverslips at a density of 0.75 × 106 cells/cm2. The cultures 
were maintained in serum-free Neurobasal medium supplemented with B-27 at 37ºC in 
a humidified atmosphere of 5% CO2, 95% air for 6 days before treatment in order to 
allow neuronal differentiation. After 6 days in vitro, cultured neurons were treated with 
5 µM Aβ1-42 , 24 h before fixation or harvesting. Where indicated, 20 mM ammonium 
chloride and 20 mM leupeptin were added in the culture medium in the last 4 h of Aβ1-42 
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treatment. The composition of the cultures was determined by immunolabeling in 
addition to physiological characterization. The majority of cells (90–95%) were positive 
for neuronal markers (Map2, βIII Tubulin) whereas, 10% of cells showed 
immunolabeling for the astrocytic marker glial fibrillary acidic protein. 
 
2.12.2 Primary cortical neurons mitochondrial membrane potential (∆Ψm) 
After 6 days of plating to allow neuronal differentiation, cells were treated with 5µM of 
Abeta1-42 and changes in mitochondrial membrane potential were detected using the 
fluorescent cationic dye or TMRM. Cells were loaded with 300nM of TMRM (in the 
dark, at 37 ºC) and the fluorescence (λexc = 540 nm and λem = 590 nm) was recorded 
during 5 min before, and 3 min after mitochondrial depolarization, using a Spectramax 
Plus 384 spectrofluoremeter (Molecular Devices). Maximal mitochondrial 
depolarization (Δψm collapse) was performed in every individual experiment by adding 
1 μM FCCP (proton ionophore), which was always preceded by oligomycin (2 μg/ml) 
to prevent ATP synthase reversal. TMRM retention was determined by the difference 
between total fluorescence (after depolarization) and the initial value of fluorescence.  
 
2.12.3 Primary cortical neurons immunobloting 
After 24h treatment with Abeta1-42 with or without N/L in the last 4h of the treatment, as 
indicated, cells were harvested and lysed in lysis buffer (25 mM HEPES, pH 7.5, 2 mM 
MgCl2, 1 mM EDTA and 1 mM EGTA supplemented with 2 mM DTT, 0.1 mM PMSF 
and a 1:1000 dilution of a protease inhibitor cocktail), supplemented with 1% Triton X-
100 for LC3 flux analysis. Cell suspensions were frozen three times in liquid nitrogen 
and centrifuged at 20,000×g for 10 min. The total amount of resulting cell lysates 
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obtained were removed and stored at −80 °C. Protein content was determined using 
Bradford protein assay (Bio- Rad, Hercules, CA, USA). Samples containing the similar 
amount of protein were resolved by electrophoresis in SDS, 10 or 15% polyacrylamide 
gels and transferred to PVDF membranes (Millipore, Billerica, MA, USA). Non-
specific binding was blocked by gently agitating the membranes in 3% BSA and 0.1% 
Tween in TBS for 1h at room temperature. The blots were subsequently incubated with 
the respective primary antibodies overnight at 4°C with gentle agitation – 1:1000 anti-
LC3B (Cell Signaling Technology, Inc., Danvers, MA, USA); 1:1000 anti-acetylated 
tubulin and 1:5000 anti-actin (Sigma). Membranes were washed with TBS and 0.1% 
Tween three times (each time for 10 min), and then incubated with the appropriate 
horseradish peroxidase-conjugated secondary antibody for 1h at room temperature with 
gentle agitation. After three washes specific bands of interest were detected by 
developing with an alkaline phosphatase enhanced chemical fluorescence reagent (ECF 
from GE Healthcare). Fluorescence signals were detected using a Biorad Versa-Doc 
Imager, and band densities were determined using Quantity One Software. 
 
2.13 Data analysis  
Data are expressed as means ± standard error of the means (SEM). To compare means 
between three groups we used one-way analysis of variance (ANOVA) followed by 
Fisher’s least significant difference (LSD) post-hoc testing.  To compare means between 
two groups we used two-way, unpaired Student’s t-tests, with p-values of <0.05 
considered significant.   
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Prodromal metabolic phenotype in MCI cybrids: 
Implications for Alzheimer´s disease. 
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3.1 INTRODUCTION  
 
The prevalence of dementia worldwide is becoming a major public health problem. 
Experts estimate more than 24 millions demented people all over the world and these 
numbers are expected to double in the next 20 years (Ferri et al., 2005). Alzheimer´s 
disease (AD) is the most common neurodegenerative disorder with a prevalence of 
4,4% for those older than 65 years old and represents at least 60% of all dementia cases 
(Lobo et al., 2000). The disease has an insidious onset that is usually heralded by a 
progressive tendency to forget recent day-to-day events and gradually other cognitive 
skills become compromised leading to loss of autonomy. This impairment in cognitive 
functions is due to anatomical atrophy of AD brains, which correlates with severe 
neuronal loss (Mattson, 2004). Moreover, AD brains show increased levels of amyloid 
beta (Aβ) plaques and tangles composed of hyperphosphorylated tau (Pereira et al., 
2005). Mild Cognitive Impairment (MCI) can be described as an intermediate state 
between normal aging and AD, where 15% of individuals develops dementia per year 
(Dawe, 1992). Indeed, MCI state is believed to be the earliest stage of the AD for the 
majority of patients (Butterfield et al., 2010). Although, the molecular mechanisms of 
AD are still uncovered, there is increasing evidence pointing out the primordial role of 
mitochondria in this pathology (Swerdlow and Khan, 2004). Interestingly, the metabolic 
changes observed in AD are at least partially observable in MCI subjects. Studies in 
MCI subjects revealed elevated levels of mitochondrial DNA (mtDNA) oxidative 
damage, which may be a major risk for AD development and progression (Hirai et al., 
2001; Manczak et al., 2004; Migliore et al., 2005; Swerdlow and Khan, 2004). Further, 
deficits in mitochondrial electric transport chain (ETC) have been verified, particularly 
in cytochrome c oxidase (COX) platelets from MCI subjects in agreement with 
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observations made in platelets from AD patients (Cardoso et al., 2004a; Valla et al., 
2006). 
The outcome of mitochondrial dysfunction-mediated oxidative stress may have an 
important contribution to AD development. When an imbalance occurs between free 
radical generation and antioxidant capacity, oxidative stress is responsible can damage a 
variety of biomolecules, such as lipids, proteins, RNA and DNA(Lovell and 
Markesbery, 2007). Human postmortem brain samples from MCI and AD subjects 
showed elevated levels of protein carbonyls and lipid peroxides as compared to controls 
(Keller et al., 2005). This increment in oxidative stress markers was specific for superior 
and middle temporal gyri, which indicates specificity for brain regions more affected by 
the disease and related with cognitive decline. In accordance, peripheral oxidative 
damage has been described in AD and MCI individuals (Baldeiras et al., 2008, 2010; 
Migliore et al., 2005). Studies in lymphocytes showed significantly higher levels of 
oxidative mtDNA damage in AD and MCI compared with control subjects (Migliore et 
al., 2005). 
Since it is now generally accepted that mitochondrial metabolic alterations begin years 
before the manifestation of the disease, this time window needs to be the basis for 
research to find more effective therapeutic targets and, in consequence, disease 
modifying therapies, to slow or stop the disease progression(Ferri et al., 2005). 
In this work we used the cytoplasmic hybrid (cybrid) model, first described by King and 
Attardi (King and Attardi, 1989), to generate a disease-specific ex-vivo model of 
mitochondrial dysfunction. Together with abnormalities in mitochondrial structure and 
morphology we found that mitochondrial deficits and increased oxidative stress where 
transversal to AD and MCI group, which we attributed to inherited mtDNA (Swerdlow 
and Khan, 2004). Indeed, mitochondrial dysfunction and oxidative stress precede the 
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increase in mitochondrial A oligomers content. We propose that mitochondrial 
impairments trigger AD sporadic pathology, since these defects are already present in 
MCI individuals and MCI itself can be considered a pre-stage for dementia. 
 
3.2 RESULTS 
 
3.2.1 Mitochondrial metabolism alterations 
 
Specific mitochondrial COX activity decreased in MCI and AD cybrids (data not 
shown). Moreover, COX/citrate synthase activities ratio also decreased in MCI and AD 
cybrids as compared to CT cybrids (Fig. 1A). We corrected COX activity with citrate 
synthase (CS) activity to overcome possible variation of mitochondrial enrichment 
between groups. IN AD, MCI and CT cybrids CS activity were equivalent (Fig. 2A). 
COX/CS activities ratio in MCI cybrids had intermediate values between CT and AD 
cybrids (Fig. 2A).  
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Table I
Demographic characteristics of patient population
CTR
(n=3)
MCI
(n=5)
AD
(n=5)
Gender F F F
Age, years 81  3.6 76  3.4 81  2.6
 
 
Figure 1. Mitochondrial function. (A) Activity of mitochondrial respiratory chain complex IV corrected 
for citrate synthase activity. The results are the means ± S.E.M. derived from five independent 
experiments and are expressed as absolute values. (B) Citrate synthase activity. Data represent the mean ± 
SEM derived from five independent experiments and are expressed as percentage relatively to control 
cybrids. . *p < 0.05, **p < 0.01; significantly different as compared to control CT cybrids.  
 
The amount of rhodamine 123 taken up and retained by mitochondria is proportional to 
the magnitude of the mitochondrial membrane potential. Under basal conditions 
rhodamine 123 levels were lower in AD cybrids when compared with CT cybrids. 
Further, MCI cybrids have rhodamine 123 retention levels in-between AD and CT 
cybrids (Fig. 2A). Mitochondrial fractions prepared from AD and MCI cybrids 
contained less cytochrome c than mitochondrial fractions prepared from CT cybrids 
(Fig. 2B, C). Mitochondrial fractions purity was previously established by us (Cardoso 
et al., 2004a) and find to be over 80%. 
 
 
CT MCI AD
0
1
2
3
**
*
C
o
m
p
le
x
 I
V
/C
S
 r
a
ti
o
(a
b
s
o
lu
te
 v
a
lu
e
s
)
CT MCI AD
0
50
100
150
C
it
r
a
te
 S
y
n
th
a
se
 a
c
ti
v
it
y
(%
 o
f 
c
o
n
tr
o
l)
B A 
Chapter 3 | Prodromal AD phenotype  
 
90 
 
C
on
tr
ol
M
C
I
A
D
0
20
40
60
80
100
***
**
R
ho
da
m
in
e 
12
3 
re
te
nt
io
n
(%
 C
on
tr
ol
)
C
on
tr
ol
s
M
C
I
A
D
0
20
40
60
80
100
*
*
M
it
o
ch
o
n
d
ri
a
l 
C
yt
c 
co
n
te
n
t
co
rr
ec
te
d
 w
it
h
 T
O
M
2
0
(%
 c
o
n
tr
o
l)
A B
15 kDa Cyt c
20 kDa TOM20
CT Cyb MCI Cyb AD Cyb
C
 
Figure 2. (A) Mitochondrial membrane potential was expressed as the percentage of CT cybrids 
rhodamine 123 retention, with the mean ± SEM derived from five independent experiments. Data are 
expressed as percentage relatively to control cybrids. (B) Basal mitochondrial cytochrome c levels were 
reduced in MCI and AD cybrids. Data represent the mean ± SEM derived from five independent 
experiments and are expressed as percentage relatively to control cybrids. (C) A representative western 
blot experiment showing mitochondrial cytochrome c content. *p < 0.05, **p < 0.01; ***p < 0.001, 
significantly different as compared to control CT cybrids.  
 
3.2.2 Mitochondria: ultrastructure and distribution. 
 
At an ultrastructural level, CT cybrids have a eukaryotic nucleus and exhibit dark, oval 
mitochondria (Fig. 3A). However, AD cybrids contained pale and enlarged shaped 
mitochondria with disrupted cristae (Fig. 3A), which is in accordance with the 
alterations observed in mitochondrial function. 
To assess mitochondrial distribution and morphology we used Tom20 staining and 
determined mitochondrial interconnectivity and elongation. Mitochondrial 
interconnectivity determines the degree of mitochondrial branching, namely the 
connectivity/dynamics between mitochondria. A higher mitochondrial interconnectivity 
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means a higher access and communication between mitochondria. We have found that 
in AD cybrids mitochondrial distribution was more perinuclear than in CT cybrids (Fig. 
3B). Moreover, AD cybrids showed a decrease in mitochondria elongation and 
interconnectivity, both features correlating with increased mitochondrial fragmentation. 
In fact, in AD cybrids mitochondria appears as small dots instead of a mitochondrial 
interconnected net. The above mentioned alteration in AD cybrid biochemical features 
are in agreement with an altered mitochondrial ultrastructure and may account for the 
clinical phenotype of the patients included in this study. Under basal conditions MCI 
cybrids showed an intermediated state between CT and AD cybrids. FCCP, a 
mitochondrial uncoupler, induced mitochondrial network disruption in CT cybrids; 
more pronounced perinuclear mitochondria localization in CT and MCI cybrids, but 
failed to induce additive changes in AD cybrids due their basal injure (Fig. 3B). 
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Figure 3. Mitochondrial ultrastructure, morphology and distribution. (A) Electron microscopy of an 
AD and a CT cybrid cell. CT cybrid have a euchromatic nucleus (n) and rod-shaped mitochondria (m) 
with a dark matrix. AD cybrids have also a euchromatic nucleus (n) and oval mitochondria (m) with pale 
matrix. AD cybrids mitochondria are enlarged and with disrupted cristae (arrows). Bars, 10 µm. (B) 
Tom20 immunostaining (green) of CT, MCI and AD cybrids showing alterations in mitochondria 
distribution, elongation and interconnectivity. AD cybrids show increased mitochondrial perinuclear 
distribution and were non-responsive to FCCP treatment. Cell nuclei were labeled with Hoechst. The 
images are representative of 3 independent experiments. Mitochondrial network outline (white) shows the 
shift of mitochondria localization to the perinuclear region and the arrows indicate an alteration of 
mitochondrial morphology to a more fragmented network. Bars, 5 µm. 
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3.2.3 Oxidative stress markers are increased in AD, MCI cybrids and patients 
plasma. 
 
Inefficient electron transport through the mitochondrial respiratory complexes can lead 
to the generation of ROS as a byproduct. Increased levels of ROS can directly damage 
various macromolecules, which lead to their loss of function and culminate in cell 
demise. Under basal conditions MCI cybrids have a slight increase in superoxide radical 
production whereas AD cybrids have significant increment in superoxide radical levels 
(Fig. 4A). When challenged with rotenone, a complex I inhibitor, CT, MCI and AD 
cybrids increase significantly superoxide radical production. MCI cybrids show 
intermediate values of superoxide radical production between AD and CT cybrids.  
Carbonyls and lipid hydroperoxides are oxidatively post-translational modifications in 
protein and lipids due to increases in oxidative stress. Indeed, we found higher levels of 
protein carbonyls and lipid peroxidation by-products in AD and MCI cybrids (Fig. 4B 
and 4C). Moreover, MCI cybrids increment of both lipid peroxides and protein 
carbonyls levels was smaller than what was observed in AD. In plasma of the studied 
subjects we found no significant changes in concentration of Vitamin E, although there 
was a slight tendency, not significant, for higher levels of protein carbonyls and of lipid 
peroxidation marker malondialdehyde (MDA) in MCI and AD groups (Table II).  
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Table II
Oxidative markers in patients plasma
CTR
(n=3)
MCI
(n=5)
AD
(n=5)
Vitamin E (mM) 26.30  5.3 26.73  3.4 30.96  10.3
MDA (mM) 1.5  0.8 1.86  0.2 1.98  0.2
Carbonyl groups (mM) 184.1  22.6 221.1  0.1 195.6  3.3
 
 
Figure 4. Oxidative stress markers. (A) Superoxide production in basal conditions and after challenging 
cells with rotenone. Data are expressed as the increasing slope per milligram of protein (RFU/mg), and as 
the mean ±S.E.M. for 5 independent experiments. (B) Lipid peroxidation products (TBARS) content was 
measured using thiobarbituric acid and was expressed as nmol of TBARS per milligram of protein 
(nmol/mg). Data are the mean ± S.E.M. for 5 independent experiments. (C) Protein carbonyl groups were 
determined using DNPH. Data are expressed as the mean ± S.E.M, for 5 independent experiments. *p < 
0.05, **p < 0.01, significantly different as compared to control CT cybrids. #p < 0.05, significantly 
different compared with untreated cells.  
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3.2.4 Mitochondrial Aβ monomers/oligomers content. 
 
Cybrid cells showed basal intracellular production of Aβ peptide, which can be 
correlated with increases of this peptide in the mitochondrial pool (Fig. 5).  
Although, is not yet clear how increases in A oligomers correlate with mitochondrial 
dysfunction in sporadic AD, it is interesting to notice that mitochondrial Aoligomeric 
content increases in AD cybrids as compared MCI or to aged-match controls (Fig. 5).  
 
 
 
 
 
 
Figure 5. Mitochondrial A oligomers content. (A) Western Blot analysis and (B) densitometry of 
mitochondrial A content, showing an increase of mitochondrial A oligomeric content in AD cybrids. 
A oligomers were quantified from 37 kDa to 100 kDa. Mitochondrial fractions were reprobed for 
Tom20 in order to correct A levels to mitochondrial mass. Blots are representative of 3 different 
experiments. Data is reported as the fold increase over untreated CT cybrids. *p<0.05, significantly 
different when compared to CT cybrid.  
 
3.3 DISCUSSION 
 
Mitochondrial dysfunction has been widely implicated in AD etiology as a primordial 
event (Moreira et al., 2006; Silva et al., 2011b; Swerdlow and Khan, 2009). Our data 
confirm prior studies showing that COX activity is decreased in AD cybrids (Cardoso et 
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al., 2004b), and show for the first time that this mitochondrial defect is also present in 
MCI cybrids. In accordance, experiments performed with platelets shown that COX 
activity is decreased in subjects with MCI and AD (Cardoso et al., 2004b; Valla et al., 
2006). Our findings corroborate the hypothesis that mitochondrial threshold effect, due 
to the synergy between inherited polymorphic variations of mtDNA and age-related 
changes, accounts for systemic alterations of mitochondrial function that ultimately 
induces sporadic AD pathology (Swerdlow et al., 2010). Since AD and MCI cybrids 
perpetuate the defects found in the brains and peripheral tissues, it is reasonable to argue 
that mtDNA could entail the responsibility for MCI progression into AD. Indeed, our 
results show that MCI cybrids have reduced mitochondrial membrane potential and 
mitochondrial cytochrome c content suggesting mitochondrial-dependent apoptotic 
activation, similarly to what we observed in AD cybrids (Cardoso et al., 2004a). This is 
further supported by ultrastrutural images showing that AD cybrids mitochondria are 
enlarged or swollen and have a pale matrix with few remaining cristae as compared with 
CT cybrids. These ultrastrutural mitochondrial changes, also demonstrated by Trimmer 
and colleagues (Trimmer et al., 2000), sustain the altered mitochondrial distribution and 
pattern observed in AD cybrids. Mitochondrial distribution is also strikingly different in 
cells that overexpress APP, Tg APP mice and A-treated neurons (Du et al., 2010; 
Wang et al., 2008b). More significantly, we show for the first time that MCI cybrids 
exhibit a shift of mitochondrial network to the perinuclear region with an increase in 
fragmentation. Mitochondrial perinuclear clustering and fragmentation can be triggered 
by depolarization, that in turn potentiates mitophagy (Cardoso et al., 2010), or by 
impaired mitochondrial transport along microtubules. Indeed, it was previously 
described in different AD models that microtubule-dependent mitochondrial 
intracellular traffic is compromised (Brunden et al., 2011; Silva et al., 2011a; Silva et 
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al., 2011b). In support of this point of view, CT cybrids treated with a mitochondrial 
uncoupler exhibited fragmentation of mitochondrial network accompanied by a more 
pronounced perinuclear localization of mitochondria. Importantly, MCI cybrids 
challenged with the mitochondrial uncoupler are still responsive, whereas AD cybrids 
are not. This data indicates that mitochondrial compromise occurs in a progressive 
manner during the course of pathology. 
Mitochondrial metabolism also regulates cellular oxidative stress (Moreira et al., 2006). 
Moreover, it has been described that oxidative stress is an early event in the 
pathogenesis of AD (Smith et al., 2010). Accordingly the majority of oxidative stress 
markers are altered in MCI, which may occur decades before the disease manifestation 
(Perrin et al., 2011). We observed that mtDNA-driven COX dysfunction leads to 
increased ROS formation (superoxide radical). Furthermore, it was found that ROS 
generation by mitochondria, namely hydroxyl radicals, is enhanced in ETC-inhibited 
and mtDNA-deleted cells (Cardoso and Oliveira, 2003; Indo et al., 2007). In fact, redox 
proteomics analysis of MCI brains revealed higher levels of protein carbonyls similarly 
to what is observed in AD brains (Aluise et al., 2011). Our results also demonstrate a 
gradual increase in protein oxidation, since the levels of carbonyl groups in MCI 
cybrids levels are between AD and CT cybrids values. Increased content in protein 
carbonyls correlates positively with increased ROS production in both MCI and AD 
cybrids.  
Lipids are molecules commonly attacked by free radicals in a process nominated lipid 
peroxidation. Lipid peroxidation products have been found augmented in postmortem 
samples of brains from MCI and AD subjects, with significant incidence in regions 
where Aβ pathology is more prominent (Ansari and Scheff, 2010; Lovell and 
Markesbery, 2007). In peripheral tissues, Baldeiras and colleagues (Baldeiras et al., 
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2008) found increased levels of nitrogen reactive species and markers of lipid 
peroxidation in both MCI and AD individuals. Other studies detected a positive 
correlation between the decreased antioxidant defense and increased lipid peroxidation 
in AD and MCI patients when compared with age-matched controls (Padurariu et al., 
2010). In our cybrid cell lines we also observed higher levels of TBARS in both MCI 
and AD groups. Baldeiras and colleagues (Baldeiras et al., 2010) evaluated the role of 
peripheral oxidative stress in MCI progression to AD. Significant changes in several 
oxidative stress markers were found in the MCI group that converted to AD, which lead 
the authors to propose that antioxidant therapy is indicated for prevention of AD, in pre-
symptomatic phases. Our MCI and AD subject’s plasma samples also show a tendency 
to increased levels of protein carbonyls, MDA but no changes in vitamin E levels (Table 
II).  
It was already demonstrated in AD cybrids that mitochondria dysfunction induces A 
pathology increasing its cellular levels, however the underlying mechanism has not 
been disclosed (Khan et al., 2000). Previously, in an attempt to address this issue, 
authors using A-treated cells or A-overproducing cells, showed that Aβ-rich synaptic 
mitochondria revealed early deficits in mitochondrial function and increased 
mitochondrial oxidative stress (Du et al., 2010). These results highlight the essential 
importance of synaptic mitochondrial dysfunction for the development of synaptic 
degeneration in AD. We now found that A oligomers levels are increased in 
mitochondrial fractions from AD in comparison with CT cybrids. On the other hand, the 
increase of theses A species in MCI cybrids did not reach statistical significance. 
Therefore, we can argue that Aβ mitochondrial enrichment is downstream of 
mitochondrial impairment and may aggravate the defect even further. Our results clearly 
indicate that A mitochondrial accumulation increases as mitochondrial function 
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declines. Moreover, it was shown that mitochondria are a privileged site for Aβ 
accumulation (Manczak et al., 2006; Pagani and Eckert, 2011; Silva et al., 2011a). 
Pavlov and colleagues (Pavlov et al., 2011) recently showed that mitochondrial-
associated amyloid precursor protein (APP) is cleaved by mitochondrial secretases 
contributing to increase Aβ content within the mitochondria, which exacerbates 
mitochondrial dysfunction.  
In conclusion, our results point out to the primordial role of mtDNA, and consequently, 
mitochondrial dysfunction, in the pathogenesis of AD. Features of mitochondrial 
dysfunction and oxidative stress are found in both MCI and AD cybrids. Furthermore, 
the alterations in MCI cybrids are often intermediate between CT and AD, indicating 
that the molecular and biochemical events occurring in MCI cells can disclosure the 
molecular mechanisms underlying AD etiopathogenesis. So, we propose that MCI may 
be an important stage for developing new therapeutic approaches, not only targeting 
oxidative stress but also mitochondrial dysfunction, in order to avoid MCI progression 
to aged-related AD. 
Although, not all cases of MCI will progress to AD, this nosologic entity does show 
alterations in mitochondrial function, which are no doubt interrelated with AD 
degenerative pathway. An early identification of individuals in this preclinical period 
that are not yet demented is imperative, in order to potentiate the effect of disease-
modifying agents. 
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Figure 6. Integrative diagram of mtDNA-drived OXPHOS impairment. The model proposes that 
inherited mtDNA is responsible for aged-related dysfunctional mitochondrial oxidative phosphorylation 
(OXPHOS), which contributes to the appearance of Aβ aggregates, a major histopathological hallmark of 
AD.  
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4.1 INTRODUCTION 
 
Perturbed bioenergetic function, and especially mitochondrial dysfunction, is observed 
in brains and peripheral tissues of subjects with Alzheimer’s disease (AD) and mild 
cognitive impairment (MCI) (Swerdlow, 2012b; Valla et al., 2006), a clinical syndrome 
that frequently represents a transition between normal cognition and AD dementia 
(Petersen, 2011). Neurons are vulnerable to mitochondrial dysfunction due to their high 
energy demands and dependence on respiration to generate ATP (Pellerin and 
Magistretti, 2003). Mitochondrial dysfunction may, therefore, drive or mediate various 
AD pathologies (Swerdlow et al., 2010).   
While AD hippocampal neurons have reduced numbers of morphologically preserved 
mitochondria (Hirai et al., 2001), other changes in overall neuron mitochondrial mass 
are less straightforward. Dystrophic neurites concentrate mitochondria within 
autophagic vesicles, a phenomenon that could reflect defective retrograde transport 
(Henriques et al., 2010; Nixon, 2007; Silva et al., 2011a).  While PCR-amplifiable 
mitochondrial DNA (mtDNA) levels are reduced (de la Monte et al., 2000), approaches 
that detect mtDNA within autophagosomes in addition to mtDNA within intact 
mitochondria suggest hippocampal neuron mtDNA levels may actually increase (Hirai 
et al., 2001). Other studies report mitochondrial mass increases in healthy-appearing 
neurons while markedly declining in tangle-bearing neurons from AD subject 
hippocampi (Nagy et al., 1999).  
Mitochondrial fission-fusion dynamics are also altered in AD and could impact 
organelle proliferation, movement, and distribution (Hoppins et al., 2007; Santos et al., 
2010; Su et al., 2010). Biopsies from AD patient hippocampi show increased Fis1 as 
well as reduced Drp1, Opa1, Mfn1, and Mfn2.  These proteins further redistribute away 
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from neuron processes and towards cell bodies (Wang et al., 2009). In AD subject 
frontal cortex, expression of the pro-fission Drp1 and Fis1 genes increases, while Mfn1, 
Mnf2, and Opa1 pro-fusion gene expression decreases (Manczak et al., 2011b). In AD 
fibroblasts, H2O2 and Aβ (amyloid beta) treatment reduces Drp1 and disrupts 
mitochondrial networks (Wang et al., 2008b). Perturbed mitochondrial fission-fusion in 
AD may relate to increased mitochondrial autophagy (mitophagy), since altering fusion 
and fission protein levels induces mitophagy (Twig and Shirihai, 2011).  
In order to study AD and MCI bioenergetic fluxes, intermediates and proteins that relate 
to those fluxes, and mitochondrial mass/morphology-related phenomena, we generated 
cytoplasmic hybrid (cybrid) cell lines using platelet mitochondria from AD, MCI, and 
age-matched control subjects. We found that bioenergetic flux and flux-associated 
parameters were altered in MCI and AD cybrid lines.  Many of the changes we observed 
either mediate or represent retrograde responses that are probably compensatory in 
nature.  These compensatory changes, though, may have mal-adaptive as well as 
adaptive consequences.  
 
4.2 RESULTS   
 
4.2.1 COX Vmax activities 
 
Numerous studies have found that following a 6 week selection process, relative to 
control cybrid cell lines AD cybrid cell lines have reduced COX Vmax activities 
(Swerdlow, 2012b). One previous study reported MCI cybrid COX Vmax activities are 
also reduced relative to that of control cybrids (Silva et al., 2012a), and another study 
found that after correcting for mtDNA synthesis rates AD cybrid COX Vmax activity 
reductions persist for at least 1-2 months after the 6-week cybrid selection process is 
complete (Trimmer et al., 2004). Our COX Vmax data, which come from cybrid cell 
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lines maintained in continuous culture for 2 additional months after the 6 week selection 
process was completed, are for the most part consistent with the existing literature. 
Although reporting whole cell COX Vmax activities only as pseudo-first order rate 
constants normalized to mg protein (sec-1/mg protein) did not reveal differences (Figure 
1A), further normalizing to a marker of COX quantity, in this case COX4I1 protein, 
found that the COX activity mean per COX subunit protein was lower in the AD cybrid 
lines than it was in the control cybrid lines (Figure 1B). The MCI cybrid COX Vmax 
activity mean was intermediate, as it was not statistically different from either the 
control or AD group means (Figure 1B). The possibility that COX function is perturbed 
in MCI cybrids is further supported by an analysis in which the MCI and AD cybrids 
were combined to create a single group.  In this case, the AD+MCI cybrid COX Vmax 
mean, when normalized to COX4I1 protein levels, was lower than that of the control 
cybrids (Figure 1C). Conversely, adding the MCI and control cybrids together created a 
group whose COX Vmax mean was statistically comparable to that of the AD cybrids 
(data not shown). 
 
 
 
 
 
Figure 
1. COX Vmax activities. The pseudo-first order rate constant in sec-1 was spectrophotometrically 
determined by following the conversion of reduced cytochrome c to oxidized cytochrome c. In (A), each 
cybrid line’s rate constant was normalized to the amount of whole cell protein in its assay cuvette to 
provide a rate in sec-1/mg protein (A). As immunochemical measurements of COX4I1 protein revealed 
the amount of COX4I1 protein differed between the groups (see Figure 8), we also normalized the sec -
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1/mg protein rate for each line to its relative amount of COX4I1 protein (B and C). * indicates a p<0.05 
difference from the control group; ** indicates a p<0.01 difference from the control group. 
 
4.2.2 Oxygen and glucose fluxes 
 
We used a Seahorse XF24 Analyzer to assess cybrid line respiration-related fluxes. To 
quantify mitochondrial OCRs under unstressed conditions, the total OCR for each cell 
line was determined in the presence of 25 mM glucose before and after the addition of 
rotenone and antimycin A to the cells. Rotenone (a complex I inhibitor) and antimycin 
A (a complex III inhibitor) blocks mitochondrial respiration, and reveals the cell non-
mitochondrial OCR contribution. Subtracting the non-mitochondrial OCR from the total 
OCR yields the mitochondrial OCR. The mitochondrial OCRs were then normalized to 
the amount of total protein that was present in the well that was being read. In the 
presence of 25 mM glucose, the MCI group OCR mean was lower than the control 
group OCR mean (Figure 2A). On post-hoc testing the AD group was statistically 
comparable to both groups (p=0.07 compared to the control group, and p=0.42 
compared to the MCI group). Combining the MCI and AD cybrids generated a single 
group whose OCR was lower than that of the controls (Figure 2B), while a group 
formed by combining the MCI with the control group was not statistically different 
from the AD group (data not shown). Glucose deprivation prevents glycolysis, which 
renders cells increasingly dependent on oxidative phosphorylation to make energy. This 
manifests as an increased OCR. Relative to total cell OCR measurements taken under 
25 mM glucose conditions, under glucose deprivation conditions the control group OCR 
increased by 67%, the MCI group OCR increased by 74%, and the AD group OCR 
increased by 61%. When no glucose was present in the assay medium the mitochondrial 
OCR rate was lower in the MCI and AD groups than it was in the control group (Figure 
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2C). Combining the MCI and AD cybrids generated a single group whose glucose-
deprived OCR was lower than that of the controls (Figure 2D), while a group formed by 
combining the MCI with the control group was not statistically different from the AD 
group (data not shown). 
To evaluate the mitochondrial proton leak rate, we determined each cell line’s OCR 
following oligomycin treatment. Oligomycin inhibits the mitochondrial ATP synthase, 
at which point all mitochondrial oxygen consumption is due to the ATP synthase-
independent leakage of protons from the intermembrane space to the mitochondrial 
matrix. The respiratory leak rate was higher in the AD cybrids than it was in the control 
cybrids. The MCI leak rate was intermediate, as its value was not significantly different 
from the other two groups (Figure 2E). Combining the MCI and AD groups in order to 
increase statistical power yielded a group whose leak rate exceeded that of the control 
group (Figure 2F). Combining the control and MCI groups yielded a group whose leak 
rate did not differ from the AD group (data not shown). In addition to measuring 
medium oxygen levels and calculating the rate at which oxygen is consumed by 
cultured cells, Seahorse Analyzers also measure medium pH and calculate the rate at 
which cells acidify their surrounding medium. Since cell lactic acid excretion is 
primarily responsible for medium acidification, and lactic acid is produced by anaerobic 
glycolysis, ECARs can be used to estimate glycolysis fluxes.  We initially placed cells 
from each of our cybrid lines in a glucose-free medium, at which point ECARs were 
quite low and equivalent between the groups; at the conclusion of each experiment 2-
deoxyglucose was added to each well, and revealed baseline ECAR measurements were 
stable throughout. The post-2-deoxyglucose ECARs were used to provide non-
glycolysis acidification rates. An initial injection introduced 10 mM glucose to the cells. 
The non-glycolysis, baseline ECAR for each line was subtracted from the rate in 10 mM 
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glucose to yield a true glycolysis-dependent ECAR. The glucose injection was followed 
by an injection of oligomycin, which eliminates mitochondrial ATP production by 
inhibiting the mitochondrial ATP synthase and forces a compensatory increase in 
glycolysis-related ATP production. The difference between the post-oligomycin ECAR 
and the post-2-deoxyglucose baseline ECAR indicates the glycolysis capacity. The 
difference between the post-glucose, pre-oligomycin ECAR and the post-glucose, post-
oligomycin ECAR indicates the glycolysis spare reserve capacity. The ECARs from 
each line were normalized to cell protein, organized by groups, and further normalized 
to the control group mean.   
The post-glucose, pre-oligomycin ECARs in the MCI and AD cybrids, as a group, were 
lower than the control cybrid ECARs (Figure 2G). This suggests that glycolysis rates 
were lower in the MCI and AD cybrids. The post-glucose, post-oligomycin ECARs 
were also lower in the MCI and AD cybrids, suggesting their glycolysis capacity was 
also lower than that of the control cybrid lines (Figure 2H). The calculated glycolysis 
spare capacities were lower in the MCI and AD cybrid groups (data not shown). 
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Figure 2. Mitochondrial respiration and ECAR values. Mitochondrial OCR values in the presence of 
non-limiting amounts of glucose (A and B) and in the absence of glucose (C and D) were determined for 
each separate cybrid group and for the combined AD+MCI group. Mitochondrial OCR values for each 
cybrid group (E) and for the AD+MCI group (F) were determined following exposure to oligomycin. The 
basal glycolysis rate for each cybrid line was estimated by determining its ECAR in the presence of non-
limiting amounts of glucose (G). The maximal glycolysis rate (the glycolysis capacity) for each cybrid 
line was estimated by determining the ECAR in the presence of glucose and oligomycin (H). * indicates a 
p<0.05 difference from the control group; ** indicates a p<0.01 difference from the control group. 
 
4.2.3 Energy and redox intermediates  
 
Similar to what was found in a prior study of AD and control cybrid cell lines prepared 
on an NT2 cell nuclear background (Cardoso et al., 2004b), inter-group differences in 
energy substrate levels were observed. These differences were subtle but distinct. Mean 
ADP levels between AD, MCI, and control cybrid lines were comparable on ANOVA, 
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although a post-hoc test suggested a potential increase in the AD cybrid ADP mean as 
compared to the control cybrid ADP mean (p<0.05 on LSD test) (Figure 3A). ATP 
levels were comparable between the three groups (Figure 3B).  The ADP/ATP ratio, 
though, was elevated in the AD group as compared to the control group, while the MCI 
group ADP/ATP ratio was intermediate between the AD and control groups as it did not 
differ from either of those groups (Figure 3C). Since MCI is often an AD precursor 
state, we attempted to increase power by generating a combined AD+MCI group. In this 
analysis, the AD+MCI group ADP concentration and ADP/ATP ratio exceeded the 
control ADP concentration and ADP/ATP ratio (Figure 3D, E). No differences were 
seen when the MCI and control cybrid values were combined and compared to the AD 
cybrid values (data not shown).MCI and AD cybrid whole cell NAD+/NADH ratios 
were lower than the control cybrid NAD+/NADH ratio (Figure 3F). This difference was 
driven by statistically significant reductions in MCI and AD cybrid NAD+ 
concentrations (Figure 3G). Increases in MCI and AD cybrid NADH concentrations 
may also have accentuated the inter-group ratio differences (see Figure 3H), although 
NADH levels were statistically equivalent between the groups.  Combining the MCI 
and AD cell lines into a single group did not alter this analysis; the combined group 
showed decreased NAD+, statistically unchanged NADH, and a decreased 
NAD+/NADH ratio (Figure 3 I-K). Combining the MCI and control groups to form a 
single group, which was then compared to the AD group, also revealed no quantitative 
differences in NAD+ concentration (data not shown). 
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Figure 3. Energy and redox intermediates. Relative ADP levels, ATP levels, and ADP/ATP ratios for 
each separate group are shown in (A), (B), and (C). Relative ADP levels and ADP/ATP ratios are shown 
for the combined AD+MCI group in (D), (E). Relative NAD+ levels, NADH levels, and NAD+/NADH 
ratios for each separate group are shown in (F), (G), and (H). Relative NAD+ levels, NADH levels, and 
NAD+/NADH ratios are shown for the combined AD+MCI group in (I), (J), and (K). * indicates a p<0.05 
difference from the control group; ** indicates a p<0.01 difference from the control group; # indicates the 
ANOVA calculation itself was not statistically significant, but the LSD post-hoc comparison with the 
control group showed a p value of <0.05. 
 
4.2.4 Flux modifying genes and proteins 
 
We assessed the status of genes and proteins that regulate or are regulated by 
bioenergetic fluxes. HIF1α, a protein that senses and responds to cell oxygenation status 
(Semenza, 2012), was lower in MCI and AD cybrids than it was in control cybrids 
(Figure 4A). HIF1α mRNA expression levels were comparable between the groups 
(p=0.054 on ANOVA), although a post-hoc analysis suggested HIF1α mRNA levels in 
the AD cybrid group could have exceeded that of the MCI and control cybrid groups 
(p<0.05 on LSD) (Figure 4B). Peroxisome proliferator-activated receptor γ coactivator 
α (PGC1α) mediates changes in mitochondrial mass and coupling efficiency (Handschin 
and Spiegelman, 2006). Total cell PGC1α protein levels were lower in MCI and AD 
cybrids than they were in control cybrids (Figure 4C). No differences in PGC1α mRNA 
expression were observed, perhaps because of an unexpectedly large variation in 
individual cell line values (Figure 4D). We also assessed the mRNA levels of two other 
PGC family members, peroxisome proliferator-activated receptor γ coactivator β 
(PGC1β) and PGC1α-related coactivator (PRC). PGC1β expression was comparable 
between the groups, while PRC expression was higher in the AD cybrid group than it 
was in the control and MCI groups (Figure 4E, F). It was recently shown that PGC1α 
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expression is also regulated by PARIS, a protein that binds the PGC1α promoter and 
blocks PGC1α gene transcription (Shin et al., 2011). While ANOVA between the 
control, MCI, and AD cybrids showed no intergroup differences in whole cell PARIS, 
whole cell PARIS levels in the combined AD+MCI group were reduced relative to the 
control group level (Figure 4G). When just nuclear PARIS was considered, protein 
levels were lower in the AD group than they were in the control group and also in the 
combined AD+MCI group (Figure 4H).  
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Figure 4. Flux regulatory pathways. Relative HIF1α protein levels are shown in (A).  Relative HIF1α 
mRNA levels are shown in (B). Relative PGC1α protein levels are shown in (C) and relative PGC1α 
mRNA levels are shown in (D). Relative PGC1β (E) and PRC (F) mRNA levels were also determined. 
Relative whole cell PARIS protein levels are shown for all three groups and for the combined AD+MCI 
group (G). Relative nuclear PARIS protein levels are shown for all three groups and for the combined 
AD+MCI group (H). * indicates a p<0.05 difference from the control group; ** indicates a p<0.01 
difference from the control group; # indicates the ANOVA calculation itself was not statistically 
significant, but the LSD post-hoc comparison with the control group showed a p value of <0.05. 
 
PGC1α activity is post-translationally regulated. Acetylation reduces its activity while 
de-acetylation, which is SIRT1-mediated, increases activity (Canto and Auwerx, 2009; 
Nemoto et al., 2005). Whole-cell SIRT1 protein and expression levels were comparable 
between the groups (Figure 5A, B). SIRT1 compartmentalization, though, changed and 
this manifested as a decrease in the protein’s nucleus to cytoplasm ratio (Figure 5C). 
Compared to the control group, on a post-hoc analysis nuclear SIRT1 trended towards a 
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lower level, and in the combined AD+MCI group nuclear SIRT1 levels were 
significantly lower (Figure 5D). Cytosolic SIRT1 protein levels were increased in both 
the MCI and AD groups, as well as in the combined AD+MCI group (Figure 5E). The 
ratio of phosphorylated to total SIRT1 was also reduced in the AD and AD+MCI groups 
(Figure 5F).  
 
 
(C)
0
0,2
0,4
0,6
0,8
1
1,2
Control MCI AD
N
u
cl
eu
s/
C
y
to
so
lS
IR
T
1
 
S
E
M
)
**
**
(D)
0
0,2
0,4
0,6
0,8
1
1,2
Control MCI AD
N
u
cl
ea
r 
S
IR
T
1
 P
ro
te
in
/
H
D
A
C
1
 (
+
S
E
M
) #
0
0,2
0,4
0,6
0,8
1
1,2
Control AD+MCI
N
u
cl
ea
r 
S
IR
T
1
 P
ro
te
in
 (
+
S
E
M
)
*
nuclear SIRT1
60 kDa HDAC1
Control MCI AD
(E)
0
0,2
0,4
0,6
0,8
1
1,2
1,4
Control MCI AD
C
y
to
so
l
S
IR
T
1
 P
ro
te
in
/
T
u
b
u
li
n
(+
S
E
M
)
* **
cytosolic p-SIRT1
cytosolic SIRT1
50 kDaTubulin
Control MCI AD
0
0,2
0,4
0,6
0,8
1
1,2
1,4
Control AD+MCI
C
y
to
so
li
c 
S
IR
T
1
 P
ro
te
in
 
(+
S
E
M
)
**
0
0,2
0,4
0,6
0,8
1
1,2
1,4
Control MCI AD
S
IR
T
1
 E
x
p
re
ss
io
n
 
(+
S
E
M
)
0
0,2
0,4
0,6
0,8
1
1,2
Control MCI AD
T
o
ta
l 
S
IR
T
1
 P
ro
te
in
/
T
u
b
u
li
n
(+
S
E
M
)
(A) (B)
120 kDa SIRT1
50 kDaTubulin
Control MCI AD
0
0,2
0,4
0,6
0,8
1
1,2
1,4
Control MCI AD
S
IR
T
1
 E
x
p
re
ss
io
n
 
(+
S
E
M
)
0
0,2
0,4
0,6
0,8
1
1,2
Control MCI AD
T
o
ta
l 
S
IR
T
1
 P
ro
te
in
/
T
u
b
u
li
n
(+
S
E
M
)
(A) (B)
120 kDa SIRT1
50 kDaTubulin
Control MCI AD
(A) (B) 
Chapter 4 | Bioenergetic flux, mitochondrial mass and dynamics  
 
115 
 
0
0,2
0,4
0,6
0,8
1
1,2
Control MCI AD
P
-S
IR
T
1
/S
IR
T
1
 (
+
S
E
M
)
**
0
0,2
0,4
0,6
0,8
1
1,2
Control AD+MCI
P
-S
IR
T
1
/S
IR
T
1
 (
+
S
E
M
)
*
(F)
 
Figure 5. SIRT1 analyses. Relative SIRT1 and whole cell protein levels (A) and mRNA levels (B) were 
similar between groups. However, the AD and MCI cybrid nucleus/cytosolic SIRT1 protein ratio 
decreased (C). This was due to a decrease in nuclear SIRT1 protein in the AD+MCI group and perhaps 
the AD group (D), as well as increased amounts of cytosolic SIRT1 protein in the AD, MCI, and 
AD+MCI groups (E). SIRT1 phosphorylation was reduced in the AD and AD+MCI groups (F). * 
indicates a p<0.05 difference from the control group; ** indicates a p<0.01 difference from the control 
group; # indicates the ANOVA calculation itself was not statistically significant, but the LSD post-hoc 
comparison with the control group showed a p value of <0.05. 
 
Phosphorylation provides another layer of PGC1α post-translational modification; 
increased phosphorylation associates with increased activity (Canto and Auwerx, 2009). 
AMPK is one enzyme that phosphorylates PGC1α (Jager et al., 2007). While total 
AMPK protein levels were comparable between groups, relative to the control group 
AMPK phosphorylation increased in the AD and AD+MCI groups (Figure 6A). We 
measured levels of a second PGC1α-phosphorylating enzyme, the p38 mitogen 
associated protein kinase (Feige and Auwerx, 2007), and found that relative to the 
control group total p38 protein levels were decreased in the AD group. Similar to what 
was previously found in other studies of AD cybrids (Onyango et al., 2010; Onyango et 
al., 2005), though, the ratio of phosphorylated to non-phosphorylated p38 was increased 
in the AD cybrids and this ratio was also increased in the AD+MCI group (Figure 6B).  
F 
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Figure 6. AMPK and p38 analyses. (A) Total cell AMPK protein levels were equivalent between the 
groups, while AMPK phosphorylation was increased in the AD and AD+MCI groups. (B) Total cell p38 
protein levels decreased in the AD group, while p38 phosphorylation increased in the AD and AD+MCI 
groups. * indicates a p<0.05 difference from the control group; ** indicates a p<0.01 difference from the 
control group. 
 
As various results were consistent with either increased or decreased PGC1α activation, 
we measured COX4I1 mRNA levels since COX4I1 expression is induced by PGC1α-
nuclear respiratory factor (NRF) complexes (Scarpulla, 2008). COX4I1 expression was 
higher in the AD group than it was in the control group, although the control and 
AD+MCI groups were comparable (Figure 7A). We further assessed mRNA and protein 
levels of transcription factor A of the mitochondria (TFAM), which is also induced by 
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PGC1α-NRF complexes (Scarpulla, 2008). Although TFAM mRNA levels were 
comparable between groups (Figure 7B), relative to the control group TFAM protein 
was increased in the MCI, AD, and AD+MCI groups (Figure 7C). Cytochrome C is 
transcribed from a nuclear gene, translated in the cytoplasm, and mostly resides in the 
mitochondrial intermembrane space. We did not measure cytochrome c protein levels in 
this study, but relative to the control group cytochrome C expression was increased in 
the AD and AD+MCI groups (Figure 7D).  
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Figure 7. Expression of PGC1α-coactivated genes.  COX4I1 mRNA levels were increased in the AD 
group but not the AD+MCI group (A). TFAM mRNA levels were equivalent between groups (B), while 
TFAM protein levels were increased in the MCI, AD, and AD+MCI groups (C). Cytochrome C mRNA 
levels were increased in the AD and AD+MCI groups (D). * indicates a p<0.05 difference from the 
control group; ** indicates a p<0.01 difference from the control group. 
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4.2.5 Mitochondrial mass and morphology 
 
We evaluated several markers of mitochondrial mass. COX4I1, a COX subunit, is 
encoded by a nuclear gene and translocates to the inner mitochondrial membrane. On 
the ANOVA comparison, COX4I1 protein was higher in the AD group than it was in 
the control group. COX4I1 protein levels were not statistically different between the 
control and MCI groups, with the p value being 0.067 (Figure 8A). COX4I1 protein 
levels were greater in the AD+MCI group than they were in the control group (Figure 
8A). COX2, another COX subunit, is encoded by an mtDNA gene and localizes to the 
inner mitochondrial membrane. On the ANOVA comparison, COX2 protein was higher 
in the AD group than it was in either the control or MCI group (Figure 8B); the control 
and AD+MCI group COX2 protein levels were comparable (data not shown). Lastly, 
we determined relative mtDNA to nDNA ratios in our cybrid cell lines. When we 
normalized the copy number of an mtDNA gene, ND1, to the copy number of a nuclear 
gene, the 18S RNA, the ratio was higher in the AD and AD+MCI groups than it was in 
the control group (Figure 8C). When the amount of the 16S RNA mtDNA gene was 
normalized to the amount of the 18S gene no statistically significant quantitative 
differences were seen between the groups, although qualitatively the 16S:18S data 
resembled the ND1:18S data (Figure 8D). 
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Figure 8. Mitochondrial mass markers. COX4I1 protein levels were increased in the AD and MCI+AD 
groups (A). COX2 protein was increased in the AD group (B). When relative mtDNA levels were 
determined using primers to the mtDNA ND1 gene, mtDNA levels trended higher in the AD group and 
were elevated in the AD+MCI group (C). When relative mtDNA levels were determined using primers to 
the mtDNA 16S gene, no inter-group differences were seen although qualitatively results obtained with 
the 16s primers resembled those obtained with the ND1 primers (D). * indicates a p<0.05 difference from 
the control group; ** indicates a p<0.01 difference from the control group; # indicates the ANOVA 
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calculation itself was not statistically significant, but the LSD post-hoc comparison with the control group 
showed a p value of <0.05. 
 
Mitochondrial morphology is partly determined by fission-fusion dynamics (Chan, 
2006b; Chen and Chan, 2009). Mitochondrial fission and fusion are enzyme-mediated 
processes that facilitate bioenergetic adaptation. In purified mitochondrial fractions, no 
differences in Opa1, a protein that drives mitochondrial fusion, were observed between 
our cybrid groups (Figure 9A). Levels of Drp1 protein, which drives mitochondrial 
fission, were comparable on ANOVA (p=0.076) but a post-hoc analysis suggested Drp1 
trended higher in the MCI and AD groups (both less than p<0.05 on LSD comparison) 
than it was in the control group (Figure 9B). Drp1 was higher in the combined 
AD+MCI group than it was in the control group (Figure 9B). Drp1 activity is also 
controlled through post-translational modification, and Drp1 phosphorylation at serine 
637 inversely correlates with Drp1 activity (Cereghetti et al., 2010; Cereghetti et al., 
2008; Cho et al., 2010). We found that Drp1 phosphorylation, when normalized to total 
mitochondrial Drp1 protein, was lower in the MCI and AD groups than it was in the 
control group (Figure 9C). Since the pro-apoptotic protein Bax reportedly enhances 
mitochondrial fission and fragmentation we quantified Bax expression (Autret and 
Martin, 2010; Sheridan et al., 2008). The inter-group ANOVA was negative (p=0.099), 
although on post-hoc analysis there was a trend for higher expression in the AD group 
as compared to the control group (p=0.036 on LSD) (Figure 9D). Bax expression was 
higher in the combined AD+MCI group than it was in the control group (Figure 9D). 
Finally, we quantified cell mTOR protein levels, as mTOR is sensitive to bioenergetic 
states and counters autophagy, a process that might predictably increase under 
conditions that favor increased mitochondrial fission (Cunningham et al., 2007; Schieke 
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et al., 2006). Relative to the control group, mTOR levels were reduced in the AD group 
and in the AD+MCI groups (Figure 9E).  
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Figure 9. Mitochondrial fission, mitochondrial fusion, and mTOR analyses. Opa1 protein levels were 
equivalent between groups (A), while Drp1 protein levels trended higher in the MCI and AD groups and 
were higher in the AD+MCI group (B). Drp1 serine 637 phosphorylation was reduced in the MCI and AD 
groups (C). Bax expression trended higher in the AD group, and was higher in the AD+MCI group (D). 
mTOR protein levels were reduced in the AD and AD+MCI groups (E). * indicates a p<0.05 difference 
from the control group; ** indicates a p<0.01 difference from the control group; # indicates the ANOVA 
calculation itself was not statistically significant, but the LSD post-hoc comparison with the control group 
showed a p value of <0.05. 
 
4.3 DISCUSSION 
 
Cybrid cell lines created through transfer of AD and MCI subject mitochondria show 
altered bioenergetic function and bioenergetics-associated infrastructures. COX 
holoenzyme function and respiratory fluxes are less efficient, glucose utilization is less 
robust, and these changes impact cell energy and redox states. Proteins that sense, 
respond to, and regulate bioenergetic fluxes are altered. While the majority of these 
retrograde responses are certainly compensatory, they appear to represent a mix of 
adaptive and mal-adaptive changes.  
COX activity in AD or MCI groups is lower than it is in age-matched control groups 
(Parker et al., 1990; Stephan et al., 2012; Swerdlow, 2012b; Valla et al., 2006). Initial 
studies reported COX activity is also lower in AD and MCI cybrid cell lines than it is in 
control cybrid lines (Silva et al., 2012a; Swerdlow, 2012b; Swerdlow et al., 1997), 
despite apparent attempts by AD cybrids to increase their mitochondrial mass (Trimmer 
et al., 2004). We again found COX in AD and, to a lesser extent, MCI cybrid cell lines 
is less efficient than it is in control cybrid lines despite the presence of seemingly 
adaptive compensations.  
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In AD and MCI cybrid cell lines mitochondrial oxygen consumption is altered under 
non-stress conditions. Respiration differences are accentuated when cells are forced to 
increase their mitochondrial ATP production. Decreased respiratory coupling in AD 
and, to a lesser extent, MCI cybrids further suggests respiration in AD and MCI cybrids 
is less efficient than it is in control cybrids.   
Despite this, glycolysis fluxes are reduced, rather than enhanced, in AD and MCI 
cybrids. Glycolysis flux is partly determined by NAD+/NADH ratios and NAD+ 
availability. We found AD and MCI cybrids have less NAD+ and lower NAD+/NADH 
ratios than control cybrids. Such changes would predictably reduce glycolysis flux. 
While activities of some glycolysis enzymes are increased in AD brain neurons (Soucek 
et al., 2003), glucose utilization is reduced in brains from AD and MCI subjects 
(Matsuda, 2007; Silverman et al., 2001). Cybrid modeling recapitulates this well-
recognized bioenergetic phenomenon. 
Reduced glucose utilization would constitute a mal-adaptive retrograde response 
because it predictably exacerbates rather than alleviates an energy shortfall. In AD and 
MCI cybrids this manifests as an elevated ADP/ATP ratio. Addressing respiration-
induced glycolysis flux reductions in AD and MCI cybrids and, ideally, subjects might 
favorably influence cell energy stores. 
HIF1α protein was reduced in AD and MCI cybrids. HIF1α enhances glycolysis by 
promoting glycolysis enzyme gene expression (Semenza, 1999, 2012). Reduced HIF1α 
levels would seem to represent an ultimately mal-adaptive compensation (Soucek et al., 
2003). One study previously reported HIF1α protein levels are reduced in AD brains 
(Liu et al., 2008). Our cybrid data support the view that increasing HIF1α protein levels 
is a justifiable AD therapeutic strategy (Soucek et al., 2003).    
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While HIF1α protein decreases in AD cybrids, HIF1expression increases. HIF1α is 
regulated more by protein degradation rates than gene expression rates, so dissociations 
should be possible. Interestingly, one study found HIF1α gene expression was increased 
in AD subject brain microvessels (Grammas et al., 2006).   
PGC1α expression is reduced in AD brains (Qin et al., 2009; Sheng et al., 2012). We 
did not replicate this finding in our AD and MCI cybrids. Levels of PARIS, a protein 
that blocks PGC1α expression (Shin et al., 2011), were low in AD and MCI cybrids and 
this also would tend to favor increased rather than decreased PGC1α expression. 
Expression of a related gene, PRC (Vercauteren et al., 2006), increased in AD cybrids. 
The status of PRC in AD brains is unknown.   
AD subject brains, AD cybrid cell lines, and MCI cybrid cell lines all show reduced 
PGC1α protein levels (Sheng et al., 2012; Swerdlow, 2012a). If this exacerbates a 
respiratory chain defect, then PGC1α protein reduction constitutes a mal-adaptive 
compensation. Alternatively, reducing PGC1α protein levels could conceivably benefit 
AD and MCI cybrid cells by limiting exposure to impaired mitochondria. 
Reductions in nuclear SIRT1 and SIRT1 phosphorylation, in conjunction with or 
perhaps due to low NAD+, would predictably increase PGC1α acetylation and decrease 
PGC1α activity (Jin et al., 2007; Piantadosi and Suliman, 2012). On the other hand, 
increased AMPK and p38 phosphorylation, which we presume occurred in response to 
energy compromise and oxidative stress, should increase PGC1α phosphorylation and 
increase PGC1α activity (Canto and Auwerx, 2009; Feige and Auwerx, 2007; Jager et 
al., 2007). These results indicate respiratory chain dysfunction alters cell milieus in 
ways that permit the coincident presence of contradictory responses. Similar 
contradictory profiles are also seen in AD brains, where SIRT1 protein is reportedly 
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reduced while AMPK and p38 are reportedly activated (Hensley et al., 1999; Julien et 
al., 2009; Salminen et al., 2011; Sun et al., 2003; Vingtdeux et al., 2011).   
COX4I1 expression, which is co-activated by PGC1α (Scarpulla, 2008), and COX4I1 
protein levels were increased in AD and, to a lesser extent, MCI cybrids. TFAM 
expression, which is also co-activated by PGC1α (Scarpulla, 2008), was unchanged in 
AD and MCI cybrids but TFAM protein levels were increased. Cytochrome C, a gene 
co-activated by both PGC1α and PRC (Scarpulla, 2008), showed increased expression 
in AD and MCI cybrids. Therefore, despite the fact that PGC1α protein levels are 
reduced in AD and MCI cybrids, we cannot conclude overall PGC1α activity is reduced. 
Whether it occurs due to PGC1α activation or despite reduced PGC1a protein, 
mitochondrial mass markers increase in AD and MCI cybrids. AD cybrids have more 
COX2 protein, COX4I1 protein, COX4I1 expression, cytochrome c expression, TFAM 
protein, and mtDNA than control cybrids. If we combine the AD and MCI cybrids to 
form one group, then the MCI cybrids also showed evidence of increased mitochondrial 
mass.   
Less mTOR protein was present in the AD and AD+MCI groups. Since mTOR counters 
autophagy (Hands et al., 2009; Ravikumar et al., 2004), decreased mTOR should predict 
increased autophagy. While total mTOR levels were unchanged in one study of AD 
brains (Li et al., 2005), autophagy markers do increase in AD (Boland et al., 2008; 
Mizushima et al., 2008; Nixon, 2007; Nixon et al., 2005). AMPK, which was activated 
in our AD and MCI cybrids, also inhibits mTOR and through this action promotes 
autophagy (Salminen et al., 2011).  
For our mitochondrial fission-fusion protein analysis, in order to more directly test 
protein-mitochondria relationships we measured Opa1 and Drp1 in mitochondrial 
fractions rather than whole cell lysates. Data obtained via this approach are consistent 
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with our mTOR and AMPK data, in that AD and MCI cybrids show enhanced 
mitochondrial fission infrastructure. An increase in fission infrastructure, which is seen 
in AD subject brains (Manczak et al., 2011b; Su et al., 2010; Wang et al., 2009), would 
predictably facilitate mitochondrial autophagy (Twig et al., 2008; Twig and Shirihai, 
2011).  
Autophagy differences may complicate mtDNA copy number measurements. While 
levels of PCR-amplifiable mtDNA are consistently reduced in AD brain (Brown et al., 
2001; Coskun et al., 2004; de la Monte et al., 2000; Hirai et al., 2001; Rodriguez-
Santiago et al., 2001) one study found, using an immunochemical rather than PCR 
approach, large amounts of mtDNA within an expanded autophagosome pool (Hirai et 
al., 2001). Since less mtDNA amplification was seen in AD brains in that study, this 
autophagosome-localized mtDNA may have eluded amplification (Hirai et al., 2001).  
While overall numbers of normal-appearing mitochondria are reduced in AD 
(Baloyannis, 2006, 2011; de la Monte et al., 2000; Hirai et al., 2001), between 
individual neurons mitochondrial mass estimations range from markedly increased to 
profoundly decreased (de la Monte et al., 2000; Manczak et al., 2004; Nagy et al., 
1999). The balance between mitochondrial biogenesis and mitochondrial autophagy 
may, therefore, vary between different neurons at any particular time, and vary over 
time within a single neuron.  
Several factors may explain the small magnitude of most inter-group changes observed 
in this study. Differences could truly be subtle, cybrids may minimize differences, or 
diagnostic inaccuracy could converge means and inflate variations. Increasing statistical 
power would address such limitations. We accomplished this by treating the AD and 
MCI groups as a single group. We believe this was justified because in most cases the 
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MCI clinical syndrome occurs in association with, or is due to, AD (Morris et al., 2001; 
Stephan et al., 2012).  
Our data suggest AD-specific bioenergetic profiles are present when clinical symptoms 
manifest and longitudinally evolve. This chronology is consistent with the 
mitochondrial cascade hypothesis, which postulates AD histopathology in sporadic, 
late-onset AD is initiated when an individual’s mitochondrial function declines below a 
critical threshold (Swerdlow et al., 2010; Swerdlow and Khan, 2004, 2009). If, as has 
previously been assumed, mtDNA accounts for differences between cybrid lines created 
from cytoplasts of different origins (Swerdlow, 2007a), then mtDNA differences are 
already present in subjects when clinical changes begin (Lu et al., 2010). 
In this cybrid study, correlative inference was occasionally used to deduce functional 
and, in particular cases, causal relationships. Some interpretive points, therefore, should 
be considered within that context. For example, we assumed changes observed in 
cytosolic or nuclear compartments arise due to changes in mitochondrial function. 
While this seems reasonable given our understanding of cybrid cell lines, the degree to 
which cytosolic or nuclear compartment changes in turn alter mitochondrial function is 
difficult to quantify. We further assumed bioenergetic flux changes impact cell 
signaling pathways more than cell signaling pathways impact bioenergetics fluxes. In a 
study like ours ascertaining the effect, and especially the magnitude of effect, of one 
parameter on another is certainly challenging since many of the parameters we studied 
are exceedingly intertwined. Future experiments designed to address this issue are 
indicated. 
In summary (Figure 10), our data suggest respiratory chain changes affect respiratory 
fluxes and cell redox states. Redox changes, in turn, reduce glycolysis flux and further 
stress cell energy supplies. Mitochondrial biogenesis and autophagy are up-regulated, at 
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least initially, but contradictions within pathways that regulate mitochondrial mass 
occur. The balance between mitochondrial biogenesis and mitochondrial autophagy is 
lost, and over time the functional mitochondrial pool shrinks. In AD, reversing 
potentially mal-adaptive compensations, such as a decline in glycolysis flux or the drive 
to maintain mitochondrial mass (Swerdlow, 2011b), would seem to represent logical 
therapeutic goals. 
 
 
Figure 10.  Suggested regulation of mitochondrial biogenesis and autophagy in AD and MCI 
cybrids. (A) Respiratory chain inefficiency induces oxidative stress, energy stress, and a decreased 
NAD+/NADH ratio. The lowered NAD+/NADH ratio reduces glycolysis, which adds to the energy stress. 
AMPK and p38 are activated, while SIRT1 input falls. Depending on the balance of these signals, PGC1α 
activity can increase or decrease. (B) Energy stress activates AMPK, reduces mTOR activity, and initiates 
autophagy. Enhanced fission of dysfunctional mitochondria also contributes to an increase in autophagy 
markers.  ROS=reactive oxygen species.   
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network disruption and autophagic-lysosomal 
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5.1 INTRODUCTION  
 
Sirtuins, an evolutionary conserved family of proteins deacetylases, which activity is 
dependent on NAD+ availability, have been related with important biological functions 
such as aging and longevity control and, as a consequently, age-associated pathologies 
(Satoh and Imai, 2014), such as Parkinson´s and Alzheimer´s disease (AD). Among the 
seven mammalian sirtuins (Sirt1-7) Sirt1, 6 and 7 are nuclear, Sirt3-5 are mitochondrial 
and SIRT2 is mainly cytoplasmic but has been found to associate with nuclear proteins 
in dividing cells (Sebastian et al., 2012). SIRT2 cellular functions remain the most 
elusive among all sirtuins. SIRT2 has been reported to regulate several cellular 
pathways, such as cell cycle progression (Inoue et al., 2007), cell differentiation, 
oxidative stress (Inoue et al., 2014). Additionally SIRT2 was found to be the most 
abundant in the brain (Pandithage et al., 2008) and, is uniformly expressed in neurites 
and growth cones exclusively in the cytoplasm of post-mitotic cells (Harting and Knoll, 
2010), which may attribute to SIRT2 a key role in neuronal motility and maintenance of 
axons and dendrites. Indeed, SIRT2 was shown to deacetylate tubulin (North et al., 
2003). Since neurons are polarized cells that strongly rely on cytoskeletal tracks for the 
movement of cargos along the cell (Stokin and Goldstein, 2006), SIRT2 is a strong 
candidate for neurodegeneration-induction in AD. Microtubule damage is long 
recognized to occur in AD brains (Cash et al., 2003; Nathan et al., 1995), either by 
reduction of total content and length of microtubules (Cash et al., 2003) or by reduction 
of tubulin acetylation, a marker for microtubule stability (Hempen and Brion, 1996). 
One possible mechanism for the contribution of SIRT2 to the neurodegenerative process 
is that its activation will impair microtubule network and, due to transport impairment, 
autophagosomes will accumulate within dystrophic neurites which culminates in cell 
Chapter 5 | Sirtuin 2 in AD  
 
133 
 
death (Silva et al., 2011b). Herein, we sought to demonstrate that inherent 
mitochondrial dysfunction, present in AD cybrids (Cardoso et al., 2004b; Silva et al., 
2013a; Silva et al., 2013b; Trimmer et al., 2000), is the unifying event that sets off a 
number of metabolic changes that activates SIRT2, driving microtubule network 
breakdown and, consequently, autophagic-lysosomal pathway impairment. 
Dysfunctional mitochondria and protein aggregates, such as Abeta oligomers, will not 
be eliminated, exerting further toxicity. We describe that mitochondrial dysfunction is 
present in AD and Mild Cognitive Impairment (MCI) cybrids, an intermediate state 
between normal aging and AD. Then we investigated the causal effect of mitochondrial 
dysfunction on SIRT2 activation, microtubule network disruption and accumulation of 
autophagosomes and the relation of these events with the appearance of the hallmarks of 
AD, the phosphorylation of Tau and Abeta oligomers accumulation. Further, we used a 
specific inhibitor of SIRT2, AK1, and showed that the inhibition of SIRT2 increases 
microtubule acetylation and rescues autophagosome clearance in AD cells harboring 
mtDNA from patients. Overall we demonstrate that microtubule disruption, through the 
activation of SIRT2, is responsible for the accumulation of autophagosomes in AD, 
rather than an increment in autophagy induction, which will result in the well 
documented neuritic dystrophy in AD brains (Nixon et al., 2005).   
 
5.2 RESULTS 
 
5.2.1 Loss of mitochondral potential correlates with mitochondria network 
alterations in MCI and sAD cybrids. 
Mitochondrial dysfunction is a striking feature of AD. Firstly described in AD brains 
(Gibson et al., 1988; Saraiva et al., 1985; Sorbi et al., 1983), early in the 90s 
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mitochondrial dysfunction was also described in platelets from AD patients (Parker et 
al., 1990), allowing the emergence of new viewpoints for AD etiology and the creation 
of AD cybrids, that results from the fusion of mtDNA depleted cells (ρ0 cells) with 
platelets isolated from AD and control subjects (Swerdlow et al., 1997). The cybrid 
technique presupposes that all cell lines have the same nuclear backgroud and differ 
only on the mtDNA. Mitochondrial cascade hypothesis was then proposed (Swerdlow 
and Khan, 2004) asserting that for sporadic AD the decline in mitochondrial function 
increases with age, reaching a threshold where the pathological hallmarks of AD - 
hyperphosphorylation of Tau and Abeta oligomers enriched senil plaques appear. Also, 
in MCI subjects mitochondrial dysfunction has been widely characterized (Silva et al., 
2013a; Silva et al., 2013b; Valla et al., 2006). Mitochondrial dysfunction in AD models 
is detected in a number of different parameters. We found decreased mitochondrial 
membrane potential in sAD cybrids, and the usual patern of MCI group, that normally 
have intermediate values between Controls and AD, is maintained (Figure 1A). Also, 
we observed  fragmented mitochondrial networks in both sAD and MCI groups, where 
mitochondria are less elongated and lost their interconectivity (Figure 1B).  
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Figure 1. Depolarization of mitochondria results in reduced mitochondrial interconnectivity, 
elongation and induces a perinuclear localization. (A) Mitochondrial membrane potential (∆Ψmit). 
Data represent the mean ± SEM derived from four independent experiments and are expressed as 
percentage relatively to control cybrids (*p<0.05, versus nCT cybrids). (B) Tom20 immunostaining 
(green) of nCT, nMCI and nAD cybrids showing alterations in mitochondria distribution, elongation and 
interconnectivity. Both nAD and nMCI cybrids show increased mitochondrial perinuclear distribution (n= 
3, *p<0.05, ** p<0.01 versus nCT cybrids). Cell nuclei were labeled with Hoechst 33342. Scale bars: 5 
µm.  
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While the origin for mitochondrial dysfunction in AD remains elusive, it is now 
recognized that mtDNA have a determinant role in AD pathogenesis. From AD models 
to patients, the early alterations on mitochondrial metabolism either due to DNA 
damage, disturbed energy metabolism or synaptic dysfunction, makes of mitochondria a 
interesting starting point to study AD (Wirz et al., 2014).  
 
5.2.2 Mitochondrial dynamics is altered in sAD cells harboting patient 
mitochondria. 
Compeling evidence have shown that the normally strict regulation of mitochondria 
morphology, by fusion and fission processes, is impaired in AD, either in cellular 
models and AD brains. Mitochondrial dynamics are critical for mitochondrial integrity 
in eukaryotic cells (Zhu et al., 2013). For once, mitochondrial fusion permits the 
exchanges of critical mitochondrial components within mitochondrial network such as 
lipid membranes, oxidative phosphorylation complexes, and mitochondrial DNA 
(mtDNA) allowing the exclusion of defective mitochondria and maintenance of a 
healthy mitochondrial pool (Detmer and Chan, 2007). Complementarily, mitochondrial 
fission enables the sequestration and subsequent elimination through autophagy of 
irreversibly damaged mitochondria and mitochondrial content (Twig et al., 2008). 
Despite some contradictory data, it is generally accepted that mitochondrial shape is 
abnormal in AD, where broken cristae are evident (Zhu et al., 2013). Transcripts and 
proteins responsible for fusion process are generally decreased in opposition to fission 
proteins that were reported to be increased. Indeed, in brain tissue from AD subjects 
mitochondrial fusion proteins are decreased namely OPA1, Mfn1 and Mfn2 whereas the 
levels of mitochondrial fission protein Fis1 are increased (Manczak et al., 2004; Wang 
et al., 2009). In peripheral samples, an increase in the levels of DRP1 and alterations in 
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mitochondrial length were found in AD fibroblasts (Wang et al., 2008a). We have 
previously demonstrated that in mitochondrial-dysfunction bearing AD and MCI 
cybrids, mitochondrial DRP1 protein levels are increased and also there is an increase in 
its phosphorylation at Serine 637 that inversely correlates with its activity, whereas no 
alteration was found in OPA1 levels (Silva et al., 2013b). Here we show that in 
differentiated cybrids the tendency is maintained and we observe no alterations in fusion 
proteins (Figure 2 A-F) and, in opposition, Fis1 and DRP1 are significantly increased in 
mitochondrial fractions of AD cybrids (Figure 2 G-J). Also increased phosphorylation 
of DRP1 at serine 616 is observed, which has been correlated with increased 
translocation of DRP1 to mitochondria and fission stimulation (Zhu et al., 2013) 
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Figure 2. Mitochondrial distribution relates to increased mitochondrial fragmentation. (A) 
Immunoblot for mitochondrial OPA1. (B) Densitometric analysis of OPA1 (n=3). (C), (E) Immunoblot 
for mitochondrial MFN1 and 2. (D) (F) Densitometric analysis of MFN1and 2 (n=4). (G) Immunoblot for 
total and phospho mitochondrial DRP1. (H) Densitometric analysis of total and phospho mitochondrial 
DRP1 (n=3, *p<0.05 versus nCT cybrids). (I) Immunoblot for mitochondrial Fis1. (J) Densitometric 
analysis for mitochondrial Fis1 (n=5, *p<0.05 versus nCT cybrids). 
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5.2.3 SIRT2 activation induce microtubule network deficits. 
Although SIRT2 is described to be activated due to an increase in NAD+ levels, we 
found no alteration in nicotinamide phosphoribosiyltransferase (NAMPT) (Figure 3 A 
and B) and decreased levels of total cellular NAD+ (nuclear plus mitochondrial and 
cytosolic pools; see Chapter 4). In RA-differentiated cybrids SIRT2 is located only in 
the cytoplasm (Figure 3 C and D) corroborating previous observations (Li et al., 2007b; 
Pandithage et al., 2008) and its levels are increased in AD. Indeed, SIRT2 was found to 
accumulate with age in brain and spinal cord from mouse (Maxwell et al., 2011). We 
hypothesize that the exclusive cytoplasmic localization and the increase in protein levels 
of SIRT2 are sufficient to result in increased activation of this protein in AD cells. It is 
described that SIRT2 primary cellular localization is the cytoplasm, where co-localizes 
with microtubules and deacetylates α-tubulin at lysine 40 (North et al., 2003). SIRT2 
transiently migrates to the nucleus during G2/M transition and regulates chromatin 
condensation during metaphase (Vaquero et al., 2006), in mitotic cells (North and 
Verdin, 2007). During neuronal differentiation, cell migration is crucial for neurons to 
acquire specific localization and to build polarity by differentiation into the axons and 
dendrites (Harting and Knoll, 2010). SIRT2 is described to block cell migration of non-
neuronal cells in wound-healing assay. In hippocampal neurons overexpression of 
SIRT2 inhibited neurite elongation whereas SIRT2 knockdown rescued the phenotype 
(Pandithage et al., 2008). These observations support our results, where we found 
decreased α-tubulin acetylation in AD cybrids (Figure 3E bottom pannel and F). In 
opposition, MCI group have increased α-tubulin acetylation, which suggests that the 
damage in these cells have not yet reached the threshold that leads to system failure, like 
in AD cells (Figure 3E bottom pannel and F). Although the relation between 
microtubule acetylation and microtubule depolymerization is poorly understood, it has 
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been hypothesized that depolymerization occurs dependently on acetylation (Suzuki and 
Koike, 2007). Anomalies in microtubule network were described in neurophatological 
studies of AD brain biopsies (Cash et al., 2003; Terry, 1998), where there was a 
decrease in microtubule length and number. We show that both MCI and AD groups 
have decreased α-tubulin fibers organization (Figure 3E, top panel) but concerning 
microtubule polymerization these groups follow different directions. MCI cybrids have 
decreased free tubulin in opposition to AD cybrids that present, although not 
statistically significant, increased free tubulin (Figure 3G), which is in accordance with 
α-tubulin acetylation levels (Figure 3 E bottom panel, H and I), supporting Suzuki and 
Koike hypothesis. These authors found that SIRT2 overexpression abolished the 
resistance to axonal degeneration in Wallerian degeneration mice granule cells (Wlds) 
and SIRT2 silencing enhanced axonal degeneration resistance in WT granule cells. We 
hypothesize that SIRT2 activation in the cytosol leads to microtubule loss of stability 
and depolymerization which facilitates Tau dissociation and consequent 
phosphorylation. The rational that microtubule damage precedes Tau phosphorylation 
was address by Miyasaka and colleagues (Miyasaka et al., 2010). It is well described 
that Tau is a microtubule-associated protein, acts in the stabilization of neuronal 
cytoskeleton and the phosphorylation state of Tau correlates with microtubule damage 
in AD (Hanger et al., 2014). Our results point to an increase in Tau phosphorylation in 
serine 396 residue but not in threonine 181, in AD cybrids (Figure 3 J-M). In AD brains 
was found that Tau phosphorylation at serine 396 is significantly increased when 
compared with other phosphorylation sites and constitutes an early site of Tau 
phosphorylation, occurring prior to the appearance of fibrillary tangles (Mondragon-
Rodriguez et al., 2014). Further, experiments show that phosphorylation at serine 396 
residue enhances Tau aggregation, affecting the binding and stabilization of 
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microtubules (Ding et al., 2006). Tau abnormal phosphorylation has been described to 
correlate with Braak and CERAD staging systems, constituting a valid biochemical 
assessment to complement other evaluations in AD diagnosis (Zhou et al., 2006).  
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Figure 3. Microtubule network disruption in sAD cells. (A) Immunoblot for cytosolic NAMPT protein 
levels. (B) Densitometric analysis of NAMPT protein levels (n=3). (C) Immunoblot for cytosolic and 
nuclear Sirtuin2 levels. (D) Densitometry for cytosolic Sirtuin2 levels (n=3, *p<0.05 versus nCT 
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cybrids). (E) α-Tubulin (red) and Ac-Tub (green) immunostaining. Hoechst 33342-stained nuclei are in 
blue. Scale bars: 5 µm. (F) Mean fluorescence intensity for Acetylated-tubulin (n=4, *p<0.05 versus nCT 
cybrids; ## p<0.01 nMCI versus nAD cybrids). (G) Densitometry for Free Tubulin analysis (n=4, *p<0.05 
versus nCT cybrids). (H) Immunoblot for Acetylated-tubulin. (I) Densitometric analysis of Ac-Tub (n=8, 
*p<0.05 versus nCT cybrids; ## p<0.01 nMCI versus nAD cybrids). (J), (K) Immuniblot for phosphor 
Tau, at serine 396 and threonine 181, respectively. (L), (M) Densitometric analysis of p-Tau serine 396 
and thr 181, respectively (n=4, *p<0.05 versus nCT cybrids). 
 
5.2.4 Microtubule breakdown impairs autophagy completion. 
Due the high polarization of neurons, axonal transport is crucial because it assures that 
proteins, vesicles, mRNAs, signaling molecules and organelles, such as mitochondria, 
are supplied from the cell body to synaptic terminals (Encalada and Goldstein, 2014). 
Compelling evidence suggests a preponderant involvement of axonal transport failure in 
AD and other neurodegenerative disorders (Goldstein, 2012; Millecamps and Julien, 
2013). Since axonal transport relies on microtubule tracks, axonal swelling and 
dystrophic neurites have been found to accumulate mitochondria, vesicles and a number 
of other cellular components indicating transports defects (Coleman, 2005; Millecamps 
and Julien, 2013). In our differentiated cybrids containing mitochondria from AD 
patients we found decreased velocity of transport of autophagosomes (Figure 4 A and 
B), corroborating previous results (Trimmer and Borland, 2005). Because axonal 
transport is compromised, autophagosomes will not reach lysosomes for degradation of 
their contents and autophagic flux is compromised (Figure 4 C-F). In opposition MCI 
cybrids are able to maintain autophagic rates, most probably eliminating dysfunctional 
mitochondria and other toxic cell waste, in accordance with increased microtubule 
stability given by increased tubulin acetylation (see Figure 3). Macroautophagy was 
found to be constitutively active in neurons and when microtubules are disrupted with 
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vinblastine, large number of double membrane AVs accumulate (Boland et al., 2008). 
Extensive autophagy involvement in AD was described by Nixon (Nixon et al., 2005), 
showing massive accumulation of AVs in neurons of affected brain regions. Other 
studies showed that in transgenic AD mice models the accumulation of AVs in 
hippocampal dystrophic neurites correlated cytoskeletal defects early in AD phenotype 
progression (Sanchez-Varo et al., 2012). 
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Figure 4. Disruption of microtubule network results in reduced autophagic vesicle movements and 
deficient autophagic turnover in sAD cybrid cells. (A) Representative kymograph images (out of three 
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experiments) of AVs movemenst in nCT and sAD cybrid cells treated. (B) Average transport velocity of 
AVs (µm/s) (n=3, *p<0.05 versus nCT cybrids). (C) Immunostaining for LC3B (green) in cells 
maintained in the presence or absence of inhibitors of lysososmal proteolysis (N/L). Hoechst 33342-
stained nuclei are in blue. (D) Mean number of LC3B-positive vesicles per cell profile (n=3, *p<0.05, ** 
p<0.01 versus nCT cybrids; ## p<0.01 nMCI versus nAD cybrids). Scale bars: 5 µm. (E) Immunoblot for 
endogenous LC3B from cells untreated or after treatment with N/L. (F) Densitometric analysis of 
endogenous levels of LC3B (n=6, *p<0.05, 01 versus nCT cybrids; ## p<0.01 nMCI versus nAD cybrids). 
 
5.2.5 Autophagic deficits in sAD cells. 
Beclin 1 is a molecular anchor that assembles an interactome, which regulates the 
initiation and nucleation of the autophagosome formation (Salminen et al., 2013). In 
samples from AD brains, Beclin1 expression is significantly reduced, when compared 
with age-matched controls (Jaeger et al., 2010; Pickford et al., 2008). Also Jaeger and 
colleagues (Jaeger et al., 2010) showed that deficiency in Beclin 1 expression impaired 
the degradation of autophagosomes in cultured cells. The inhibition of autophagosome 
fusion with lysosomes with bafilomycin A caused the accumulation of vesicles and 
further reduction in Beclin 1 levels, which implies that a mechanism of negative 
feedback may be occurring blocking the formation of autophagosomes when fusion 
with lysosomes is impaired. This was the case with our cybrid model, where Beclin1 
protein levels are reduced in AD cybrids, and further reduced when fusion is blocked 
with ammonium chloride and leupetine, while MCI group shows no changes (Figure 5 
A and B). A number os studies have shown that enhancing the number of lysosomes is 
benefficial in terms of protein agregate degradation, namely Aβ degradation, in various 
AD models (Butler et al., 2011; Xiao et al., 2014). Nontheless we claim that due to 
defficient axonal transport and consequent impaired autophagosomes fusion with 
lysosomes, increasing lysosomal biogenesis may not be the most adequante approach. 
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In fact, both MCI and AD cybrids show increased Lamp1 protein levels (Figure 5 C and 
D), which we consider to be a compensatory response where cells are trying to 
eliminate autophagosomal contents. At leat for AD cybrids this increment in lysosomal 
biogenesis does not seem to improve autophagosomes fusion with lysosomes, as 
autophagic flux is impaired (see Figure 5) and p62 is accumulating in both MCI and AD 
groups (Figure 5 E and F). p62 is a multifunctional protein that is described to play a 
role in protein aggregation and protein degradation, targeting protein aggregates for 
autophagic or proteasomal degradation (Salminen et al., 2012). Interestingly p62 levels 
are decreased in AD brain tissue (Du et al., 2009) and this is associated with increased 
protein aggregation and deposition.  
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Figure 5. Autophagy is compromised in sAD cybrids. (A) Immnunoblot for Beclin1 protein levels 
from cells untreated or after treatment with N/L. (B) Densitometric analysis of Beclin1 levels (n=6, 
*p<0.05, 01 versus untreated nCT cybrids, #p<0.05 untreated nMCI versus nAD cybrids, &p<0.05 
untreated versus N/L treated sAD cells). (C) Immunostaining for Lamp1 (red). Hoechst 33342-stained 
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nuclei are in blue. Scale bars: 5 µm. (D) Mean fluorescence intensity for Lamp1 (n=8, *p<0.05 versus 
nCT cybrids). (E) Immunobloting for p62 from cells untreated or after treatment with N/L. (F) 
Densitometric analysis of p62 (n=7, *p<0.05, ** p<0.01 versus nCT cybrids).  
 
5.2.6 Mitophagy alterations in MCI and sAD cells. 
The elimination of dysfunctional mitochodria, through mitophagy, occurs via an 
elegantly regulated process. Following a decrease in mitochondrial membrane potential, 
PINK1 is autophosphorylated (Okatsu et al., 2012) and sequestered within the 
mitochondria (Meissner et al., 2011) triggering Parkin translocation to mitochondrial 
outer membrane. Parkin ubiquitinates several mitochondrial proteins that control 
mitochondrial dynamics, such as Mfn1 and 2 and ultimatly activates mitochondrial 
removal by mitophagy. PINK1 was demonstrated to interact with Beclin 1 in 
mitochondria and its overexpression enhanced autophagy mediated by Beclin 1 
(Michiorri et al., 2010). In aggrement with loss of mitochondrial membrane potential 
(see Figure 1), mitochondrial PINK1 protein levels are increased in AD cybrids while 
MCI cybrids only show a tendency for an increase (Figure 6 A and B). Also Parkin 
whole cell protein levels are increased in AD cybrids, suggesting that although 
autophagy process is impaired in AD cells, dysfunctional mitochondria are recognized 
and targeted for degradation. Given that dysfunctional mitochondria and protein 
aggregates are tageted for degradation and the completion of this process is 
comprimised, ubiquitinated proteins will accumulate within the cytoplasm of MCI and 
AD groups (Figure 6 E and F). Early accumulation of ubiquitin and its co-localization 
within neurofribrillary tangles and senile plaques in hippocampus of AD subjects occur 
(Perry et al., 1989). Further, since dysfunctional mitochondria accumulate within 
autophagosomes favouring Aβ production (Nixon, 2007) it is expected that Aβ levels 
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rise in AD group, as our results show (Figure 6 G and H). In agreement with our data, 
TgCRND8 mice overexpressing human APP with two FAD mutations, show 
incomplete autophagy digestion with accumulation of LC3II, ubiquitinated proteins and 
Aβ peptides in autophagosomes (Yang et al., 2011).  
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Figure 6. Mitophagy is impaired in nMCI and nAD cells. (A) Immunobloting for mitochondrial 
PINK1 levels. (B) Densitometric analysis of mitochondrial PINK1 (n=4, *p<0.05 versus nCT cybrids). 
(C) Immunobloting for total Parkin levels. (D) Densitometric analysis of total Parkin (n= 3, *p<0.05 
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versus CT cybrids). (E) Immunobloting for total ubiquitination levels. (F) Densitometric analysis of total 
ubiquitinated proteins (n=8, *p<0.05 versus nCT cybrids). (G) Immunobloting for mitochondrial Aβ 
oligomers. (H) Densitometric analysis of mitochondrial Aβ oligomers content (n=6, *p<0.05 versus nCT 
cybrids).  
 
5.2.7 Lysosomal inhibition induces AD related features 
After characterizing microtubule and autophagy related features in the differentiated 
cybrid cell lines the next step was to evaluate wether this alterations were recapitulated 
when lysosomal function is blocked. In parental SHSY5Y cells treated with NH4Cl, a 
weak base that becomes concentrated in acidic compartments, such as lysosomes, cause 
pH to increase and, consequently, the inhibition of lysosomal hydrolases, and 
leupeptine, we show that mitochondrial membrane potential decreased after 12h of 
exposure (Figure 7A). We attribute this fact to the accumulation of dysfunctional 
mitochondria within the cells, which account for the reduction in membrane potential. 
Reports on Lysosomal Storage Diseases (LSD) demonstated that dysfunctional 
lysosomes leads to the accumulation of ubiquitinated proteins, dysfunctional 
mitochondria, which culminates in the activation of apoptotic cell death mechanisms, in 
this sense sharing common pathways with neurodegenerative disease such as AD 
(Settembre et al., 2008). In line with this rational, if the number of dysfunctional 
mitochondria is rising and their elimination is blocked, microtubule dynamics may get 
compromised and loose stability by decrease tubulin acetylation (Figure 7 B and C). 
When microtubule network is disassembled Tau dissociates and becomes susceptible of 
kinase action, increasing its phosphorylation (Figure 7 D and E). Also, it was described 
that lysosomal protease inhibition induces defective axonal transport and causes axonal 
accumulation of AVs in dystrophic neurites in AD (Lee et al., 2011). Finally, as 
predicted total levels of protein ubiquitination increase and, interestingly, also 
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mitochondrial Aβ oligomers (Figure 7 F-I). This results allows us to infer that 
mitochondria are definetly a priviledged site for Aβ targeting and when mitopahgy  
becomes impaired, Aβ production is favoured within accumulated AVs. These results 
corroborate others that observed that increased Aβ metabolism is strongly associated 
with macroautophagy impairment for both for Aβ production and secretion, enhancing 
neurodegeneration (Nilsson et al., 2013; Nilsson and Saido, 2014; Nixon, 2007). 
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Figure 7. Inhibiting lysosomal degradation recapitulates AD-related features. (A) Mitochondrial 
membrane potential. Data represent the mean ± SEM derived from three independent experiments and are 
expressed relatively to untreated cells versus N/L treated cells (*p<0.05, versus untreated cells). (B) 
Immunobloting for Ac-Tub levels. (C) Densitometric analysis of Ac-Tub (n=3, *p<0.05 versus untreated 
cells). (D) Immunobloting for phospho Tau, Thr 181. (E) Densitometric analysis of phospho Tau, Thr 181 
(n=3, *p<0.05 versus untreated cells). (F) Immunoloting for total ubiquitination. (G) Densitometry 
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analysis of total ubiquitination (n=3, *p<0.05 versus untreated cells). (H) Immunobloting for 
mitochondrial Aβ oligomers. (I) Densitometric analysis of mitochondrial Aβ oligomers (n=3, *p<0.05 
versus untreated cells). 
 
5.2.8 Sirtuin 2 loss of function prevents ALP dysfunction through the restoration 
of tubulin acetylation. 
Beneficial effects of SIRT2 inhibition were described in a variety of neurodegenerative 
diseases models. In one study, the inhibition of SIRT2 has been proved to be beneficial 
in the attenuation of α-synuclein-mediated toxicity in PD and multiple system atrophy 
(MSA) models (Hasegawa et al., 2010; Outeiro et al., 2007). Others have shown that 
either genetic as well as pharmacological inhibition of SIRT2 exerts neuroprotection 
through sterol biosynthesis in Huntington´s disease (HD) models (Luthi-Carter et al., 
2010). Our preliminary data shows that SIRT2 knock-out (KO) mice neurons are 
protected against the toxicity of soluble Aβ1-42, displaying no effect in decreasing 
microtubule acetylation levels (Figure 8A). Further, mitochondrial membrane potential 
and autophagic flux are maintained in SIRT2 KO mice (Figure 8 B-D). Given these 
encouraging results, we hypothesized that specific SIRT2 inhibition rescue AD cybrids 
in terms of loss of microtubule acetylation and impairment in ALP. SIRT2 specific 
inhibitor AK1 was proven to prevent neuronal loss in rTg4510 mice when injected 
directly in the hippocampus while having no toxic effects (Spires-Jones et al., 2012). 
Our results show an increase in acetylated tubulin leves in AD cybrids treated with 
10µM of AK1 (Figure 8 E and F). In control cells lines we have the same trend but, 
interestingly, MCI group fails to further increase the acetylation of tubulin with AK1. 
As a positive control cells were also treated with HDAC6 inhibitor, Tubastatin A. In 
this case it is evident the large increase in tubulin acetylation levels, nevertheless, it 
seems that AD cybrids have a chronic inability to increase tubulin acetylation levels 
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above a certain point, as its values are lower that control and MCI groups (Figure 8 F). 
Since microtubule network is restored, ALP should be recovered since axonal transport 
can be effectuated and fusion of autophagosomes and lysosomes can occur. Indeed our 
first data shows that AK1 treatment can successfully increase autophagic flux in AD 
cybrids (Figure 8 G and H). In the remaining groups AK1 does not seem to have an 
effect, which may be due to control and MCI cybrids having autophagic degradation at 
their optimal rates. Recent evidence suggest that SIRT2 play an important role in 
autophagy since SIRT2 overexpression is able to inhibit autophagic flux and cause the 
accumulation of autophagosomes components given by as LC3II and p62 proteins (Gal 
et al., 2012). 
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Figure 8. SIRT2 inhibition with AK1 and ablation in SIRT2 KO mice rescues ALP malfunction 
through microtubule network restoration. (A) Mitochondrial membrane potential. Data represent the 
mean ± SEM derived from three or five independent experiments, for WT or SIRT2 KO primary neurons 
respectively, and are expressed relatively to untreated cells (*p<0.05, versus untreated cells) (B) 
Immunobloting for Ac-Tub levels in WT and Sirt KO mice from primary cortical neurons treated with 
Aβ1-42 for 24h.. (C) Immunobloting for endogenous LC3B from primary cortical neurons treated with 
Aβ1-42 for 24h. Where indicated, cells were co-treated with N/L, in the last 4h. (D) Densitometric analysis 
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of LC3B endogenous levels (n=4, *p<0.05 versus untreated wildtype cortical neurons). (E) 
Immunobloting for Ac-Tub from Control, MCI and AD cybrids, untreated or exposed to 10µM of AK1 
and 5µM of Tubastatin A for 24 h. (F) Densitometric analysis of Ac-Tub (n=3, *p<0.05; **p<0.01 or *** 
p<0.001 versus respective control; ## p<0.01 Tubastatin A treated MCI versus AD) . (G) Immunobloting 
for endogenous LC3B from Control, MCI and AD cybrids untreated or exposed 10µM of AK1 for 24h. 
(H) Densitometric analysis of endogenous LC3B.  
 
5.3 DISCUSSION  
 
AD has long been associated with mitochondrial dysfunction, observed in many 
pathways govern by mitochondria and measurable in various cellular models from AD 
subject brains to the periphery (Swerdlow et al., 2014). Many mitochondrial-derived 
pathogenic processes have been described but to date no effective mechanism or target 
was described that enabled an effective therapeutic. Here we propose a mechanism that 
unifies many well described pathways affected in AD: mitochondrial dysfunction, 
microtubule disassembly and axonal transport impairment. First we evaluated 
mitochondrial dynamics and metabolism in RA differentiated control, MCI and AD 
cybrids and found depolarized and fragmented mitochondria. A body of evidence points 
to mitochondrial dynamics proteins to be suitable targets for AD pathology rescue, 
namely mitochondrial fission protein DRP1 (Reddy, 2014). In one study using AD 
cybrids, the expression of dominant negative DRP1 attenuated mitochondrial functional 
defects observed in AD cybrid cell lines (Gan et al., 2014). Microtubule damage 
jeopardizes axonal transport hampering the fusion of AVs and lysosomes in the 
autophagic pathway. One aspect of microtubule disassembly, the loss of acetylation, 
was proven to be crucial for the completion of autophagy. When microtubule 
acetylation is lost there is no fusion of autophagosomes and lysosomes, into 
autolysosomes (Xie et al., 2010). Further, tubulin acetylation is required for motor 
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protein, responsible for axonal transport, to bind to microtubules (Reed et al., 2006). 
Some microtubule targeted drugs were shown to prevent protein accumulation and 
synaptic loss (Butler et al., 2007) and have a beneficial effect on Aβ peptides production 
(Ashur-Fabian et al., 2003). These compounds often have brain accessibility issues and 
may become toxic. On the other hand SIRT2 is abundant and preferentially expressed in 
mammalian CNS and in a much lower extend in peripheral tissues (Maxwell et al., 
2011). It is detected exclusively in the cytosol of neuronal cells and although the exact 
role of SIRT2 in the cytosol is still elusive, the tubulin deacetylase activity and 
microtubule damage in AD makes of SIRT2 a desirable candidate for therapeutic 
intervention. We showed that SIRT2 inhibition with AK1 rescued microtubule 
acetylation in AD and our preliminary data point to a recovery of autophagic flux. 
Further studies are needed to address the efficacy of AK1 in ameliorating other AD-
related neurophatological hallmarks such as Tau phosphorylation and Aβ oligomers. We 
hypothesize that targeting microtubule network through SIRT2 manipulation in adult 
brain may be a more brain-specific approach, and holds a great promise in future AD 
therapeutics.  
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CONCLUDING REMARKS  
 
AD, first described by Alois Alzheimer in the early 1900s, is the most common form of 
dementia with no effective therapeutic available that could slow or stop the disease 
progression, despite the efforts made by clinicians and scientist around the world , 
(Silva et al., 2012b). The fact that Aβ-based therapies failed on both familial and 
sporadic AD forms (Iqbal et al., 2014), the multifactorial nature of AD and the 
suggested, although not well understood, relationship between brain aging and this 
disease, lead to mitochondria being a strong candidate for AD´s initiation. The 
recognition of mitochondrial metabolism failure in very early AD stages within the 
brain and the periphery, namely complex IV of ETC, and the involvement of 
mitochondria in a wide range of cellular functions, namely those who dictate cell death 
or survival, suggests that mitochondria play a key role in AD pathogenesis. We believe 
that mitochondria unifies both familial and sporadic AD forms by linking Tau and Aβ 
pathologies, in a way that mitochondria may be the missing link between mitochondrial 
and Aβ cascade hypothesis (Silva et al., 2011b). The use of the ex-vivo model of cybrids 
from AD, MCI subjects and age-matched controls, allowed us to show that 
mitochondrial dysfunction sets off the pathological mechanisms described for MCI and 
AD cybrids. We showed that mitochondrial dysfunction is inherent to AD group and, in 
a minor extension, is also present in MCI cybrids. In Chapter 3 we showed that 
mitochondrial dysfunction, namely reduced Complex IV activity, drives the increase of 
oxidative damage within the AD cybrids, whereas MCI group present intermediate 
values. AD cybrids also present intrinsic higher levels of Aβ oligomeric forms when 
compared to control or MCI groups. We further explored this mitochondrial dysfunction 
state and found that both AD and MCI cybrids have compromised mitochondria which 
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results in decreased ATP and a shift of whole cell NAD+/NADH ratio towards a more 
oxidized state (Chapter 4). Moreover we were able to show that mitochondria from MCI 
and AD have decreased respiration accompanied by decreased levels of PGC1α and 
decreased activation of SIRT1. Nevertheless, we found increased mitochondrial mass 
markers in MCI and AD cybrids. At this point we had clear evidence that AD and MCI 
cybrids bearing mitochondrial dysfunction  have decreased mitochondrial biogenesis, 
which lead us to investigate cellular quality control pathways, namely ALP (Chapter 5). 
We then used RA-differentiated cybrids into neurons and found depolarized and 
fragmented mitochondria, in accordance with increased mitochondrial fission proteins, 
in MCI and AD cybrids. We found that SIRT2, a tubulin deacetylase, is only located in 
the cytoplasm of differentiated cybrids and its levels are increased in AD cybrids. This 
increment in SIRT2 expression induces microtubule disassembly decreasing 
significantly the APH trafficking to lysosomes. In accordance AD cells have decreased 
autophagic flux resulting in the accumulation of dysfunctional mitochondria loaded 
with Abeta oligomers and protein aggregates that will cause further toxicity. 
Interestingly, MCI group is able to increase autophagic flux as well as tubulin 
acetylation. We hypothesize that this is a compensatory response by which these cells 
are attempting to degrade dysfunctional mitochondria and protein aggregates that are 
accumulating within their cytoplasm. Further, we present evidence that SIRT2 chemical 
inhibition with AK1 protects AD cells against deleterious effects resulting from loss of 
tubulin acetylation, a known marker for microtubule stability, inherent for AD cybrids. 
Once we restored microtubule acetylation by SIRT2 inhibition, we are able to restore 
proper ALP function and future studies will be performed in order to access the effects 
of AK1 dependent SIRT2 inhibition on other neurophatolgical hallmarks of AD, such as 
Tau phosphorylation and Abeta production.  
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Overall we show evidence that mitochondrial dysfunction is widely present in AD 
cybrids, occupies an upstream position in the pathogenesis of AD and starts a sequence 
of events converging in increased oxidative stress, impairment of ALP and, ultimately, 
the activation of SIRT2 and consequent microtubule disruption. Targeting 
mitochondrial function directly or improve microtubule stabilization, namely through 
SIRT2 inhibition, seem to represent a valid approaches to prevent ALP dysfunction and 
consequent toxicity through the accumulation of damaged, dysfunctional mitochondria 
and Aβ protein aggregates.  
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